

10/552326

JC20 Rec'd PCT/PTO 07 OCT 2005  
478.1072

**IN THE UNITED STATES PATENT & TRADEMARK OFFICE**

Re: Application of: **Nicholas John STANIFORTH, et al.**

Serial No.: **To Be Assigned**

Filed: Herewith as national phase of International Application  
No. PCT/GB2004/001628, filed April 14, 2004

For: **DEVICES AND PHARMACEUTICAL  
COMPOSITIONS FOR ENHANCING DOSING  
EFFICIENCY**

**LETTER RE: PRIORITY**

Mail Stop PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

October 6, 2005

Sir:

Applicant hereby claims priority from Great Britain Patent Application No. 0321612.4, filed September 15, 2003, from U.S. Patent Application Serial No. 10/413,022, filed April 14, 2004, and U.S. Patent Application Serial No. 10/621,964, filed July 17, 2003, through PCT/GB2004/001628, filed April 14, 2004.

Respectfully submitted,  
DAVIDSON, DAVIDSON & KAPPEL, LLC

By: 

\_\_\_\_\_  
Cary S. Kappel  
Reg. No. 36,561

Davidson, Davidson & Kappel, LLC  
485 Seventh Avenue, 14<sup>th</sup> Floor  
New York, New York 10018  
(212) 736-1940



PCT/GB 2004 / 0 0 1 6 2 8



INVESTOR IN PEOPLE

The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ

REC'D 04 JUN

WIPO

REC'D 04 JUN 2004

WIPO


PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

Dated

*P. Mahoney*  
26 May 2004

**PRIORITY DOCUMENT**  
SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH  
RULE 17.1(a) OR (b)

Request for grant of a patent



**1/77**

The Patent Office

Cardiff Road  
Newport  
Gwent NP9 1RH

1.	Your reference	SVH/44266GB1		
2.	Patent application number	0321612.4	15 SEP 2003	
3.	Full name, address and post code of the or each applicant	Vectura Ltd 1 Prospect West Chippenham Wiltshire SN14 6FH 861 0727001		
	Patents ADP number			
	If the applicant is a corporate body, give the country/state of its incorporation	United Kingdom		
4.	Title of the invention	Devices and Pharmaceutical Compositions for Enhancing Dosing Efficiency		
5.	Name of your agent	VENNER, SHIPLEY & CO		
	"Address for service" in the United Kingdom to which all correspondence should be sent	20 LITTLE BRITAIN LONDON EC1A 7DH		
	Patents ADP	1669004 ✓		
6.	If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or each of these earlier applications and the or each application number	Country	Priority application number	Date of filing
7.	If this application is divided or otherwise derived from an earlier UK application, give the number and filing date of the earlier application	Number of earlier application	Date of Filing	

Patents Form 1/77

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'YES' if:

a) any applicant in 3. above is not an inventor, or

b) there is an inventor who is not named as an applicant, or

c) any named applicant is a corporate body)

YES

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description	129
Claim(s)	2
Abstract	1
Drawing(s)	46 + 46

10. If you are also filing any of the following state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77)

Request for substantive examination (Patents Form 10/77)

Any other documents

11. I/We request the grant of a patent on the basis of this application.

Signature

Vener, Shipton & Co.

Date

15 September 2003

12. Name and daytime telephone number of person to contact in the United Kingdom

Siân Hughes  
020 7600 4212

## Devices and Pharmaceutical Compositions for Enhancing Dosing Efficiency

5 The present invention relates to enhancing the dosing efficiency of pharmaceutical dry powder formulations administered by pulmonary inhalation. In particular, the present invention relates to the provision of dry powder inhalers and dry powder compositions which reproducibly achieve a much higher delivered dose of the pharmaceutically active agent than currently achieved.

10 The metered dose (MD) of a dry powder formulation is the total mass of active agent present in the metered form presented by the inhaler device in question. For example, the MD might be the mass of active agent present in a capsule for a Cyclohaler (trade mark), or in a foil blister in an Aspirair (trade mark) device.

15 The emitted dose (ED) is the total mass of the active agent emitted from the device following actuation. It does not include the material left inside or on the surfaces of the device. The ED is measured by collecting the total emitted mass from the device in an apparatus frequently identified as a dose uniformity sampling apparatus (DUSA), and recovering this by a validated quantitative wet chemical assay.

20 The fine particle dose (FPD) is the total mass of active agent which is emitted from the device following actuation which is present in an aerodynamic particle size smaller than a defined limit. This limit is generally taken to be  $5\mu\text{m}$  if not expressly stated to be an alternative limit, such as  $3\mu\text{m}$  or  $1\mu\text{m}$ , etc. The FPD is measured  
25 using an impactor or impinger, such as a twin stage impinger (TSI), multi-stage impinger (MSI), Andersen Cascade Impactor or a Next Generation Impactor (NGI). Each impactor or impinger has a pre-determined aerodynamic particle size collection cut points for each stage. The FPD value is obtained by interpretation of the stage-by-stage active agent recovery quantified by a validated quantitative wet  
30 chemical assay where either a simple stage cut is used to determine FPD or a more complex mathematical interpolation of the stage-by-stage deposition is used.

The fine particle fraction (FPF) is normally defined as the FPD divided by the ED and expressed as a percentage. Herein, the FPF of ED is referred to as FPF(ED) and is calculated as  $FPF(ED) = (FPD/ED) \times 100\%$ .

- 5 The fine particle fraction (FPF) may also be defined as the FPD divided by the MD and expressed as a percentage. Herein, the FPF of MD is referred to as FPF(MD), and is calculated as  $FPF(MD) = (FPD/MD) \times 100\%$ .

10 The FPF(MD) can also be termed the 'Dose Efficiency' and is the amount of the dose of the pharmaceutical dry powder formulation which, upon being dispensed from the delivery device, is below a specified aerodynamic particle size.

It is well known that particle impaction in the upper airways of a subject is predicted by the so-called impaction parameter. The impaction parameter is defined  
15 as the velocity of the particle times the square of its aerodynamic diameter. Consequently, the probability associated with delivery of a particle through the upper airways region to the target site of action, is related to the square of its aerodynamic diameter. Therefore, delivery to the lower airways, or the deep lung is dependant on the square of its aerodynamic diameter, and smaller aerosol particles  
20 are very much more likely to reach the target site of administration in the user and therefore able to have the desired therapeutic effect.

Particles having aerodynamic diameters in the range of  $5\mu\text{m}$  to  $2\mu\text{m}$  will generally be deposited in the respiratory bronchioles whereas smaller particles having  
25 aerodynamic diameters in the range of 3 to  $0.05\mu\text{m}$  are likely to be deposited in the alveoli. So, for example, high dose efficiency for particles targeted at the alveoli is predicted by the dose of particles below  $3\mu\text{m}$ , with the smaller particles being most likely to reach that target site.

30 At present, many of the commercially available dry powder inhalers exhibit very poor dosing efficiency, with sometimes as little as 10% of the active agent present in the dose actually being properly delivered to the user so that it can have a therapeutic effect. Whilst isolated incidences of high percentages of dose delivered

have been possible in the prior art, it has not previously been possible to repeatedly and consistently achieve a dose efficiency at 5 or 3 $\mu$ m of 70% or more.

5 The reason for this lack of dosing efficiency is that a proportion of the active agent in the dose of dry powder tends to be effectively lost at every stage the powder goes through from expulsion from the delivery device to deposition in the lung. For example, substantial amounts of material may remain in the device. Material may be lost in the throat of the subject due to excessive plume velocity. However, it is frequently the case that a high percentage of the dose delivered exists in particulate  
10 forms of aerodynamic diameter in excess of that required.

Therefore, the present invention provides ways in which the loss of the pharmaceutically active agent is reduced at each of these stages, so that a high dosing efficiency can be achieved.

15 In the past, efforts to increase dosing efficiency and to obtain greater dosing reproducibility have tended to focus on preventing the formation of agglomerates of fine active particles. Such agglomerates increase the effective size of these particles and therefore prevent them from reaching the lower respiratory tract or  
20 deep lung, where the active particles should be deposited in order to have their desired therapeutic effect.

However, it has now been recognised that other loss of active agent occurs during known delivery of powder formulations.

25 Firstly, it is common for at least some of the dose of powder formulation, including some of the active agent, to be left in the dispensing device or in the dose storage container, such as a blister or capsule after use. There are several points at which such retention in the device may occur and these will be discussed in greater detail  
30 below.

Secondly, the dynamics of the cloud of powder released by the dispensing device will affect the amount of the powder and therefore of the active agent which will

become deposited in the throat of the user. Once again, active agent is effectively lost if it is deposited in the throat as it will not have any therapeutic effect. It has been found that the shape of the plume of powder formed by the device, and the velocity of the active particles in particular, will affect the deposition in the throat.

5

Thirdly, as recognised in the art, the fine particles of active agent tend to agglomerate and if these agglomerates are not broken up upon actuation of the dispensing device, the active agent particles will not reach the desired part of the lung. It has been found that the deagglomeration of the fine powder particles can be greatly enhanced by the addition of force control agents which reduce particle cohesion to allow agglomerates to break up more easily, as well as by the methods used to prepare the particles.

All of the ways of improving dosing efficiency disclosed herein may be added to techniques already known and used in the art in order to achieve a dosing efficiency at  $5\mu\text{m}$  of preferably at least 70%, preferably at least 75%, more preferably at least 80%, more preferably at least 85%, more preferably at least 90%, and most preferably at least 95%. The improvements may also lead to a dosing efficiency at  $3\mu\text{m}$  of preferably at least 60%, preferably at least 70%, more preferably at least 75%, more preferably at least 80%, more preferably at least 85%, and most preferably at least 90%. The improvements may also allow one to achieve a dosing efficiency at  $2\mu\text{m}$  of preferably at least 40%, preferably at least 50%, more preferably at least 55%, more preferably at least 60%, and most preferably at least 70%. These efficiencies are far greater than anything consistently achieved prior to this invention.

High dosing efficiency will have a large number of benefits. For example, as it is possible to repeatedly and reliably deliver a higher proportion of the active agent in a dose, it will be possible to reduce the size of the doses whilst still achieving the same therapeutic effect. Thus, if at present a usual dose of  $100\mu\text{mg}$  of an active agent is used to achieve a desired therapeutic effect and only 10% of the active agent is being properly delivered so that it actually has a therapeutic effect, a dosing



efficiency of 70% will allow the dose to be reduced to less than 15µg whilst still achieving the same therapeutic effect! This is clearly very attractive.

5 Use of the techniques disclosed herein allow high levels of dose reproducibility, in the order of less than plus or minus 10, 7.5, 5, 2.5 and, in best cases 1%, to be achieved. Additionally, the lower dose and the high reproducibility achieved by the present invention means that the therapeutic effect achieved by a given dose will be more predictable and consistent. This obviates the risk of having an unexpected and unusually high dosing efficiency with the conventional devices and powders, which  
10 could lead to an undesirably high dose of active agent being administered, effectively an overdose.

Furthermore, high doses of therapeutically active agents has long been linked with the increased incidence of undesirable side effects. Thus, the present invention may  
15 help to reduce the incidence of side effects by reducing the dose administered to all patients.

Yet another advantage associated with the higher dosing efficiency of the present invention is that it may be possible to achieve a longer-lasting therapeutic effect  
20 without having to increase the dose administered to the patient. The greater dosing efficiency means that a greater amount of a given dose is actually delivered. This can lead to a greater therapeutic effect and, in cases where the active agent does not have a short half-life, this will also mean that the therapeutic effect lasts for a longer period of time. In some circumstances, this may even mean that it is possible to use  
25 the present invention to administer an active agent in an immediate release form and achieve the same extended therapeutic effect as a sustained release form of the same active agent.

Naturally, the reduction in the amount of an active agent required to achieve the  
30 same therapeutic effect is attractive because of the cost implications. However, it is also likely to be deemed much safer by regulatory bodies such as the FDA in the United States.

Yet another advantage associated with the reduced throat deposition, in that any unpleasant taste effects of the active will be minimised. Also, any side effects such as throat infections caused by deposition of steroids on the throat are reduced.

5 Thus, according to a first aspect of the present invention, a dry powder dispensing device is provided with a pharmaceutical dry powder formulation, wherein the at least 70% of the dose of active agent in the dry powder is administered so as to have a therapeutic effect on the body of a patient. Preferably, the dosing efficiency remains at least 70% over numerous consecutive doses, i.e. the dosing efficiency is  
10 reproducible and constant, not an isolated good result.

This high dosing efficiency is achieved by ensuring that each stage of the dose delivery is optimised.

15 In a preferred embodiment of the present invention, the amount of active agent retained in the blister or capsule following actuation of the device is less than 15%, preferably less than 10%, more preferably less than 7% and most preferably less than 5% or 3%.

20 In another preferred embodiment, the amount of the powder formulation retained in the dispensing device, for example in the blister or capsule, in the mouthpiece and in any vortex chamber or equivalent device part, is less than 15%, preferably less than 10%, more preferably less than 7% and most preferably less than 5% or 3%.

25 In a yet further embodiment, upon being expelled from the dispensing device, the powder formulation has a dosing efficiency at 5 $\mu$ m of preferably at least 70%, preferably at least 75%, more preferably at least 80%, more preferably at least 85%, more preferably at least 90%, and most preferably at least 95%.

30 Preferably, upon being expelled from the dispensing device, the powder formulation has a dosing efficiency at 3 $\mu$ m of preferably at least 60%, preferably at least 70%,

more preferably at least 75%, more preferably at least 80%, more preferably at least 85%, and most preferably at least 90%.

5 Preferably, upon being expelled from the dispensing device, the powder formulation has a dosing efficiency at 2 $\mu$ m of preferably at least 40%, preferably at least 50%, more preferably at least 55%, more preferably at least 60%, and most preferably at least 70%. These efficiencies are far greater than anything consistently achieved prior to this invention.

10 In another preferred embodiment, the particles comprising a pharmaceutically active agent (active particles) have a mass median aerodynamic diameter (MMAD) of less than 10 $\mu$ m. Preferably the MMAD of the active particles is less than 7 $\mu$ m, more preferably less than 5 $\mu$ m, more preferably less than 2 $\mu$ m, and most preferably less than 1.5 $\mu$ m.

15 Finally, in another preferred embodiment, the amount of the active agent which is deposited in the throat of the user is less than 15% of the active agent in the metered dose. Preferably, throat deposition is less than 10%, more preferably it is less than 7% and most preferably it is less than 5% or less than 3%.

20 The foregoing powder retention, FPF, MMAD and throat deposition figures may be achieved by adopting one or more of the following adaptations to conventional dry powder dispensing devices, dry powder formulations or methods for preparing dry powder formulations. Combinations of these will lead to a dose delivery of at least  
25 70%.

Preferred embodiments of the invention will now be described in detail in the following sections of this specification. These embodiments represent various separate means of putting the present invention into effect. These embodiments  
30 may be used separately or in combination. When used in combination, the embodiments described in the following sections will provide enhanced results in terms of dosing efficiency and dose reproducibility.

Reference is made to various numbered tables of results and data in the following sections. Where a table is mentioned by number in the text, it is the table carrying that number in the section where it is mentioned, and not any similarly numbered table in a separate section of this specification, to which reference is made.

5

## Delivery Devices

### Dose Extraction

It is common for dry powder formulations to be pre-packaged in individual doses, usually in the form of capsules or blisters which each contain a single dose of the powder. In such devices, the doses will be accurately measured and consistent.

However, it is also known for powders to be held in a reservoir in a dispensing device. In such a case, a predetermined amount of powder is measured out and then dispensed by the device. Inevitably, such an arrangement will allow for some variation in the size of the dose between actuations of the same device. This will especially be the case where the amount of powder to be dispensed is relatively small, as it is difficult to accurately measure out small amounts of dry powder in such devices. Therefore, as the present invention is concerned with dose accuracy and reproducibility, devices which hold the dry powder to be dispensed in a reservoir are not preferred.

Actuation of the dispensing device refers to the process during which a dose of the dry powder formulation is removed from its rest position in the inhaler (be it in a blister or capsule or other container). The actuation may be caused by the user of the device inhaling in the case of a passive device, or by firing an active device. The actuation of a dispensing device occurs after the powder has been loaded ready for use within the device.

### Improved Evacuation of dose from packaging

As already mentioned above, it is common for some of the dose to be deposited in the inhaler when it is used or, for some of the dose to remain in the pack in which the dose is stored. Reference will now be made to embodiments of the invention

which seek to minimise the deposition of the dose on the inhaler and the retention of dose within the pack.

It will be appreciated that an important factor in maintaining the efficiency,  
5 accuracy and repeatability of the dose is to minimise the amount of drug that is retained in the inhaler mechanism and in the medicament pack in which the drug is stored prior to inhalation using the device. A conventional pack for an individual dose of dry powder medicament may include a gelatin capsule or a foil blister which is cold formed from a ductile foil laminate. A piercable foil laminate lid usually  
10 covers the blister which is heat sealed around the periphery of the blister. These types of package are preferred because each dose is protected from the ingress of water and penetration of gases such as oxygen in addition to being shielded from light and UV radiation and so offer excellent environmental protection. To administer a dose using a compressed gas powered inhaler, the capsule or foil lid is  
15 punctured by a piercing mechanism so that the drug can be entrained and carried to an aerosolising means, such as a nozzle, in a charge of gas which passes through the capsule or blister to the nozzle.

In an active inhaler of the aforementioned type, the same charge of gas provides the  
20 energy needed for both entraining the drug to evacuate the packaging and for aerosolising the drug once it has reached the nozzle. It is therefore important that the primary packaging does not present a significant restriction to the gas flow from the source of pressurised gas to the aerosolising nozzle. Bearing in mind that the amount of gas available for each dose is limited by what can be stored in a  
25 pressurised canister or generated in the device by the user by, for example, using a manually operated pump, the efficiency by which the drug is entrained in the airflow and so evacuated from its packaging must be as high as possible.

As mentioned above, a problem with known inhalation devices is that it is possible  
30 for not all of the drug to be entrained in the airflow each time the device is used because the blister or capsule, in which the dose is stored, is typically pierced in such a way that the gas flowing into the blister through the pierced foil only partially scours the blister surfaces before flowing out of the blister. This problem is

often exacerbated by the flap of foil cut by the piercing element as this can obscure parts of the blister from the flow of gas thereby restricting the free flow of gas throughout the entire volume of the blister and creating "dead" regions where gas flow is minimal or where secondary eddies form leading to powder becoming  
5 trapped. This trapped powder will have a significant detrimental effect on the repeatability and accuracy of the delivered dose as well as on the overall efficiency of the inhaler.

This aspect of the invention seeks to provide a dry powder inhaler in which all, or  
10 substantially all, of the internal surfaces of a pack containing a medicament dose are swept by the airflow so that substantially all of the drug is evacuated from the pack for delivery through an aerosolising nozzle and out of the device into the airway of a patient, thereby improving the delivered dose and hence the fine particle fraction of the delivered dose.

15 Accordingly, there is provided a dry powder inhaler for delivering a dose of medicament for inhalation by a user, the dose being contained in a medicament pack having a puncturable lid, the inhaler comprising a drug entrainment device including a drug outlet tube terminating with a primary piercing element to pierce an opening  
20 in said lid when a pack is located in the inhaler, a secondary piercing member to pierce a plurality of peripheral openings in said lid and, an airflow path to enable the supply of a charge of gas into the pack via said peripheral openings to scour the interior of a pierced pack such that substantially all of the dose is entrained in the gas and flows out of the pack via the drug outlet tube.

25 Preferably, the drug entrainment device includes an airflow inlet for the flow of air from the airflow path into a plenum chamber formed above the pierced lid of a pack, the inlet and the plenum chamber being configured such that a swirling airflow is generated in the plenum chamber.

30 In a preferred embodiment, the plenum chamber is substantially cylindrical in shape and the inlet intersects the curved wall of the chamber at a tangent thereto.

The secondary piercing member is preferably configured to direct the swirling flow of air in the plenum chamber into the pack through the openings formed therein by the secondary piercing member. Advantageously, the secondary piercing member comprises a plurality of blades with a vane depending from each blade for piercing  
5 the lid of the pack and to direct the swirling airflow into the pack. This introduces swirl into the blister to improve the entrainment of the dose by ensuring that the surfaces of the blister are swept by the gas flow. The generation of swirl in the blister or capsule containing the drug also reduces the speed of delivery of the drug to the aerosolising nozzle and therefore assists in reducing the likelihood of  
10 deposition of drug in the aerosolising nozzle. The maximum loading of powder passing through the nozzle must be kept below a threshold otherwise the nozzle can become overloaded and its efficiency reduces. If the dose is introduced over a longer period of time, the powder density in the nozzle is kept sufficiently low and its efficiency is maintained.

15 Many drug formulations suitable for inhalation are highly cohesive and tend to adhere to the internal surfaces of the inhaler. Therefore, in addition to evacuating the primary packaging efficiently, it is also equally important to prevent deposition of the drug on the internal parts of the inhaler once it has been entrained in the  
20 airflow and whilst it travels through the aerosolising nozzle and mouthpiece into a users airway as this can also have a detrimental effect on the delivered dose. Furthermore, deposited drug may become detached during subsequent use of the inhaler resulting in an unpredictable variation in the delivered dose. Although this problem is partially alleviated because each dose is individually packaged so that any  
25 drug remaining in a used primary package is removed and disposed of together with that primary package and so cannot have any effect on the delivered dose during subsequent uses of the inhaler, any residual drug remaining in unwiped or inaccessible parts of the inhaler can still have an appreciable effect on the delivered dose and in subsequent uses of the inhaler. Although the passage from the primary  
30 packaging to the nozzle does not present a significant restriction to the gas flow and hence regions where deposition may easily occur, the aerosolising nozzle is particularly susceptible to deposition as the medicament entrained in the airflow

enters the nozzle at high speed and over a very short period of time resulting in a proportion of the powdered medicament adhering to the walls of the nozzle.

5 The present aspect of the invention also seeks to overcome or substantially alleviate the aforementioned problem caused by residual drug remaining in the nozzle and in the flow path between the primary package and the nozzle during subsequent inhalations which can have a detrimental effect on the delivered dose of medicament and the fine particle fraction of the delivered dose.

10 Accordingly, there is also provided a medicament pack for use in an inhalation device comprising a drug storage chamber to contain a single dose of medicament and an aerosolising nozzle for generating an inhalable aerosol of the dose for inhalation by a user when a charge of gas is passed through the pack. Preferably the pack, incorporating both the drug storage chamber and the nozzle is disposed of  
15 after the drug has been discharged therefrom and is not re-filled.

In a preferred embodiment, the drug storage chamber and the aerosolising nozzle are integrally formed into a single module.

20 In one embodiment, the medicament pack comprises a blister having two compartments forming the drug storage chamber and the aerosolising nozzle respectively, each compartment being sealed with a piercable lid to enable an inhaler to pierce an inlet for the gas in the dose storage chamber and an outlet for the aerosolised dose in the aerosolising nozzle.

25 Preferably, an integral drug feed path communicates the drug storage chamber with the aerosolising nozzle.

30 In another embodiment, the drug storage compartment and the aerosolising nozzle are integrally formed from a moulded plastics material which is sealed with a piercable lid to enable an inhaler to pierce an inlet for the flow of gas into the dose storage chamber and an outlet for aerosolised dose in the aerosolising nozzle.



Alternatively, the drug storage compartment and the aerosolising nozzle are integrally formed from a moulded plastics material which is sealed with a piercable lid to enable an inhaler to pierce an inlet for the flow of gas into the drug storage chamber, an aperture being formed in the moulded plastic to form an outlet for the dose from the aerosolising nozzle.

In another embodiment, the medicament pack comprises a sheet in which is formed a plurality of drug storage chamber and nozzle pairs. Alternatively, a single nozzle and a plurality of drug storage chambers can be formed in the sheet, a drug feed path connecting each of the drug storage chambers with the nozzle.

In a preferred embodiment, the nozzle is a substantially cylindrical vortex chamber. The inlet from the drug feed tube intersects the chamber at a tangent and the outlet is coaxial with the longitudinal axis of the cylinder. The cylinder may be provided with a frustoconical portion in the region of the outlet for directing the airflow within the chamber towards the outlet.

Embodiments of this aspect of the invention will now be described, by way of example only, with reference to Figures 2(A) to 11(A) of the accompanying drawings, in which:-

FIGURE 1(A) represents a schematic diagram of a conventional pressurised gas powered active dry powder inhaler;

FIGURE 2(A) shows a cross-sectional side elevation of a portion of a drug entrainment device according to the invention, after piercing of a blister has taken place, for use in the pressurised gas powered inhaler of Figure 1(A);

FIGURE 3(A) illustrates a perspective view of the secondary piercing element used in the drug entrainment device shown in Figure 2(A);

FIGURE 4(A) shows a cross-sectional side elevation of a portion of the drug entrainment device of Figure 2 (A);

FIGURE 5(A) illustrates an alternative embodiment of the drug entrainment device shown in Figure 2(A);

FIGURE 6A(A), 6B(A) and 6C (A) illustrate top plan and side views respectively, of an alternative version of secondary piercing element which serves to impart a swirling motion to the airflow as it passes into and through the blister;

FIGURE 7A (A) and 7B (A) illustrate two cross-sectional side elevations of a  
5 modified version of the drug entrainment device shown in Figure 2 (A), using the secondary piercing element of Figure 6A (A) and 6B (A);

FIGURE 8A (A) to 8G (A) illustrate various versions of medicament packs which promote the entrainment and evacuation of the dose therefrom;

FIGURE 9 (A) illustrates another embodiment of blister pack for containing a dose  
10 of medicament for use in an inhaler;

FIGURE 10 (A) is a table to illustrate the performance of some of the medicament packs shown in Figures 8A (A) to 8G (A), and

FIGURE 11A(A) to 11G (A) illustrate various medicament packs incorporating a aerosolising nozzle according to the invention.

15

Referring now to the prior art drawing of Figure 1(A), a pressurised gas powered active dry powder inhaler 1 for aerosolising a powdered medicament for inhalation by a user is shown. The inhaler 1 comprises a vortex chamber or nozzle 2 having an exit port 3 and an inlet port 4 for generating an aerosol of medicament M. The  
20 nozzle 2 is located within a mouthpiece 5 through which a user inhales the aerosolised medicament M.

The powdered medicament or drug M is supplied to the nozzle 2 in a gas or airflow generated by a pump represented in Figure 1(A) as a piston pump 6 comprising a  
25 plunger 7 received in a pump cylinder 8 and a reservoir fluidly connected to the pump via a non-return valve. An airflow path 9 extends from the pump cylinder 8 to a drug entrainment device 10 disposed above a housing 11 to support a foil blister 12 containing a single dose of medicament (typically between 0.5 and 5mg). The blister 12 has a cold formed foil blister base 12a sealed with a hard rolled foil  
30 laminate lid 12b chosen to facilitate piercing. A drug feed tube 13 extends from the inlet port 4 of the nozzle 2 and into the housing 11 where it terminates in a piercing element 14. When the inhaler 1 is to be used, the reservoir is primed with a charge of compressed air by sliding the plunger 7 into the pump cylinder 8 (in the direction

of arrow "A" in Figure 1(A) to compress the air contained therein. Thereafter, the housing 11 and the drug feed tube 13 are moved relative to each other to cause the piercing element 14 to break the foil laminate layer 12b and penetrate into the blister 12 so that when the user inhales through the mouthpiece, a valve, which may  
5 be breath actuated, releases the charge of compressed air from the reservoir so that it flows along the airflow path 9 through the blister 12 where it entrains the medicament contained therein. The airflow together with the entrained drug flows up through the drug feed tube 13 and into the nozzle 2 via the inlet 4 where a rotating vortex of medicament and air is created between the inlet and outlet ports  
10 4,3. As the medicament passes through the nozzle 2, it is aerosolised by the high turbulent shear forces present in the boundary layer adjacent thereto as well as by the high level of turbulence in the vortex chamber and through collisions between agglomerates and other agglomerates and between agglomerates and the walls of the nozzle. The aerosolised particles exit the nozzle 2 via the exit port 3 and are inhaled  
15 by the user through the mouthpiece 5.

Figure 2 (A) illustrates part of a drug entrainment device 16 suitable for use with the conventional dry powder inhaler 1 illustrated in Figure 1. The drug entrainment device 16 improves access to the medicament contained in a blister 12 and ensures  
20 that its internal surface is swept and scoured by the airflow so that all or substantially all of the medicament (at least 95%) is entrained in the airflow and carried to the aerosolising nozzle thereby increasing the delivered dose and reducing the respirable dose variation between successive uses of the inhaler.

25 Prior to use, the blister 12 is inserted into the housing 11 within the inhaler 1 so that its piercable lid 12b is located below the drug entrainment device 16. The drug entrainment device 16 comprises a body 17 having a lower end 18 in which is formed a channel 19 to receive a sealing member 20 which makes contact with the blister 12 around the periphery of the laminate lid 12b so as to form a fluid tight  
30 seal therewith. An annular conduit 21 extends through the drug entrainment device 16 via a plurality of holes which join and widen at their lower end 18 in the vicinity of the sealing member 20 so as to form a plenum chamber 22 above the blister lid 12b when the sealing member 19 is in sealing engagement with the periphery

thereof. The opposite unillustrated end of the annular conduit 21 is connected via a valve to a source of pressurised gas such as a piston pump 6 as described with reference to Figure 1 (A). A central drug feed tube 23 extends axially through the annular conduit 21 and protrudes beyond the lower end 18 and the sealing member 20 and terminates in an angled face to form a central piercing element 24 for cutting the lid 12b of the blister 12. A secondary peripheral piercing member 25 is mounted on the central drug feed tube 23 adjacent to the angled end forming the central piercing element 24 for making multiple additional piercings in the surface of the blister lid 12b for reasons that will become apparent. The opposite end of the drug feed tube 25 is in communication with an aerosolising nozzle such as the nozzle 2 described with reference to the inhaler of Figure 1 (A).

A perspective view of the secondary piercing member 25 is shown in Figure 3(A) from which it will be appreciated that it comprises a star shaped ring incorporating a plurality of peripheral pointed piercing elements 26 which are deflected or angled out of the plane of the body 27 of the ring. In the illustrated embodiment, there are eight pointed piercing elements 26. However, it has been found that the improved drug entrainment provided by the invention is achieved with 4 piercing elements 26, although 8 piercing elements 26 have been found to provide the most significant advantages. An aperture 28 in the centre of the body 27 is dimensioned so as to engage with a mounting member 29 fixedly attached to the lower end of the outer surface of the drug feed tube 23 so that the pointed piercing elements 26 point in the same direction as the central piercing element 24 and towards the lid 12b of a blister 12 mounted in the housing 11 prior to use.

The secondary piercing member 25 is preferably manufactured by chemical milling from stainless steel sheet and subsequent pressing. A further advantageous embodiment for high volume manufacture is to integrate the primary and secondary piercing members 24,25 in a single injection moulded part. Possible materials include Polyetheretherketone (PEEK), liquid crystal polymer (LCP), Polyamide, Polysulphone (PS) Polyetherimide (PEI), Polyphenylsulphone (PPS) thermosetting plastics.

When the device is used, a blister 12 is inserted into the housing 11 and is brought up to meet the drug entrainment device 16 such that the central piercing element 24 and each of the secondary piercing elements 26 pierce the foil lid 12b and thereby create a pattern of openings in the surface of the blister 12b. When the valve (not  
5 shown) between the source of compressed air and the annular conduit 21 is opened, possibly in response to the user's inhalation, a charge of pressurised gas flows down through the annular conduit 21 and into the plenum chamber 22 and from there through the multiple piercings in the lid 12b formed by the secondary piercing elements 26 into the blister 12 so that the medicament is entrained in the airflow  
10 and flows up the drug feed tube 23 to the aerosolising nozzle.

It has been found that by using the aforementioned combination of central piercing element 24 and secondary peripheral piercing elements 26, the airflow through the blister is significantly improved so that nearly all of the medicament is entrained and  
15 evacuated from the blister 12 without any powder becoming trapped in spaces that have not been swept or scoured by the airflow. As a result, the delivered dose of medicament is improved, as is the fine particle fraction of total dose. It will be appreciated that the secondary piercing elements 26 create a smoothly controlled and predictable cut as the tip of each secondary piercing element 26 first creates a  
20 hole in the foil laminate 12a and "pushes" the cut foil flap out of the way. This should be contrasted with conventional pin type piercing elements which effectively burst through and tear the foil laminate forming unpredictable cut edges and flaps which can have a detrimental effect on the airflow through the blister 12.

Furthermore, the secondary piercing elements 26 act as baffles to prevent the  
25 airflow entering the blister 12 from passing straight through it from the openings made by the secondary piercing elements 26 to the outlet feed tube 23. It should also be noted that the charge of compressed gas flows directly into and through the blister rather than being used to induce a secondary flow of air through the blister. By allowing the charge of compressed gas to pass directly through the blister  
30 entrainment of the medicament is significantly more efficient.

The inventors have also found that a number of factors have a significant influence on the amount of drug that is consistently evacuated from the blister during

repeated use of the device. In particular, the shape, angle number and configuration of the secondary piercing elements 26 has a significant effect on the airflow through the blister 12, as does the diameter of the outlet feed tube 23 and its depth of penetration into the blister 12. To explain these factors in more detail, reference will  
5 be made to Figure 4(A) and Tables 1(A) to 3 (A).

A number of tests were conducted. These tests were part of a fractional factorial design experiment in which 10 variables were evaluated. A 3mg dose of pure micronised Sodium Cromoglycate was used with a reservoir of 15ml of air at a  
10 pressure of 1.5 bar gauge. The dose was contained in a foil blister of the type described and having the dimensions referred to in Table 3 (A) with reference to Figure 4 (A). All the variables together with the preferred ranges, most preferred ranges and preferred values are shown in Table 3 (A) which should be considered in conjunction with the drawing of Figure 3 (A).

15 Considering first the drug feed tube 23, Table 1 (A) shows the results of evacuation from the blister 12 using a drug feed tube 23 having a first internal diameter ("d" in Figure 4 (A)) of 1.50mm and another drug feed tube 23 having a second internal diameter "d" of 1.22mm. It can be ascertained from Table 1 (A) that both the  
20 average evacuation and the repeatability of evacuation are better with a 1.22mm diameter outlet tube than with a 1.5mm diameter feed tube 23. As can be seen from Table 3 (A), it was found that 1.22mm was the most preferred value for the internal diameter of the drug feed tube 23.

	Average evacuation over four sets of 10 tests	Average standard deviation of evacuation for four sets of 10 tests.
Outlet tube internal diameter (d) = 1.50mm	80.0	7.5
Outlet tube internal diameter (d) = 1.22mm	96.4	2.0

*Table 1(A) : Blister evacuation with different outlet tube diameters.*

Referring now to Table 2 (A), this shows the effect on the evacuation from a blister 12 when the distance by which the drug feed tube 23 protrudes into the blister 12 ("b" in Figure 4 (A)) is altered. In the first test, the drug feed tube 23 is positioned so as to protrude into blister 12 by 2.1mm and in a second test, the drug feed tube 23 is allowed to protrude into the blister 12 by a distance of 2.4mm. The results show that evacuation from the blister 12 is improved if the drug feed tube 23 protrudes less far into the blister 12. As can be seen from Table 3 (A), it was found that 1.6mm was the most preferred value for the depth of penetration of the drug feed tube 23 into the blister 12. However, it was found that penetration depths in the range 1.5 to 2.7mm produced satisfactory results although a range of between 1.5 to 1.9mm is largely preferred.

	Average % evacuation over four sets of 10 tests	Average standard deviation of evacuation for four sets of 10 tests.
Protrusion of outlet tube into blister (b) = 2.1mm	96.7	1.9
Protrusion of outlet tube into blister (b) = 2.4mm	79.6	7.6

*Table 2 (A) : Blister evacuation when the protrusion of the outlet tube is at two different settings.*

The evacuation quoted in Figures 6(A) to 9 (A) was measured as follows: Sodium Cromoglycate was weighed into an empty foil blister using a five figure balance and the fill weight recorded. The blister was then tested in an Aspirair device (described in the Applicant's earlier published PCT application No. WO 01/00262) delivering a reservoir of 10ml of air at a pressure of 1.5bar. The blister was then re-weighed and the new weight recorded (as evacuated weight). The evacuation efficiency of the entrainment device was calculated using the following formula:

$$\text{Evacuation} = \frac{\text{Fill Weight} - \text{Evacuated Weight}}{\text{Fill Weight}} \times 100$$

As mentioned above, Table 3 (A) lists all the additional factors that affect the evacuation of the drug from the blister 12 with particular reference to the dimensions and shape of the secondary piercing elements 26.

10

Feature	Preferred range	Most preferred range	Most preferred value
Inscribing diameter, $D$ of the secondary piercing elements	4 - 9mm	5 - 7mm	6.8mm
Height of secondary piercing member, $H$	1.2 - 2.0mm	1.4 - 1.8mm	1.6mm
Internal diameter, $d$ , of the outlet tube	1.0 - 1.5mm	1.20 - 1.30mm	1.22mm
Number of secondary piercing elements	4 - 10	6 - 8	8
Protrusion, $a$ , of the secondary piercing member into the blister	0.9 - 2.0mm	1.1 - 1.5mm	1.20mm
Protrusion, $b$ , of the outlet tube into the blister	1.5 - 2.7mm	1.5 - 1.9mm	1.6mm
Angle, $\alpha$ , of the face of the outlet tube to its axis	30 - 70 degrees	45 - 70 degrees	60 degrees
Angle, $\beta$ , of the secondary piercing elements to the axis of piercing	30 - 60 degrees	25 - 45 degrees	40 degrees
Blister diameter, $C$	4 - 12mm	6 - 9mm	8.0mm



Blister depth, e	2.0 - 3.50mm	2.5 - 3.0mm	2.8mm
------------------	--------------	-------------	-------

*Table 3 (A) : Preferred dimensions for the secondary piercing member of Figure 3 (A).*

The preferred dimensions for the secondary piercing member 25 have been selected  
5 for evacuation from a circular blister 12 having a diameter of 8mm and a depth of  
2.8mm. This size of blister 12 is sufficient to carry a dose of up to 5mg of typical  
inhalable medicaments and provides a headspace in the blister 12 to facilitate  
straightforward loading of the drug into the blister 12 in high volume production. A  
preferred number of secondary piercing elements 26 on the secondary piercing  
10 member 25 is eight. In order to create an even airflow around the periphery of the  
blister 12 it is desirable to provide a large number of piercings therein. However, it  
is also necessary to open up a sufficient area of the foil lid 12b to allow free flow of  
the air through the blister 12. With many piercings in a given size of blister 12 either  
the holes have to become smaller or they have to be pierced so close to each other  
15 that the foil 12b between them is likely to tear during piercing. Eight secondary  
piercing elements 26 can easily be accommodated within the circumference of the  
blister 12 whilst still allowing each secondary piercing element 26 to open up a  
sufficient area of flow into the blister 12. A larger blister 12 may allow a secondary  
piercing member 25 with more piercing elements 26 to be used and a smaller blister  
20 12 would allow fewer.

To facilitate even evacuation of the powder from the blister 12, the drug outlet tube  
23 would ideally have a flat end (i.e.  $\alpha = 90$  degrees). However, the tube 23 must  
also pierce a controlled cut into the lid 12b of the blister 12 and fully open a flap so  
25 that the powder exit is not impeded. If the angle  $\alpha$  is close to 90 degrees a higher  
force is required to pierce the foil lid 12b and the drug feed tube 23 pierces the lid  
12b in an uncontrolled manner. An angle of 60 degrees creates a controlled and  
repeatable cut in the foil 12b without unduly increasing the piercing force. The  
angle  $\beta$  influences how much pierced area is opened up to the airflow when the lid  
30 12b is pierced. An angle close to 45 degrees is desirable to gain the greatest open  
area when fully pierced, as shown in Figure 4 (A). For a given length from the root  
to the tip of the primary piercing element 24,  $l$ , the greatest open area for flow is

given when  $\cos\beta\sin\beta$  is maximised. This occurs when  $\beta = 45$  degrees. A slightly lower value has been chosen (40 degrees) in the preferred embodiment, to make the piercing process more tolerant of variations in piercing depth due to tolerance variations from device to device.

5

The dimensions that have the most significant influence on performance are the depths of the secondary piercing member 25 and the outlet tube 23 in the pierced position. If the pierced area is too small, the airflow resistance of the blister increases and the evacuation of powder from the blister is reduced. The preferred ranges for the secondary piercing member 25 are chosen to open as much pierced area in the top of the blister as possible without the piercing elements 26 touching the blister base 12a or punching a contiguous ring through the lid 12b. The preferred ranges for the outlet tube 23 are chosen such that the tube 23 fully cuts and opens a flap in the lid 12b but does not go too close to the base 12a of the blister 12. In order to fully open a flap, the tube 23 must pierce a full diameter hole therein. (i.e. pierce to a depth below the lid 12b of  $>OD/\tan \alpha$  where OD is the outer diameter of the outlet tube 23 and  $\alpha$  is as shown in Figure 4 (A)). If the tube 23 is close to the base 12a of the blister 12, the flow of powder from the blister 12 up the tube 23 is impeded and evacuation of powder is reduced. The point of the primary piercing element 24 of the outlet tube 23 should be 0.2mm and preferably greater than 0.5mm from the base 12a of the blister 12.

An alternative embodiment of drug entrainment device which also promotes efficient evacuation from a foil blister 12 is illustrated in Figure 5 (A). In this configuration, the secondary piercing member 25 is replaced by a plurality of solid pointed piercing pins 30 arranged around the central drug feed tube 23. In use, the drug entrainment device 16 pierces the lid 12b and the blister 12 is then retracted by a small distance indicated by "C" in the Figure. Retraction of the blister 12 moves the pins 30 out of the apertures they have created to allow access to the interior of the blister 12 by the air flow passing down through the annular conduit 21. In practice, the retraction mechanism would ideally comprise a cam arrangement associated with the blister 12 that causes the blister 12 to withdraw by a small distance once the lid 12b has been pierced. In this way, a number of peripheral inlet

holes 31 are formed in the lid 12b of the blister 12 together with the central hole formed by the central piercing element 24.

Table 4 (A) is a table comparing the performance of the second embodiment with that of the first embodiment. In these tests, the first embodiment provides improved evacuation from the blister, improved delivered dose and improved fine particle fraction of total dose. Furthermore, the first embodiment is preferred because no retraction mechanism is then required making the device simple to manufacture and operate. However, the performance of the drug entrainment device with retractable pins or retractable blister is also an improvement over known configurations.

Each result average of two MSLI tests	Delivered dose as % of total dose	FP dose as % of total dose	% evacuation from the blister
Retracting pierce head	92.2%	69.2%	97.7%
Non-retracting piercing star	93.7%	71.9%	99.6%

Table 4(A) : Blister evacuation and inhaler performance of the retracting drug entrainment device and the non-retracting drug entrainment device

In addition to altering the pattern and configuration of air inlets into and out of the blister 12, it has also been found that drug entrainment can be significantly improved by altering the shape of the secondary piercing member 25 to enhance the creation of a swirling airflow within the blister 12. Evacuation of the medicament from the blister 12 is thereby improved by ensuring that the internal surface thereof is completely swept by the gas flow.

Reference will now be made to the drawing of Figure 6A (A), 6B (A) and 6C (A) which illustrates a top plan view and two side elevational views of another embodiment of secondary piercing member 35 which would take the place of the secondary piercing member 25 mounted on the central feed tube 23 in the

embodiment of Figure 2 (A). As can be seen, the secondary piercing member 35 now comprises a ring having a plurality of arms or blades 36 extending from a central aperture 37 in opposite directions (four being shown in the embodiment of Figure 6 (A)) such that they extend substantially at right angles to the axis of the central feed tube 23 when the secondary piercing member 35 is mounted on the central feed tube 23 so that the central feed tube 23 extends through the aperture 37. On the side of the end of each arm 36 remote from the aperture 37, a flap is formed having an arcuately shaped outer periphery 38. Each flap is angled downwardly out of the plane of the arms 36 to form a vane surface 39 which is used to pierce the foil lid 12b. The vane surface 39 also serves to induce a swirling motion to the charge of compressed gas passing down through the annular conduit 21 and as it flows from the annular conduit 21 through the plenum chamber 22 and into the blister 12 via the openings therein created by the vanes 39 so as to cause the air to circulate around the blister 12 substantially around the axis of the central feed tube 23.

Although Figure 6B (A) shows the secondary piercing element 35 with the vanes almost entirely received within the blister 12, it will be appreciated that a proportion of the vane surfaces 39 may remain above and outside of the blister 12 so as to induce a swirling motion to the airflow within the plenum chamber 22 before it passes into the blister 12 through the apertures formed in the blister 12 by the vanes 39.

In a modified and preferred version of the aforementioned embodiment, as illustrated in Figure 7A (A) and 7B (A), a swirling motion, indicated by arrow "B", may be generated in the plenum chamber 22 above the blister 12 and secondary piercing member 35 by introducing some or all of the charge of compressed air into the plenum chamber 22 via a tangential gas inlet 40 rather than via the annular airflow conduit 21. In this case, the vanes 39 serve to maintain the swirling airflow generated in the plenum chamber as the air enters the blister. Without the vanes, a substantial portion of the swirling effect is lost as the air enters the blister and so the combination of the vanes and tangential flow inlet 40 prevent "straightening out" of the flow as it enters the blister 12.

The preferred dimensions and angles referred to on Figures 6C (A) and 7B (A) are shown in Table 5 (A). The size of the star, or secondary piercing member, is related to the size of the blister. In a preferred embodiment, the blister diameter is 8mm and its depth 2.8mm. If a different sized blister were to be employed, the piercing star would be scaled accordingly. The vanes of the secondary piercing element have two functions: to open up a sufficiently large piercing to allow air flow and to promote, or at least not diminish, swirl in the air as it enters the blister. Accordingly, their size is chosen to be as large as can practicably be accommodated by the blister. The vane profile is chosen to match the curved profile of the blister bowl although they do not touch the sides of the blister when in the pierced position. The angle of the vanes is chosen to be close to  $45^\circ$  to the foil to open up the largest possible flow area for a given size of vane. In the preferred embodiment, four vanes are used. In an ideal case a large number of vanes would allow swirling flow to enter the blister uniformly at all points around the periphery of the blister. However, piercing at many points can cause the foil to tear in an uncontrolled and therefore undesirable manner. Four vanes provide a controlled pierce and allow sufficient airflow into the blister. A larger blister might allow more vanes and a small blister would accommodate fewer. The dimensions of the plenum chamber 22 are chosen to create a strongly swirling airflow above the blister that will be transmitted to the dose therein. The inlet is sized to present a minimal resistance to the airflow compared with the resistance of the vortex nozzle downstream of the blister. The remaining dimensions such as the internal diameter (d) of the drug feed tube 23, the depth of penetration (b) of the drug outlet tube 23 into the blister, the angle ( $\alpha$ ) of the face of the outlet tube 23 to its axis, the blister diameter (C) and, the blister depth (e) are all the same as those shown in Table 3 (A).

Feature	Preferred range	Most preferred range	Most preferred value
Span, B of the secondary piercing element	4 - 9mm	6 - 7.5mm	7.2mm

Height of the secondary piercing element, $s$	1.2 - 2.0mm	1.4 - 1.8mm	1.6mm
Width, $w$ of piercing vanes	1 - 3mm		1.7mm
Number of secondary piercing elements	2-8		4
Angle, $\beta$ , of the piercing vanes to the axis of piercing	30 - 60 degrees	35 - 55 degrees	45 degrees
Plenum diameter, $D_o$	5 - 8mm		6.8mm
Plenum inner diameter, $D_i$	1.6 - 5mm		3.8mm
Plenum height, $H$	1 - 5mm		3.75mm
Plenum inlet height, $f$	30 - 100% of plenum height		1.5mm
Plenum inlet projected width, $g$	50-100% of $(D_o - D_i)/2$		1.5mm

*Table 5 (A) : Preferred dimensions for the secondary piercing element and plenum chamber of Figures 6(A) and 7 (A).*

As already mentioned, the introduction of a swirling airflow into the blister 12 increases the amount of medicament that is entrained in the airflow and evacuated from the blister 12 through the drug feed tube 23 to the aerosolising nozzle 2 and so the delivered dose and fine particle fraction of delivered dose is improved.

In addition to the foregoing, it is not always possible to ensure that the inhaler is used in the correct orientation by the user. It is therefore important that performance is not adversely affected for example when the inhaler is used upside down. A key benefit of introducing swirl to the powder in the blister is that the evacuation is less affected by the orientation of the inhaler.

Table 6 (A), below, shows the results of tests with the inhaler device held upside down during piercing of the blister. Foil blisters were filled with 3mg of Sodium Cromoglycate and then tested in a device with a reservoir volume of 15ml and a reservoir gauge pressure of 1.5bar. The emitted dose was measured using a DUSA apparatus and wet chemical assay to evaluate the quantity of drug. Five consecutive

shots were evaluated in this way and the mean and RSD (=standard deviation/mean) calculated.

With the standard plenum and secondary piercing element of Figures 2 (A) and 4 (A), the emitted dose drops by 9 percentage points when the blister is pierced upside down. The dose to dose variation over five shots is also significantly worse when pierced upside down with the RSD increasing from 2% to 10%. With the tangential airflow inlet to the plenum chamber 22 and the secondary piercing element of Figures 6 (A) and 7 (A), the mean emitted dose is improved and the change in performance when piercing the blister upside down is reduced to 3 percentage points. Importantly, the dose to dose variation over five shots is the same whether the blister is pierced upside down or in the correct orientation. This is a significant benefit over the standard arrangement because the swirl arrangement will be able to achieve more consistent dosing regardless of the orientation of use.

Standard piercing arrangement (secondary piercing element and inlet to plenum as in Figure 2(A))		Swirling flow in the blister (secondary piercing element of Figures 6 (A) and tangential inlet to plenum of Figure 7 (A))	
Correct pierce orientation	Pierced upside down	Correct pierce orientation	Pierced upside down
Mean ED: 86%	Mean ED: 77%	Mean ED: 96%	Mean ED: 93%
RSD: 2%	RSD: 10%	RSD: 2%	RSD: 2%

*Table 6 (A): Effect of inhaler orientation with standard piercing arrangement and swirl generating piercing arrangement*

Table 7 (A) shows the results obtained when the embodiment of Figure 2 (A) is tested with the secondary piercing member used in Figure 11 (A) and, when the embodiment of Figure 11 (A) is used with the secondary piercing element of Figure 3 (A). This shows that the best performance is obtained when the tangential airflow inlet to the plenum chamber 22 is combined with the secondary piercing element of Figure 11 (A).

Standard plenum (as in Figure 2(A)) with secondary piercing element of Figure 6(A)		Tangential inlet to plenum (as in Figure 7 (A)) with secondary piercing element of Figure 2 (A))	
Correct pierce orientation	Pierced upside down	Correct pierce orientation	Pierced upside down
Mean ED: 78%	Mean ED: 83%	Mean ED: 89%	Mean ED: 87%
RSD: 12%	RSD: 8%	RSD: 7%	RSD: 10%

*Table 7 (A): Effect of inhaler orientation with combinations of standard and swirl piercing arrangements.*

It has also been found that with a vortex nozzle aerosolising system it is desirable  
 5 that the maximum loading of powder going through the nozzle (i.e. mass of powder  
 per second) is kept below a threshold. Above this threshold the nozzle can become  
 overloaded and its efficiency is reduced and this has a detrimental effect on the  
 delivered dose. It is therefore desirable to spread out the introduction of the  
 powder to the nozzle over a period of time so that the powder density in the nozzle  
 10 is kept sufficiently low to maintain the nozzle's efficiency.

A further benefit of generating swirl in the blister is that the time over which the  
 powder is entrained in the airflow is increased, thus helping to achieve a more even  
 flow of powder into the aerosolising nozzle.

15

#### Dose Storage Pack

In addition to providing devices which enhances the evacuation of the drug from a  
 conventional blister 12, the inventors have also developed a new type of  
 medicament pack for storage of a drug dose especially for use with a dry powder  
 20 inhaler which is designed to minimise restriction to the gas flow from the  
 pressurised gas source to the aerosolising nozzle as well as generate a swirling air  
 flow between the air inlet and outlet to the packaging so as to entrain the drug and  
 evacuate substantially all of the drug from the pack.

25 Two preferred embodiments of medicament pack according to the invention are  
 illustrated in Figures 8A (A) and 8B (A). Figure 10 (A) is a table showing the



percentage of drug (3mg Sodium Cromoglycate – the entrainment device was attached to airflow control apparatus set up to deliver a flow rate of 2lpm for a period of 3 seconds, apart from the embodiment of Figure 8B (A) which was tested at 3lpm) evacuated using each of these chamber designs together with the results  
5 obtained using a number of other packages illustrated in the cross sectional views of Figures 8C (A) to 8G (A), as well as a conventional gelatin capsule, for comparison purposes.

As can be seen, the inventors have found that very efficient entrainment of dry  
10 powder is obtained when the dose is contained in a cylindrical swirl chamber 45 having facing opposite end walls and a tangential inlet 46 and outlet 47, the inlet 46 and outlet 47 being situated at opposite ends of the swirl chamber 45, as shown in the embodiment of Figure 8A (A) and 13AA (A) showing a perspective view, and two cross-sectional views, respectively. Preferably, the chamber diameter is 4mm  
15 and the its length is 7mm.

Slightly less efficient entrainment is obtained when the dose is contained in a cylindrical swirl chamber 48 provided with a tangential inlet 49 and an outlet 50  
20 coaxial with the longitudinal axis of the chamber, as shown in the perspective view of Figure 8B (A).

When one of the aforementioned medicament packs are used, the outlet of the swirl chamber 47,50 is connected to an aerosolising nozzle and the swirl chamber inlet 46,49 is connected to a valve which is in turn connected to a source of pressurised  
25 gas. In use, when the valve is opened, for example, in response to the user's inhalation, a charge of pressurised gas flows into the chamber 45,48 creating a swirling flow from the inlet 46,49 to the outlet 47,50, due to the shape of the chamber 45,48, which scours a very high proportion of the dry powder dose and delivers it through the outlet 47,50 to the aerosolising nozzle.

30

Another embodiment of medicament pack according to the invention is illustrated in the cross-sectional view of Figure 9 (A). As can be seen, the pack 51 comprises a plastic moulded housing 52 in the form of a short tube with open ends. A piercable

foil laminate 53a, 53b seals each open end. When the pack 51 is to be used, the foil 53a is pierced to allow an airflow inlet tube 54 to penetrate into the pack 51 and the foils 53b is pierced to allow a drug outlet tube 55 which communicates with an aerosolising nozzle 55a to penetrate into the pack. The foils 53a, 53b are pierced  
5 such that the air must pass substantially through the whole of the pack before it reaches the outlet so that the dose contained therein is entrained in the airflow. This type of pack may be used with a number of inhalers each having a different design as the pack can be pierced on both sides or, just on one side as with a conventional blister pack.

10

As previously mentioned, any deposition of drug within the device can have a significant effect on the variation of the delivered dose in successive uses of the device as well as on the fine particle fraction of total dose. Therefore, it is desirable to minimise the components of the device with which the drug entrained in the  
15 airflow can come into contact. To this end, the present invention also provides a medicament pack in which the drug storage chamber, the aerosolising nozzle and the drug feed tube between the nozzle and the blister are formed together in a single use integrated module that is discarded after each time the device is used. Figures 11A (A) to 11G (A) illustrate various embodiments of drug packages  
20 incorporating one or more aerosolising nozzles according to the invention. A preferred embodiment of pack 60 is illustrated in Figure 11A (A) in which the aerosolising nozzle 61 and the dose storage blister 62 are both formed from a cold formed foil base 64 covered with a puncturable lidding foil 65. The lid 65 is sealed to the base 64 preferably by heat sealing. The dose storage chamber 62 may be  
25 shaped as a half cylinder so as to promote the swirling flow of air as it enters via an inlet 66 formed therein as a result of piercing the lidding foil 65. The other chamber 61 may be configured as a nozzle or vortex chamber with a tangential inlet 67 and a central axial outlet 68 which is also formed by piercing the lid 65. When a charge of pressurised gas is passed into the drug storage chamber 62 via the inlet 66, the dose  
30 contained in the chamber 62 is entrained in the airflow. The entrained dose flows into the nozzle 61 via an intermediate conduit 69 between the drug storage chamber 62 and the nozzle 61 where the dose is aerosolised by the action of shear forces, turbulence and impaction. The aerosolised dose leaves the nozzle 61 via the outlet

port 68. Preferably, the diameter of the nozzle 61 is 8mm and its depth is in the range 1.0 to 2.8mm.

5 A modified version of the preferred embodiment of Figure 11A (A) is illustrated in Figure 11B (A). In this arrangement, the dose storage chamber 66 is cylindrical in shape has a tangential inlet 70 from an additional inlet cavity in which the inlet 66 is pierced by the inhaler.

10 Another embodiment is illustrated in Figure 11C (A). Instead of forming the dose storage chamber 62 and aerosolising nozzle 61 from foil using cold forming, the dose storage chamber 62 and nozzle 61 are formed from a plastic moulding 72 onto which the lid 65 is sealed, as with the embodiments of Figures 11A (A) and 11B (A). The advantage of moulding the nozzle 61 and dose storage chamber 62 allows greater accuracy and definition to be achieved in the geometry of the chambers  
15 61,62 than is achievable when the dose storage chamber 62 and nozzle 61 is formed entirely of foil.

Figure 11D (A) shows a modified version of the combined dose storage chamber 62 and nozzle 61 of Figure 11C (A). Instead of forming the outlet 68 from the nozzle  
20 61 in the lidding foil 65, an outlet 73 is formed in the moulded plastic component which may be sealed with a foil flap 74 prior to use and which is peeled away to open the outlet 73. This improves the definition achievable in the geometry of the outlet 73.

25 Another embodiment is illustrated in Figure 11E (A). In this version, there is no intermediary conduit 69 between the drug storage chamber 62 and the nozzle 61. Instead, this is formed in the inhaler which pierces an outlet 75 for the drug in the foil covering the drug storage chamber 62 in addition to the inlet 66. The inhaler must also pierce an opening in the lid 65 covering the nozzle 61 to form an inlet for  
30 the compressed air together with the drug entrained therein. The outlet 73 may be formed in the plastic moulding as described with reference to Figure 11D (A). The advantage of this arrangement is that the powder is contained in the dose storage

chamber 62 and cannot migrate into the vortex chamber 61 until the lid 65 is pierced when the pack is used.

Further arrangements are shown in Figures 11F (A) and 11G (A). In the embodiment of Figure 11F (A), multiple drug storage chambers 62 are shown which feed a single aerosolising nozzle 61. It will be appreciated that this embodiment is not as efficient as those which embody a single use nozzle as deposition of drug may occur during, for example, evacuation of the first dose storage chamber 62a, which will have an affect on the delivered dose when the second and/or third dose storage chambers 62b,62c are used together with the same nozzle 61. Figure 11G (A) illustrates multiple dose storage 62a,62b,62c and nozzle 61a,61b,61c pairs in a single assembly. Preferably, the dose storage and vortex chambers are formed from cold formed foil covered with piercable lidding foil.

Although the embodiments described in this part of the application refer primarily to active, i.e. powered, dry powder dispersion inhalers, the concepts apply equally to passive dry powder inhalers where the dispersion energy is provided by the user of the device. As will be appreciated by a skilled person, the dimensions of the air pathways through the entrainment blister or chamber and the aerosolising nozzle would need to be enlarged in order to provide a sufficiently low pressure drop for passive inhalation. For example, this could be achieved by scaling up the size of the device in proportion.

## Valve Enhancements

As discussed briefly above, it is necessary to ensure that the dry powder including the therapeutically active agent is completely expelled from the pack in which it is stored as well as from the delivery device so that there is minimal deposition within the device. Another way of achieving this will now be described below.

To increase the efficiency of entrainment of the dose, it is important that the valve which releases the charge of compressed gas is opened quickly so that the charge enters the blister over a very short period of time and the dose receives sufficient

fluid energy from the gas so that all or substantially all of the dose is entrained in the airflow. If the valve opens slowly, the dose will receive the charge of gas over a longer period with less energy and so some of the dose may not be entrained in the airflow resulting in a reduction in the efficiency of the device.

5

It will be appreciated from the foregoing, that a valve is required that both opens rapidly and, presents a minimum resistance to flow once open. The speed by which a valve opens may be defined by the shortest time between the valve being fully closed and the valve being fully open. Additionally, it is also desirable that the  
10 forces required to operate the valve are as low as possible to reduce strain on components and facilitate ease of operation.

The effort required to keep a valve closed against a pressure is called the sealing force. The sealing force comprises two components: the pressure force  $F_p$  and the  
15 seat force  $F_s$ . The pressure force is the force generated by the pressure within a chamber and is given by the equation  $F_p = PA$ , where  $P$  is the pressure acting on the valve and  $A$  the area over which the pressure acts. Depending on the configuration of the valve, the pressure force may act to bias the valve towards the open or the closed position. The seat force,  $F_s$ , is the force required to create a continuous loop  
20 of intimate contact between the compliant part of the valve (the seal) and the valve seat.

An inhaler having a valve which is sealed by an immobilising mechanism and arranged so that the pressure acting on the valve acts to bias it towards an open  
25 position is known from US 6,029,662. Although the valve opens rapidly because the compressed gas biases the valve to the open position and so assists opening, it is possible for the valve to leak because the closing mechanism has to oppose the pressure force generated in the chamber rather than use this pressure force to assist sealing. Therefore, in practice a high closing force to ensure sealing is required. A  
30 further disadvantage with this type of valve is that it must be re-set prior to re-pressurisation of the chamber.

To reduce the pressure force that must be overcome to seal the valve, the area of the valve exit orifice is minimised. However, this introduces the additional drawback that the speed of flow through the valve is considerably reduced so that although the valve opens rapidly, the speed at which the chamber empties is limited by the  
5 small size of the valve exit orifice.

In an alternative valve configuration, the pressure in the chamber biases the valve into a closed position to reduce the risk of leakage. The advantage of this approach is that the only force required to keep the valve closed is the seat force and this  
10 force may be provided by the pressure force. However, to open the valve, the pressure force acting on it must be overcome and this requires an actuation force much greater than the pressure force, especially if the valve is to be opened rapidly.

It will be appreciated from the foregoing that each of the above described types of  
15 valve embody an undesirable compromise. With a valve configuration of the first type, the valve opens rapidly but requires high forces to hold the valve closed and needs to be reset, for example by manually resetting. In the second case, the valve has a low closing force and can potentially be self-resetting, but a high opening force is needed for rapid opening.

20 The present invention seeks to provide a dry powder inhaler having a valve that overcomes or substantially alleviates the disadvantages associated with an inhaler having either of the types of valve described above.

25 According to one embodiment of the invention, there is provided a dry powder inhaler for delivering a dose of medicament for inhalation by a user, including a drug entrainment device and a valve actuable by a user to cause pressurised gas to flow through a dose of medicament disposed in the drug entrainment device to  
30 entrain said dose in the gas, the valve comprising a valve member configured such that, in a first mode, pressurised gas biases the valve member into an open state to allow the flow of gas through the valve and, in a second mode, pressurised gas biases the valve member into a closed state to prevent the flow of gas through the

valve. Although reference is made to pressurised gas, it should be understood that this includes compressed air in addition to gases.

5 Preferably, the valve is configured such that pressurised gas acts over both sides of the valve member when it is in the closed state. Although the pressure of the gas acting over each side of the valve member may be the same, it may act over a larger cross-sectional area of one side of the valve member than the pressurised gas acting over the other side of the valve member. This means that for the same given pressure, the force acting over a greater cross sectional area of the valve will be  
10 larger. As the force generated over one side of the valve member is larger, the valve member is maintained in a closed state.

In a preferred embodiment, the valve is configured such that the valve member moves from the closed state to the open state in response to a change in pressure of  
15 the gas acting on one side of the valve member relative to the pressure acting on the other side of the valve member.

The inhaler preferably comprises a reservoir for pressurised gas and a valve orifice for the passage of pressurised gas from the reservoir through the drug entrainment  
20 device. A first side of the valve member forms a seal with the valve orifice when in the closed state such that pressurised gas in said reservoir acts over only a portion of said first side of the valve member defined by the cross-sectional area of the valve orifice.

25 Conveniently, the valve orifice is located at the mouth of a tube in communication with the reservoir, the tube including a valve seat at the end thereof for cooperation with said first side of the valve member to form a seal therewith when the valve member is in the closed state.

30 The valve is preferably configured such that when the seal between the first side of the valve member and the valve seat is broken, the pressure of the gas in the reservoir acts over substantially the entire surface of the first side of the valve member to bias the valve member into the open state. As the pressure acting over

one side of the valve is discharged, a threshold is reached at which the pressure of the gas in the reservoir acting over the other side of the valve is sufficient to cause the valve member to lift from the valve seat. When this occurs, the whole of the underside of the valve member is exposed to the pressure of the gas in the reservoir causing it to open rapidly.

In one embodiment the inhaler includes biasing means to bias the valve member into a closed state when the pressure of the gas in the reservoir has been discharged through the valve. This re-sets the valve member automatically into the closed state and removes any need to pressurise the other side of the valve member in advance of pressurisation of the reservoir.

The biasing means may conveniently comprise a spring.

In a preferred embodiment, means are provided to discharge the pressure that biases the valve member into the closed state to cause the valve member to move from the closed to the open state.

The valve preferably includes a primary chamber in which pressure to bias the valve member into the closed state is generated and said means for discharging the pressure that biases the valve member into the closed state comprises a discharge port in the primary chamber.

The valve advantageously includes means for opening the discharge port to atmosphere. Most advantageously, the means for opening the discharge port is breath actuated.

When the valve is breath actuated, it preferably includes a secondary valve member which is movable, in response to inhalation by a user, from a first closed position in which the discharge port is not in communication with the primary chamber to prevent discharge of the primary chamber to the atmosphere, into a second open position in which the discharge port is in communication with the primary chamber to discharge the primary chamber to the atmosphere.



The secondary valve member is preferably configured such that the pressure in the primary chamber acts over a smaller cross-sectional area of a first side of the secondary valve member than the cross-sectional area of the other side of the valve member over which atmospheric pressure acts, when the secondary valve member is in the closed position.

Conveniently, the valve member and secondary valve member may be flexible diaphragms.

10

The inhaler also preferably includes means for charging the reservoir with pressurised gas or air. Most preferably said means is also operable to charge the primary chamber.

15 A conduit may communicate the reservoir with the primary chamber to facilitate the charging of the primary chamber during charging of the reservoir with pressurised gas.

Embodiments of the invention will now be described, by way of example only, and with reference to Figures 2 (B) to 9 (B) of the accompanying drawings, in which:-  
FIGURE 1(B) is a schematic drawing of a conventional pressurised gas powered active dry powder inhaler;

FIGURE 2(B) is a simplified cross-sectional side elevation of a valve assembly according to the invention;

25 FIGURE 3(B) is a first modified version of the valve assembly illustrated in Figure 2(B);

FIGURE 4(B) is second modified version of the valve assembly illustrated in Figure 2(B);

FIGURE 5(B) is a third modified version of the valve assembly illustrated in Figure 2(B);

30

FIGURE 6(B) is a perspective view of an actual breath actuated valve module forming part of an inhaler according to the invention;

FIGURE 7(B) is top plan view of the breath actuated valve module shown in Figure 6(B);

FIGURE 8(B) is a cross-sectional side elevation of the breath actuated valve module taken along the section A-A in Figure 7(B);

5 FIGURE 9(B) is a cross-sectional side elevation of the breath actuated valve module taken along the section B-B in Figure 7(B).

A schematic drawing of a conventional gas powered dry powder inhaler for aerosolising a powdered medicament for inhalation by a user is illustrated in Figure 10 1(B). The inhaler 1 comprises a vortex chamber or nozzle 2 having an exit port 3 and an inlet port 4 for generating an aerosol of medicament M. The nozzle 2 is located within a mouthpiece 5 through which a user inhales the aerosolised medicament M.

15 The dose is supplied to the nozzle 2 in an airflow generated by a pump represented in Figure 1(B) as a piston pump 6 containing a plunger 7 received in a pump cylinder 8. An airflow path 9 extends from the pump cylinder 8 to a drug entrainment device 10 comprising a housing 11 to support a foil blister 12 containing a single dose of medicament (typically between 0.5 and 5mg). The blister 20 12 has a cold-formed foil blister base 12a sealed with a hard rolled foil laminate lid 12b chosen to facilitate piercing. A drug feed tube 13 extends from the inlet port 4 of the nozzle 2 and into the housing 11 where it terminates in a piercing element 14. When the inhaler 1 is to be used, the pump 6 is primed with a charge of compressed air by sliding the plunger 7 into the pump cylinder 8 (in the direction of arrow "A" 25 in Figure 1 (B)) to compress the air contained therein. Thereafter, the housing 11 and the drug feed tube 13 and moved relative to each other to cause the piercing element 14 to break the foil laminate layer 12a and penetrate into the blister 12 so that when the user inhales through the mouthpiece 5 a valve 15, which may be breath actuated, releases the charge of compressed gas from the cylinder 8 so that it 30 flows down the airflow path 9 into the blister 12 and up through the drug feed tube 13. As the air passes through the blister, the dose contained therein is entrained and is carried by the airflow up the drug feed tube 13 and through the inlet port 4 into the nozzle 2.

A rotating vortex of medicament and air is created in the nozzle 2 between the inlet and outlet ports 4,3. As the medicament passes through the nozzle 2, it is aerosolised by the high turbulent shear forces present in the boundary layer adjacent thereto as well as by the high level of turbulence in the vortex chamber and through collisions between agglomerates and other agglomerates and between agglomerates and the walls of the nozzle 2. The aerosolised dose of medicament and air exit the nozzle 2 via the exit port 3 and is inhaled by the user through the mouthpiece 5

10 Figures 2 ((B) to 5 (B) represent three highly simplified representations of valves that operate according to the principle of the invention and reference is first made to them for the purpose of explanation and to facilitate understanding of the invention.

15 Referring now to Figure 2(B), there is shown an assembly 20 comprising a reservoir 21 containing a source of compressed gas or air. The reservoir 20 may be charged using a variety of means including a piston pump, a multiple action pump charging an accumulator via a check valve, a canister of compressed gas or a canister of propellant such as HFA. The reservoir 21 has a compressed gas outlet orifice 22 defined by a tube 23 terminating in a seat 24 through which gas may pass from the reservoir 20 via a servo chamber 25 and out of the assembly 20 through an exit orifice 26 to drug aerosolising means via a drug entrainment device (not shown). A valve member 27 is associated with the outlet orifice 21 to selectively permit or prevent the flow of compressed gas from the reservoir 21 into the servo chamber 25.

25 The valve member 27 comprises a flexible diaphragm 28 which extends across the end of the tube 22. A central region 29 of the diaphragm contacts the seat 24 to make a seal therewith when the valve is closed. It will be appreciated that only a relatively small central region 29 of the underside of the diaphragm 28 will be exposed to the effects of the pressure acting against it due to the source of compressed gas in the reservoir 20. The size of this region depends on the internal cross-sectional area of the tube 23.

The diaphragm 28 is located within and extends between the walls of a housing 30 to define a space or primary chamber 31 above the diaphragm 28, for reasons that will now be described.

5

It will be appreciated that when the reservoir 21 is pressurised to a pressure  $P_{res}$ , a pressure force will be acting over the central region 29 of the diaphragm 28 which will tend to cause the diaphragm 28 to lift off the seat 24 and thus allow the gas to escape from the reservoir 21. To counteract this pressure force against the central  
10 region 29 of the diaphragm 28, the primary chamber 31 is also pressurised to a pressure  $P_p$  such that the force acting against the opposite side of the diaphragm 28 is sufficient to hold the central region 29 against the seat 24 and therefore keep the valve closed. The sealing force that must be generated by the pressure  $P_p$  in the primary chamber 31 which is sufficient to keep the valve closed is the sum of the  
15 seat force  $F_s$  of the diaphragm 28 against the seat 24 and the force  $F_p$  due to the pressure  $P_{res}$  acting on the diaphragm 28 over the central region 29 of the diaphragm 28. Typically, the primary chamber 31 only needs to be pressurised to the same pressure as the reservoir 21, i.e.  $P_p = P_{res}$  to keep the valve closed. This is because the pressure  $P_p$  acts over a much greater surface area of the diaphragm 28 than does  
20 the pressure  $P_{res}$ .

The diameter of the tube 23 may be sufficiently large so as not to impede flow once the diaphragm 28 is open. The cross-sectional area of the tube 23 is limited only by needing to be smaller than the total cross sectional area of the diaphragm 28 so that  
25 the net force acting on the diaphragm is sufficient to ensure that its central region 29 seals against the valve seat 24, i.e. net force > seat force  $F_s$ .

To open the valve, it is necessary to lift the diaphragm 28 so that the seal is broken between the central region 29 of the diaphragm 26 and the seat 24. To do this, the  
30 diaphragm 28 can be lifted using a mechanical device (not shown). It will be appreciated that once the diaphragm 28 has been unseated, the pressure  $P_{res}$  will now act over the whole of the underside of the diaphragm 28 rather than just the central region 29 thereof. As a result, the sealing force required to keep the valve

closed and the force due to the pressure in the chamber 31 acting over the upper side of the diaphragm 28 will be equalised. As the net force now acting on the diaphragm 28 is zero, the valve opens rapidly.

5 To reset the valve by moving the diaphragm 28 back to its original closed position in which it locates against the seat 24, the primary chamber 31 is pressurised before the reservoir 20 so that the net force on the diaphragm 28 exceeds the required seat force between the central region 29 of the diaphragm 28 and the seat 24.

10 A first modified version of the assembly described with reference to Figure 2 is shown in Figure 3(B). In this arrangement, advanced pressurisation of the primary chamber 31 is rendered unnecessary as a biasing means, such as a spring 29, is disposed between the diaphragm 28 and the housing 30 and serves to bias the central region 29 of the diaphragm 28 against the seat 24 thereby making the valve  
15 self-resetting.

A second modified version of the assembly described with reference to Figure 2(B) is shown in Figure 4(B). In this arrangement, the diaphragm 26 is lifted from its seat 23 to open the valve by allowing pressure in the chamber 31 to decay to a point at  
20 which the force  $F_p$  due to the pressure acting on the diaphragm 28 is no longer sufficient to hold the central region 29 of the diaphragm 28 against the seat 24. Preferably, the pressure is allowed to decay by opening a port 32 in the housing 30 to communicate the chamber 31 to the atmosphere. This embodiment is particularly advantageous because the reservoir pressure  $P_{res}$  acts to force the diaphragm 28  
25 open therefore the discharge from the reservoir 21 is particularly rapid.

Although a mechanical device can be provided for opening and closing the port 32, the modified version of Figure 2(B) can be adapted so that the port opens in response to the user's inhalation, as will now be described with reference to Figure  
30 5(B). For this purpose, the assembly is provided with a secondary valve member 33 which may be a breath actuated diaphragm 34, a vane or piston (not shown) mounted in a second housing 35 in a similar manner to the first diaphragm 28. The breath actuated diaphragm 34 has a central region 36 which seals against a seat 37

formed at the end of a tube 38 which extends from an aperture 40 that communicates the primary chamber 31 with the underside of the central region 36 of the breath actuated diaphragm 34 to block the flow of air from the primary chamber 31 to a primary chamber dump port 39 which is open to atmosphere. The  
5 upper surface of the secondary diaphragm 34 is in communication with the mouthpiece 5 via an opening 38.

When a user inhales through the mouthpiece 5, the central region 36 of the breath actuated diaphragm 34 is lifted from its seat 37 due to the lower pressure created in  
10 the mouthpiece 5 which is transmitted to the upper surface of the breath actuated diaphragm 34 via the opening 38. When the breath actuated diaphragm 34 is unseated, the primary chamber 31 is opened to the atmosphere via the aperture 40, the tube 38 and the primary chamber dump port 39. When this occurs, the pressure in the primary chamber 31 reaches a threshold at which the diaphragm 28 lifts  
15 rapidly releasing the charge of compressed gas from the reservoir 21 through the servo chamber 25 and the exit orifice 26 to deliver the dose of medicament via an airflow conduit 41 to a drug entrainment device and aerosolising means 43. It will be appreciated that when the breath actuated diaphragm 34 is lifted from its seat 37 when the user inhales, the pressure of the gas in the primary chamber will then act  
20 over the whole of the cross-sectional area of the underside of the breath actuated diaphragm rather than just over the central region 36. The pressure of the air in the primary chamber 31 therefore assists the breath actuated diaphragm 34 to open.

A biasing means such as a spring 44 acts against the breath actuated diaphragm 34  
25 so that when the charge of gas in the primary chamber 31 has discharged, the breath actuation diaphragm 34 is automatically returned to the closed position by the spring 44. This arrangement allows the breath actuation diaphragm 34 to be self-resetting without the need for a separate resetting action by the user.

30 It will be appreciated that the valve uses a servo type action. When the diaphragm 28 is opened to a certain extent, high pressure air from the reservoir 21 floods the servo chamber 25 below the diaphragm 28 which then empties via the downstream drug entrainment and aerosolising means 43. If the flow resistance of the

downstream entrainment device and aerosolising means 43 is much greater than that of the tube 22, the pressure in the servo chamber 25 will rapidly become almost equal to the reservoir pressure 21. This pressure acts on the underside of the diaphragm 28 and holds it open whilst the reservoir 21 is discharged.

5

It has been found by the inventors that the diameter of the chamber dump port 39 needs to be sufficiently large to facilitate rapid discharge of the primary chamber 31. If the primary chamber 31 is too small, the breath actuated diaphragm 34 can “bounce” or “flutter” causing the primary chamber 31 to discharge in stages compromising the efficiency of the inhaler. The cross-sectional area of the chamber dump port 39 should be greater than  $0.15\text{mm}^2$  and should preferably be between  $0.15\text{mm}^2$  and  $0.75\text{mm}^2$ . In a most preferable embodiment, the cross-sectional area of the chamber dump port 37 is  $0.4\text{mm}^2$ . If the dump port 39 has a cross-sectional area less than  $0.15\text{mm}^2$ , a delay is introduced between movement of the second diaphragm and the opening of the main valve diaphragm 26. Such a delay is undesirable, although if the dose is to be delivered later during an inhalation by the user, the dump port 39 could be designed so as to introduce a desired delay.

Although the chamber 31 can be provided with its own means to enable it to be pressurised, it is particularly desirable to use the means for charging the reservoir 21 to also charge the chamber 31. This can be achieved by, for example, incorporating a port (not shown) communicating the chamber 31 with the reservoir 21 which is closed prior to actuation of the valve.

25 The presence of a port between the reservoir 21 and the chamber 31 also prevents premature firing of the valve in the event of a leak from between the breath actuated diaphragm 34 and its seat 37 which can be caused due to, for example, imperfect sealing as a result of dirt ingress therebetween. As the diaphragm 28 is designed to open when the pressure difference between the primary chamber 31 and the reservoir 21 drops below a particular threshold, the possibility exists that a leak could cause the valve to open prematurely wasting the drug dose. However, it has been found that the diaphragm 28 will not servo open if the pressure is reduced sufficiently slowly and will instead open fractionally to allow gas to escape so that

the reservoir pressure will drop in proportion to the slowly decreasing pressure in the chamber 31.

5 The assembly may be additionally provided with a control orifice (not shown) communicating the primary chamber 31 with the reservoir 21 so that any pressure drop in the chamber 31 due to a leak therein which is smaller than the control orifice constriction will be topped up from the reservoir 21.

10 Reference will now be made to the breath actuated valve module 50 forming part of an actual dry powder inhaler according to the invention which is illustrated in Figures 6(B) to 9(B). The breath actuated valve module 50 works as described with reference to Figures 2(B) to 5(B) and so like components will be referred to by the same reference numerals for ease of understanding.

15 A perspective view of the breath actuated valve module is shown in Figure 6(B) and comprises an upper casing part 53 mounted on a lower casing part 54 using screws 55. The exit 26 through which the compressed air flows from the module to the aerosolising nozzle via the drug entrainment device can be seen, as can a connector 56 which connects the valve module 50 to the mouthpiece and through which the  
20 breath actuated diaphragm is controlled in response to inhalation by a user.

Figure 7(B) illustrates a top plan view of the module 50 shown in Figure 6(B) and Figures 8(B) and 9(B) illustrate two cross-sections taken along the lines A-A and B-B respectively. The cross-sectional illustrations show the outlet orifice 22 from the  
25 reservoir 21 and the tube 22 with the diaphragm 28 seated against the valve seat 28. The primary chamber 31 extends across the module and discharge of the compressed air from this chamber 31 through the chamber dump port 39 is selectively prevented by the breath actuated diaphragm 34 which is located against the valve seat 37 at the end of tube 38.

30



## Powder Entrainment & De-Agglomeration

Upon actuation of the dispensing device, the powder formulation becomes entrained in an airflow which is generated (actively or passively) within the device. The manner in which the powder becomes entrained in this airflow and is then expelled from the device is also crucial in ensuring that as much of the active agent is dispensed as possible.

It is not simply a question of entraining as much of the powder as possible in the airflow. In addition, the entrainment should be such that the plume of powder expelled from the device is such that deposition of the active agent in the throat is minimised. Finally, it is also desirable for any agglomerates in the powder to be broken up as the powder becomes entrained in the airflow.

This deagglomeration is possible where the airflow is controlled so that it applies shear forces on the powder formulation as it becomes entrained in the airflow. These shear forces can serve to break up agglomerated particles, thereby enhancing the FPF and FPD of the powder.

One way in which deagglomeration of agglomerates in the dry powder formulation may be achieved during powder entrainment within the dispensing device is to arrange the airflow so that it applies shear forces to the powder, breaking the agglomerates apart.

Whilst this may occur, as discussed above, in connection with the emptying of the blister or capsule in which the individual doses are held prior to actuation of the inhaler device, such deagglomeration may also occur as the powder becomes entrained in the airflow.

In addition to deagglomeration, it is also very important for the entrainment of the powder in the airflow to be as efficient as possible, leaving as little powder behind. Finally, another consideration is the dynamics of the powder as it leaves the inhaler device. Once again, this is linked to the entrainment of the powder in the airflow. As discussed below in greater detail, the movement of the active particles in the

plume created by the inhaler will affect the amount of active agent which is deposited in the throat of the user, rather than in the lung.

5 Naturally, the entrainment of the dry powder formulation in an airflow will be affected by the properties of the formulation itself, as well as the device used. For example, entrainment of a fine powder, that is, one which does not include a population of larger particles, such as carrier particles is more difficult than entrainment of a powder comprising a combination of large and fine particles. However, the arrangement of the device itself also affects the powder entrainment. 10 In particular, it is the path of the airflow through the powder and out of the device which will determine any deagglomeration, powder entrainment and powder velocity, etc.

15 According to an aspect of the present invention, a method is provided comprising entraining agglomerated particles in a gas flow. The method comprises depositing the agglomerate particles onto one or more surfaces, and applying, via the gas flow, a shear to the deposited agglomerated particles to deagglomerate them.

20 In one embodiment, the method comprises entraining a powdered substance in a gas flow stream from an inlet port of a vortex chamber having a substantially circular cross-section. The method further comprises directing the gas flow through the vortex chamber in a tangential direction; directing the gas flow through the vortex chamber so as to aerosolise the powder composition; and directing the gas flow with the powder composition out of the vortex chamber in an axial direction 25 through an exit port. Preferably, the velocity of the gas flow at a distance of 300mm outside of the exit port is less than the velocity of the gas flow at the inlet port.

30 In another embodiment, the method comprises entraining a powdered composition including agglomerated particles in a gas flow upstream from an inlet port of the vortex chamber. In this embodiment, the method comprises directing the gas flow through the inlet port into the vortex chamber; depositing the agglomerated particles onto one or more of the walls of the vortex chamber; applying, via the gas flow through the vortex chamber, a shear to the deposited agglomerated particles to

deagglomerate the particles; and directing the gas flow, including the deagglomerated particles, out of the vortex chamber; wherein the velocity of the gas flow at a distance of 300mm outside the exit port is less than the velocity of the gas flow at the inlet port.

5

The invention further provides an arrangement for generating an air flow through a chamber containing powder, so that the powder becomes entrained in the air flow and is carried out of the chamber via an exit port. This involves directing the air flow through the chamber. The chamber has an axis and a wall curved around the axis and the air rotates around this axis. The air flow is also directed through an inlet port of the chamber, wherein the direction of the air flow through the inlet port is tangential to the chamber wall. The direction of the air flow through the exit port is parallel to the axis. A cross-sectional area of the air flow through the chamber is in a normal plane to the air flow and decreases with increasing distance from the inlet port.

15

In another aspect, an inhaler is provided, for providing the air flow and deagglomeration discussed above. Such inhalers comprise an aerosolising device including a substantially tangential inlet port and a substantially axial exit port. The inhalers also comprise one or more sealed blisters (or capsules) containing the pharmaceutical dry powder composition to be dispensed, and an input device for removably receiving one of these blisters. Upon actuation, the inhaler couples the tangential inlet port with the powder composition in the received blister.

20

With regard to the aerosolising device, in some embodiments, the aerosolising device is in the form of a vortex chamber of substantially circular cross-section having a substantially tangential inlet port and a substantially axial outlet port. Preferably, the ratio of the diameter of the vortex chamber to the diameter of the exit port is between 4 and 12.

25

In other embodiments, the aerosolising device is in the form of a vortex chamber of substantially circular cross-section having a substantially tangential inlet port, wherein the inlet port has an outer wall which defines the maximum extent of the

30

inlet port in the radially outward direction of the vortex chamber. The extent of the outer wall in the axial direction of the vortex chamber is substantially equal to the maximum extent of the inlet port in the axial direction of the vortex chamber, the outer wall is substantially parallel with a wall of the vortex chamber.

5

In other embodiments, the aerosolising device is in the form of a vortex chamber of substantially circular cross-section having a substantially tangential inlet port. A bottom surface defines the furthest extent of the vortex chamber from the exit port in the axial direction, and the bottom surface further defines the furthest axial extent of the inlet port from the exit port.

10

In yet further embodiments, the aerosolising device is in the form of a vortex chamber of substantially circular cross-section having a substantially tangential inlet port and an inlet conduit arranged to supply a powdered composition entrained in a gas flow to the inlet port, in use, wherein the cross-sectional area of the inlet conduit decreases towards the vortex chamber. The inlet conduit is, upon actuation of the inhaler, coupled to the powder composition in the received blister.

15

In other embodiments, the aerosolising device is in the form of a vortex chamber of substantially circular cross-section having a substantially tangential inlet port and an arcuate inlet conduit arranged to supply a powdered composition entrained in a gas flow to the inlet port, in use. The inlet conduit is, upon actuation of the inhaler, coupled to the powder composition in the received blister.

20

In other embodiments, the aerosolising device is in the form of a vortex chamber having an axis defined, at least in part, by a wall which forms a curve about the axis. The vortex chamber has a cross-sectional area in a plane bounded by the axis, and the plane extends in one direction radially from the axis at a given angular position ( $\theta$ ) about the axis. The vortex chamber has a substantially tangential inlet port and a substantially axial exit port, and said cross-sectional area of the vortex chamber decreases with increasing angular position ( $\theta$ ) in the direction, in use, of the gas flow between the inlet port and the outlet port.

25

30

In other embodiments, the aerosolising device is in the form of a vortex chamber having an axis defined, at least in part, by a wall which forms a curve about the axis. The vortex chamber has a substantially tangential inlet port and a substantially axial exit port. The vortex chamber is further defined by a base, and the distance (d)  
5 between the base and a plane which is normal to the axis and is located on the opposite side of the base to the exit port increase with radial position ( $r$ ) relative to the axis.

In other embodiments, the aerosolising device includes a chamber defined by a top wall, a bottom wall, and a lateral wall, the lateral wall being curved about an axis  
10 which intersects the top wall and the bottom wall. The chamber encloses a cross-sectional area defined by the axis, the top wall, the bottom wall and the lateral wall, and the chamber has an inlet port and an outlet port. The inlet port is tangential to the lateral wall, the outlet port is co-axial with the axis, and the cross-sectional area  
15 decreases with increasing angular position from the inlet port in a direction of a gas flow through the inlet port.

In still other embodiments, the aerosolising device is a chamber including a wall, a base, an inlet port and an exit port. The chamber has an axis that is co-axial with  
20 the exit port and intersects the base. The wall is curved about the base, the inlet port is tangential to the wall, and a height between the base and a plane normal to the axis at the exit port decreases as a radial position from the axis to the inlet port increases.

25 One embodiment of the invention is described in detail, by way of example only, with reference to the following drawings.

Figure 1 shows an inhaler and a blister according to the present invention.

30 Figure 2 is a top cross-section of a vortex nozzle.

Figure 5(a) is a side-view of a vortex chamber with a round inlet port.

Figure 5(b) is a sectional view along line D-D of the vortex chamber of Figure 5(a).

Figure 6(a) is a side view of a vortex chamber with a rectangular inlet port.

5     Figure 6(b) is a sectional view along line E-E of the vortex chamber of Figure 6(a).

Figure 7 shows a vortex chamber with an arcuate inlet conduit.

10     Figures 8-11 show detail of embodiments of the exit port of the inhaler in accordance with the invention.

Figure 12 illustrates an asymmetric vortex chamber in accordance with an embodiment of the invention.

15     Figure 13 is a sectional view of a vortex chamber of an asymmetric inhaler in accordance with another embodiment of the invention.

Figure 14 is a perspective view of a vortex chamber according to Figure 13.

20     Figure 15 is a sectional view of the vortex chamber of Figure 14.

Figure 16 is a perspective view of a detail of the vortex chamber of Figures 14 and 15.

25     Figure 17 is a plan view of the detail of Figure 16.

Figure 18 is a plan view of a variation of the detail of Figure 17.

30     Figure 1 shows schematically a preferred inhaler that can be used to deliver a powder formulation to a patient. The inhaler includes a vortex chamber 1 having an exit port 2 and an inlet port 3 for generating an aerosol of the powder formulation. The vortex chamber is situated in a mouthpiece 10 through which the user inhales to use the inhaler. Air passages (not shown) may be defined between the vortex chamber 1

and the mouthpiece 10 so that the user is able to inhale air in addition to the powdered medicament.

5 The powder formulation is stored in a blister 60 defined by a support 70 and a pierceable foil lid 75. As shown, the support 70 has a cavity formed therein for holding the powder formulation. The open end of the cavity is sealed by the lid 75. An air inlet conduit 7 of the vortex chamber 1 terminates in a piercing head (or rod) 50 which pierces the foil lid 75. A reservoir 80 is connected to the blister 60 via a passage 78. A regulated air supply 90 charges the reservoir 80 with a gas (e.g. air) to  
10 a predetermined pressure (e.g. 1.5 bar). Preferably, the blister contains from 1 to 5mg of powder formulation.

When the user inhales, a valve 40 is opened by a breath-actuated mechanism 30, forcing air from the pressurised air reservoir through the blister 60 where the  
15 powdered formulation is entrained in the air flow. The air flow transports the powder formulation to the vortex chamber 1, where a rotating vortex of powder formulation and air is created between the inlet port 3 and the outlet port 2. Rather than passing through the vortex chamber in a continuous manner, the powdered formulation entrained in the airflow enters the vortex chamber in a very short time  
20 (typically less than 0.3 seconds and preferably less than 20 milliseconds) and, in the case of a pure drug formulation (i.e. no carrier), a portion of the powder formulation sticks to the walls of the vortex chamber. This powder is subsequently aerosolised by the high shear forces present in the boundary layer adjacent to the powder. The action of the vortex deagglomerates the particles of the powder  
25 formulation, or in the case of a formulation comprising a drug and a carrier, strips the drug from the carrier, so that an aerosol of powdered formulation exits the vortex chamber 1 via the exit port 2. The aerosol is inhaled by the user through the mouthpiece 10.

30 The vortex chamber 1 can be considered to perform two functions: deagglomeration, the breaking up of clusters of particles into individual, respirable particles; and filtration, preferentially allowing particles below a certain size to escape more easily from the exit port 2. Deagglomeration breaks up cohesive

clusters of powdered formulation into respirable particles, and filtration increases the residence time of the clusters in the vortex chamber 1 to allow more time for them to be deagglomerated. Deagglomeration can be achieved by creating high shear forces due to velocity gradients in the airflow in the vortex chamber. The velocity gradients are the highest in the boundary area close to the walls of the vortex chamber.

As shown in the detail of Figure 2, the vortex chamber 1 is in the form of a substantially cylindrical chamber. The vortex chamber has a frustoconical portion in the region of the exit port 2. The inlet port 3 is substantially tangential to the perimeter of the vortex chamber and the exit port is generally concentric with the axis of the vortex chamber. Thus, gas enters the vortex chamber tangentially via the inlet port 3 and exits axially via the exit port 2. Between the inlet port 3 and the exit port 2, a vortex is created in which shear forces are generated to deagglomerate the particles of medicament. The length of the exit port 2 is preferably minimised to reduce the possibility of deposition of the active agent in the walls of the exit port 2.

The ratio of the diameter of the vortex chamber to the diameter of the exit port can be significant in maximising the fine particle fraction of the active agent aerosol which is expelled from the exit port. Thus, the ratio of the diameter of the vortex chamber to the diameter of the exit port is preferably between 4 and 12. It has been found that when the ratio is between 4 and 12 the proportion of the particles of the powdered medicament with an effective diameter in the range of 1-3 $\mu$ m is maximised. For an enhanced FPF, the ratio is preferably greater than 5, more preferably greater than 6 and preferably less than 9, most preferably less than 8. In the preferred arrangement the ration is 7:1.

In certain embodiments of the invention, the diameter of the vortex chamber is between 2 and 12mm. The diameter of the vortex chamber is preferably greater than 4mm, more preferably at least 5mm and preferably less than 8mm, more preferably less than 6mm. In the preferred embodiment, the diameter of the vortex chamber is 5mm. In these embodiments, the height of the vortex chamber is



generally between 1 and 8mm. The height of the vortex chamber is preferably less than 4mm and more preferably less than 2mm. In the preferred embodiment, the height of the vortex chamber is 1.6mm.

- 5 In general, the vortex chamber is substantially cylindrical. However, the chamber may take other forms. For example, the vortex chamber may be frustoconical. Where the diameter of the vortex chamber or the exit port is not constant along its length, the ratio of the largest diameter of the vortex chamber to the smallest diameter of the exit port should be within the range specified above.

10

The aerosolising device comprises an exit port, for example as described above. The diameter of the exit port is generally between 0.5 and 2.5mm. The diameter of the exit port is preferably greater than 0.6mm and preferably less than 1.2mm, more preferably less than 1.0mm. In a preferred embodiment, the diameter of the exit

15 port is 0.7mm.

Table 1

Dimension		Preferred Value
D	Diameter of chamber	5.0mm
H	Height of chamber	1.6mm
h	Height of conical part of chamber	0.0mm
D <sub>e</sub>	Diameter of exit port	0.7mm
t	Length of exit port	0.3mm
a	Height of inlet port	1.1mm
b	Width of inlet port	0.5mm
$\alpha$	Taper angle of inlet conduit	12°

- Figures 3 and 4 show the general form of the vortex chamber of the inhaler in
- 20 Figure 1. The geometry of the vortex chamber is defined by the dimensions listed in Table 1. The preferred values of these dimensions are also listed in Table 1. It should be noted that the height h of the conical part of the chamber is 0mm, because it has been found that the vortex chamber functions most efficiently when the top of the chamber is flat.

As shown in Table 2 below, the proportion of the particles of active agent emitted in the aerosol having an effective particle diameter of less than  $6.8\mu\text{m}$  generated by the vortex chamber (the  $6.8\mu\text{m}$  particle fraction) depends on the ratio of the diameters of the chamber (D) and the exit port ( $D_e$ ). The normalised average  $6.8\mu\text{m}$  particle fraction of the powdered active agent loaded into the inhaler. The active agent used was pure Intal (trade mark) sodium cromoglycate (Fisons, UK).

Table 2

Ratio $D/D_e$	Average particle fraction $<6.8\mu\text{m}$ (%)	Normalised average particle fraction $<6.8\mu\text{m}$ (%)
2.0	64.7	73.1
3.1	70.8	79.9
4.0	75.5	85.2
6.0	81.0	91.4
7.1	83.5	94.3
8.0	83.2	93.9
8.6	80.6	91.0

10

From Table 2, it can be seen that where the ratio of the diameters of the vortex chamber and the exit port is 4 or more, the normalised  $6.8\mu\text{m}$  particle fraction is over 85%. Thus, the deagglomeration efficiency of the vortex chamber is significantly improved where the ratio is in this range. With the preferred ratio of 7.1, a normalised  $6.8\mu\text{m}$  particle fraction of 94.3% is achieved.

15

Figures 5a and 5b show a vortex chamber 1 in which the inlet port 3 has a circular cross-section. As represented by the solid arrow in Figure 5b, a portion of the airflow entering the vortex chamber via the inlet port 3 follows the lateral wall 12 of the vortex chamber 1. The powder entrained in this airflow is therefore introduced directly into the airflow at the boundary layer adjacent to the lateral wall 12 of the vortex chamber, where the velocity gradient in the radial direction is at a maximum. The maximal velocity gradient results in maximal shear forces on the agglomerated particles of the powder and thus maximum deagglomeration.

20

However, as represented by the dashed arrow in Figure 5b, a portion of the airflow entering the vortex chamber via the inlet port 3 does not follow the chamber wall 12, but rather crosses the chamber and meets the wall 12 at a point opposite the inlet port 3. At this point, there is increased turbulence, because the flow must make an abrupt change of direction. This turbulence disturbs the boundary layer adjacent the wall of the chamber and thereby reduces the effectiveness of the deagglomeration of the powder.

Figures 6a and 6b show a vortex chamber 1 in which the inlet chamber has a rectangular cross-section. The rectangular cross-section maximises the length of the perimeter of the inlet port that is coincident with the wall 12 of the chamber, such that the maximum air flow is introduced into the boundary layer of the vortex. Similarly, the rectangular cross-section maximises the width of the perimeter of the inlet port 3 that is coincident with the bottom surface 13 of the vortex chamber. In this way, deposition of powder in the vortex chamber 1 is prevented, because the vortex occupies the entire chamber.

In addition to having a rectangular cross-section, the inlet port 3 of Figures 6a and 6b is supplied by an inlet conduit 7 which tapers towards the vortex chamber 1. Thus, the inlet conduit is defined by an inner wall 14 and an outer wall 15. The outer wall is substantially tangential to the wall 12 of the vortex chamber 1. The spacing of the inner wall 14 from the outer wall 15 decreases towards the vortex chamber 1, so that the inner wall 14 urges the air flow into the vortex chamber 1 towards the boundary layer.

Furthermore, the decreasing cross-sectional area of the inlet conduit 7 causes the flow velocity to increase, thereby reducing deposition of powder on the way to the vortex chamber 1.

As indicated by the arrows in Figure 6b, all of the airflow entering the vortex chamber via the inlet port 3 follows the wall of the chamber 12. The powder entrained in this airflow is therefore introduced directly into the airflow at the

boundary layer adjacent the wall 12 of the chamber, and the deagglomeration is maximised.

Figures 8 to 11 show various options for the exit port 2 of the vortex chamber. The characteristics of the exit plume of the aerosol are determined, at least in part, by the configuration of the exit port 2. For example, if the aerosol leaves an exit port 2 of 1mm diameter at a flow rate of 2 litres per minute, the velocity at the exit port will be approximately 40m/s. This velocity can be reduced to a typical inhalation velocity of 2m/s within a few centimetres of the chamber or nozzle by providing a strongly divergent aerosol plume.

In Figure 8, the exit port 2 is a simple orifice defined through the upper wall 17 of the vortex chamber. However, the thickness of the upper wall 17 means that the exit port 2 has a length which is greater than its diameter. Thus, there is a risk of deposition in the exit port as the aerosol of powder exits. Furthermore, the tubular exit port tends to reduce the divergence of the exit plume. These problems are solved in the arrangement of Figure 9, by tapering the upper wall 17 of the vortex chamber 1 towards the exit port 2, so that the exit port 2 is defined by a knife edge of negligible thickness. For an exit port with a diameter of 1mm, an exit port length of 2.3mm gives a plume angle of 60°, whereas reducing this length to 0.3mm increases the angle to 90°.

In Figure 10, the exit port is annular and is also defined by a knife edge. This arrangement produces an exit plume that slows down more quickly than a circular jet, because the annular exit port has a greater perimeter than a circular port of the same diameter and produces a jet that mixes more effectively with the surrounding static air.

In Figure 11, multiple orifices form the exit port 2 and produce a number of smaller plumes which break up and slow down in a shorter distance than a single large plume.

Figure 7 shows an embodiment of the vortex chamber 1 in which the inlet conduit 7 is arcuate and tapers towards the vortex chamber. As shown by the arrows in Figure 13, the arcuate inlet conduit 7 urges the entrained particles of the powdered formulation to wards the outer wall 15 of the inlet conduit 7. In this way, when the powder enters the vortex chamber through the inlet port 3, the powder is introduced directly into the boundary layer next to the wall 12 of the vortex chamber 1, where the shear forces are at a maximum. In this way, improved deagglomeration is achieved.

The inhaler in accordance with some embodiments of the invention is able to generate a relatively slow moving aerosol with a high fine particle fraction. The inhaler is capable of providing complete and repeatable aerosolisation of a measured dose of powdered active agent and of delivering the aerosolised dose into the patient's inspiratory flow at a velocity of less than or equal to the velocity of the inspiratory flow, thereby reducing deposition by impaction in the patient's mouth. Furthermore, the efficient aerosolising system allows for a simple, small and low cost device, because the energy used to create the aerosol is small. The fluid energy required to create the aerosol can be defined as the integral over time of the pressure multiplied by the flow rate. This is typically less than 5 joules and can be as low as 3 joules.

It is clear that similar effects can be achieved using asymmetric inhalers. In such inhalers, the vortex chamber has an asymmetric shape.

In the embodiment shown in Figure 12, the wall 12 of the vortex chamber 1 is in the form of a spiral or scroll. The inlet port 3 is substantially tangential to the perimeter of the vortex chamber 1 and the exit port 2 is generally concentric with the axis of the vortex chamber 1.

Thus, the gas enters the vortex chamber tangentially via the inlet port 3 and exits axially via the exit port 2. The radius  $R$  of the vortex chamber measured from the centre of the exit port 2 decreases smoothly from a maximum radius  $R_{\max}$  at the

inlet port to a minimum radius  $R_{\min}$ . Thus, the radius  $R$  at an angle of  $\theta$  from the position of the inlet port 3 is given by  $R=R_{\max}(1-\theta k/2\pi)$  where  $k=(R_{\max}-R_{\min})/R_{\max}$ .

5 The effective radius of the vortex chamber decreases as the air flow and entrained particles of active agent circulate around the chamber. In this way, the effective cross-sectional area of the vortex chamber 1 experienced by the air flow decreases, so that the air flow is accelerated and there is reduced deposition of the entrained particles of active agent. In addition, when the flow of air has gone through  $2\pi$  radians ( $360^\circ$ ), the air flow is parallel to the incoming airflow through the inlet port  
10 3, so that there is a reduction in the turbulence caused by the colliding flows.

Between the inlet port 3 and the exit port 2, a vortex is created in which shear forces are generated to deagglomerate the particles of the powdered formulation. As discussed above, the length of the exit port 2 is preferably as short as possible,  
15 to reduce the possibility of deposition of the drug on the walls of the exit port 2.

Figure 13 shows the general form of the vortex chamber of the inhaler of Figure 12. The geometry of the vortex chamber is defined by the dimensions listed in Table 3. The preferred values of these dimensions are also listed in Table 3. It should be  
20 noted that the height of the conical part of the chamber is 0mm, because it has been found that the vortex chamber functions most efficiently when the top (roof 16) of the chamber is flat.

Table 3

Dimension		Preferred Value
$R_{\max}$	Maximum radius of chamber	2.8mm
$R_{\min}$	Minimum radius of chamber	2.0mm
$H_{\max}$	Maximum height of chamber	1.6mm
$h$	Height of conical part of chamber	0.0mm
$D_e$	Diameter of exit port	0.7mm
$t$	Length of exit port	0.3mm
$a$	Height of inlet port	1.1mm

b	Width of inlet port	0.5mm
$\alpha$	Taper angle of inlet conduit	9°, then 2°

The 6.8 $\mu$ m particle fraction of the aerosol generated by the vortex chamber 1 according to Figure 12 is improved relative to a circular vortex chamber (as shown in Figures 1-11).

5

Figures 14 to 18 show another asymmetric inhaler in accordance with the present invention in which the vortex chamber 1 includes a ramp 20 which reduces the height of the vortex chamber 1 from the bottom up with increasing angular displacement  $\theta$  from the inlet port 3. A substantially circular region 21 in the centre  
10 of the vortex chamber 1 remains flat.

## Particle Cohesiveness

For formulations to reach the deep lung or the blood stream via inhalation, the active agent in the formulation must be in the form of very fine particles, for  
5 example, having a mass median aerodynamic diameter (MMAD) of less than  $10\mu\text{m}$ . It is well established that particles having an MMAD of greater than  $10\mu\text{m}$  are likely to impact on the walls of the throat and generally do not reach the lung. Particles having an MMAD in the region of  $5\mu\text{m}$  to  $2\mu\text{m}$  will generally be deposited in the respiratory bronchioles whereas particles having an MMAD in the range of 3 to  
10  $0.05\mu\text{m}$  are likely to be deposited in the alveoli or be absorbed into the bloodstream.

Preferably, for delivery to the lower respiratory tract or deep lung, the MMAD of the active particles is not more than  $10\mu\text{m}$ , and preferably not more than  $5\mu\text{m}$ , more preferably not more than  $3\mu\text{m}$ , and may be less than  $1\mu\text{m}$ . Ideally, at least 90% by  
15 weight of the active particles in a dry powder formulation should have an MMAD of not more than  $10\mu\text{m}$ , preferably not more than  $5\mu\text{m}$ , more preferably not more than  $3\mu\text{m}$  and most preferably not more than  $1\mu\text{m}$ .

When dry powders are produced using conventional processes, the active particles  
20 will vary in size, and often this variation can be considerable. This can make it difficult to ensure that a high enough proportion of the active particles are of the appropriate size for administration to the correct site. It is therefore desirable to have a dry powder formulation wherein the size distribution of the active particles is as narrow as possible. This will improve dose efficiency and reproducibility.

25 Fine particles, that is, those with an MMAD of less than  $10\mu\text{m}$ , are thermodynamically unstable due to their high surface area to volume ratio, which provides a significant excess surface free energy and encourages the particles to agglomerate. In the inhaler, agglomeration of fine particles and adherence of such  
30 particles to the walls of the inhaler are problems that result in the fine particles leaving the inhaler as large, stable agglomerates, or being unable to leave the inhaler and remaining adhered to the interior of the inhaler, or even clogging or blocking the inhaler.



The uncertainty as to the extent of formation of stable agglomerates of the particles between each actuation of the inhaler, and also between different inhalers and different batches of particles, leads to poor dose reproducibility. Furthermore, the  
5 formation of agglomerates means that the MMAD of the active particles can be vastly increased, with agglomerates of the active particles not reaching the required part of the lung.

The tendency of fine particles to agglomerate means that the FPF of a given dose is  
10 highly unpredictable and a variable proportion of the fine particles will be administered to the lung, or to the correct part of the lung, as a result.

In an attempt to improve this situation and to provide a consistent FPF and FPD, dry powder formulations often include additive material.

15 The additive material is intended to decrease the cohesion between particles in the dry powder formulation. It is thought that the additive material interferes with the weak bonding forces between the small particles, helping to keep the particles separated and reducing the adhesion of such particles to one another, to other  
20 particles in the formulation if present and to the internal surfaces of the inhaler device. Where agglomerates of particles are formed, the addition of particles of additive material decreases the stability of those agglomerates so that they are more likely to break up in the turbulent air stream created on actuation of the inhaler device, whereupon the particles are expelled from the device and inhaled. As the  
25 agglomerates break up, the active particles return to the form of small individual particles which are capable of reaching the lower lung.

In the prior art, dry powder formulations are discussed which include distinct particles of additive material (generally of a size comparable to that of the fine  
30 active particles). In some embodiments, the additive material may form a coating, generally a discontinuous coating, on the active particles and/or any carrier particles.

Preferably, the additive material is an anti-adherent material and it will tend to reduce the cohesion between particles and will also prevent fine particles becoming attached to the inner surfaces of the inhaler device. Advantageously, the additive material is an anti-friction agent or glidant and will give better flow of the  
5 pharmaceutical composition in the inhaler. The additive materials used in this way may not necessarily be usually referred to as anti-adherents or anti-friction agents, but they will have the effect of decreasing the cohesion between the particles or improving the flow of the powder. The additive materials are often referred to as force control agents (FCAs) and they usually lead to better dose reproducibility and  
10 higher fine particle fractions.

Therefore, an FCA, as used herein, is an agent whose presence on the surface of a particle can modify the adhesive and cohesive surface forces experienced by that particle, in the presence of other particles. In general, its function is to reduce both  
15 the adhesive and cohesive forces.

In general, the optimum amount of additive material to be included in a dry powder formulation will depend on the chemical composition and other properties of the additive material and of the active material, as well as upon the nature of other  
20 particles such as carrier particles, if present. In general, the efficacy of the additive material is measured in terms of the fine particle fraction of the composition.

Known additive materials usually consist of physiologically acceptable material, although the additive material may not always reach the lung, for example where the  
25 additive particles are attached to the surface of carrier particles so that they will generally be deposited, along with those carrier particles, at the back of the throat of the user.

Preferred additive materials for used in prior art dry powder formulations include  
30 amino acids, peptides and polypeptides having a molecular weight of between 0.25 and 1000 kDa and derivatives thereof, dipolar ions such as zwitterions, phospholipids such as lecithin, and metal stearates such as magnesium stearate.

In a further attempt to improve this situation and to provide a consistent FPF and FPD, dry powder formulations often include coarse carrier particles of excipient material mixed with fine particles of active material. Rather than sticking to one another, the fine active particles tend to adhere to the surfaces of the coarse carrier particles whilst in the inhaler device, but are supposed to release and become dispersed upon actuation of the dispensing device and inhalation into the respiratory tract, to give a fine suspension. The carrier particles preferably have MMADs greater than 90µm.

The inclusion of coarse carrier particles is also very attractive where very small doses of active agent are dispensed. It is very difficult to accurately and reproducibly dispense very small quantities of powder and small variations in the amount of powder dispensed will mean large variations in the dose of active agent where the powder comprises mainly active particles. Therefore, the addition of a diluent, in the form of large excipient particles will make dosing more reproducible and accurate.

Carrier particles may be of any acceptable excipient material or combination of materials. For example, the carrier particles may be composed of one or more materials selected from sugar alcohols, polyols and crystalline sugars. Other suitable carriers include inorganic salts such as sodium chloride and calcium carbonate, organic salts such as sodium lactate and other organic compounds such as polysaccharides and oligosaccharides. Advantageously the carrier particles are of a polyol. In particular the carrier particles may be particles of crystalline sugar, for example mannitol, dextrose or lactose. Preferably, the carrier particles are of lactose.

Advantageously, substantially all (by weight) of the carrier particles have a diameter which lies between 20µm and 1000µm, more preferably 50µm and 1000µm. Preferably, the diameter of substantially all (by weight) of the carrier particles is less than 355µm and lies between 20µm and 250µm.

Preferably at least 90% by weight of the carrier particles have a diameter between 60µm to 180µm. The relatively large diameter of the carrier particles improves

the opportunity for other, smaller particles to become attached to the surfaces of the carrier particles and to provide good flow and entrainment characteristics and improved release of the active particles in the airways to increase deposition of the active particles in the lower lung.

5

The ratios in which the carrier particles (if present) and composite active particles are mixed will, of course, depend on the type of inhaler device used, the type of active particles used and the required dose. The carrier particles may be present in an amount of at least 50%, more preferably 70%, advantageously 90% and most preferably 95% based on the combined weight of the composite active particles and the carrier particles.

10

However, a further difficulty is encountered when adding coarse carrier particles to a composition of fine active particles and that difficulty is ensuring that the fine particles detach from the surface of the large particles upon actuation of the delivery device.

15

The step of dispersing the active particles from other active particles and from carrier particles, if present, to form an aerosol of fine active particles for inhalation is significant in determining the proportion of the dose of active material which reaches the desired site of absorption in the lungs. In order to improve the efficiency of that dispersal it is known to include in the composition additive materials of the nature discussed above. Compositions comprising fine active particles and additive materials are disclosed in WO 97/03649 and WO 96/23485.

20

25

In light of the foregoing problems associated with known dry powder formulations, even when including additive material and/or carrier particles, it is an aim of the present invention to provide dry powder compositions which have physical and chemical properties which lead to an enhanced FPF and FPD. This leads to greater dosing efficiency, with a greater proportion of the dispensed active agent reaching the desired part of the lung for achieving the required therapeutic effect.

30

It is highly desirable to be able to prepare fine particles comprising an active agent using simple methods and simple apparatus. As discussed below, dry powder formulations can be prepared, without requiring elaborate, multi-step methods, wherein the active particles have an MMAD suitable for deposition in the deep lung and wherein the dry powder formulations exhibit the preferred FPF and FPD discussed above, regardless of the type of device used to dispense them.

### Spray Dried Powder Particles

It has been discovered that the FPF and the FPD of a dry powder formulation may be greatly increased by co-spray drying the active agent with a force control agent.

Thus, according to an aspect of the present invention, a method of making a dry powder composition for pulmonary inhalation is provided, the method comprising spray drying a pharmaceutically active agent to form active particles, wherein the active agent is co-spray dried with a force control agent.

This aspect of the present invention is described below in detail, with reference to the following drawings.

Figure 1 shows a schematic set-up of a 2-fluid nozzle spray drier.

Figures 2a-2d are SEM micrographs of 2-fluid nozzle spray dried powders which were co-spray dried with increasing amounts of l-leucine (0%, 5%, 25% and 50% w/w), without secondary drying.

Figures 2e-2h are SEM micrographs of 2-fluid nozzle spray dried powders which were co-spray dried with increasing amounts of l-leucine (2%, 5%, 10% and 50% w/w), after secondary drying.

Figure 3 shows a schematic diagram of an ultrasonic nebuliser producing fine droplet.

Figure 4 shows a schematic set-up of a spray drier incorporating an ultrasonic nebuliser.

Figures 5a and 5b show SEM micrographs of spray dried nebulised heparin alone  
5 and with 10% w/w leucine, without secondary drying.

Figure 6 shows a typical size distribution curve of three repeated tests of spray dried nebulised heparin (with no FCA).

10 Figures 7a-7c show a comparison between particle size distribution curves of 2-fluid nozzle spray dried powders and ultrasonic nebulised powders comprising a blend of heparin and leucine (2% w/w, 5% w/w and 10% w/w).

Figure 8 shows a comparison between particle size distribution curves of secondary  
15 dried and not secondary dried powders. The powder used was heparin with leucine (10% w/w).

### **Co-Spray Drying the Active Agent and a Force Control Agent**

It has been discovered that the FPF and the FPD of a dry powder formulation may  
20 be greatly increased by co-spray drying the active agent with a force control agent.

Thus, according to a first aspect of the present invention, a method of making a dry powder composition for pulmonary inhalation is provided, the method comprising  
25 spray drying a pharmaceutically active agent to form active particles, wherein the active agent is co-spray dried with a force control agent (FCA).

In one embodiment of the invention, the dry powder compositions comprising such co-spray dried active particles exhibit a fine particle fraction ( $<5\mu\text{m}$ ) of at least 50%. Preferably, the FPF(ED) will be between 70 and 99%, more preferably between 80  
30 and 99%. Furthermore, it is desirable for the FPF (MD) to be at least 50%. Preferably, the FPD will be between 50 and 99%, more preferably between 60 and 99%.

The combination or blend of active agent and FCA which is spray dried to form a dry powder formulation can be a solution or suspension in a host liquid. In embodiments, all or at least a proportion of the active agent and/or FCA is or are in solution in the host liquid before being subjected to spray drying. Substantially all  
5 of the active agent and FCA can be in solution in the host liquid before being subjected to spray drying.

The active agent is preferably at least 1.5, 2, 4 and, more preferably, at least 10 times more soluble than the FCA in the host liquid at the spraying temperature and  
10 pressure. In preferred embodiments, this relationship exists at a temperature between 30 and 60°C and atmospheric pressure. In other embodiments, this relationship exists at a temperature between 20 to 30°C and atmospheric pressure, or, preferably, at 20°C and atmospheric pressure.

15 Preferably, the FCAs used in the present invention are film-forming agents, fatty acids and their derivatives, lipids and lipid-like materials, and surfactants, especially solid surfactants.

Advantageously, the FCA includes one or more compounds selected from amino  
20 acids and derivatives thereof, and peptides and derivatives thereof. Amino acids, peptides and derivatives of peptides are physiologically acceptable and give acceptable release of the active particles on inhalation.

It is particularly advantageous for the FCA to comprise an amino acid. The FCA  
25 may comprise one or more of any of the following amino acids: leucine, isoleucine, lysine, cysteine, valine, methionine, and phenylalanine. The FCA may be a salt or a derivative of an amino acid, for example aspartame or acesulfame K. Preferably, the FCA consists substantially of an amino acid, more preferably of leucine, advantageously L-leucine. The D- and DL-forms may also be used. As indicated  
30 above, L-leucine has been found to give particularly efficient dispersal of the active particles on inhalation.

The FCA may include one or more water soluble substances. This helps absorption of the substance by the body if the FCA reaches the lower lung. The FCA may include dipolar ions, which may be zwitterions.

- 5 Alternatively, the FCA may comprise a phospholipid or a derivative thereof. Lecithin has been found to be a good material for use as an FCA.

The FCA may comprise a metal stearate, or a derivative thereof, for example, sodium stearyl fumarate or sodium stearyl lactylate. Advantageously, the FCA  
10 comprises a metal stearate. For example, zinc stearate, magnesium stearate, calcium stearate, sodium stearate or lithium stearate. Preferably, the FCA comprises magnesium stearate.

The FCA may include or consist of one or more surface active materials, in  
15 particular materials that are surface active in the solid state. These may be water soluble or able to form a suspension in water, for example lecithin, in particular soya lecithin, or substantially water insoluble, for example solid state fatty acids such as oleic acid, lauric acid, palmitic acid, stearic acid, erucic acid, behenic acid, or derivatives (such as esters and salts) thereof, such as glyceryl behenate. Specific  
20 examples of such materials are: phosphatidylcholines, phosphatidylethanolamines, phosphatidylglycerols, phosphatidylinositol and other examples of natural and synthetic lung surfactants; lauric acid and its salts, for example, sodium lauryl sulphate, magnesium lauryl sulphate; triglycerides such as Dynsan 118 and Cutina HR; and sugar esters in general. Alternatively, the FCA may be cholesterol or  
25 natural cell membrane materials, including pollen or spore cell wall components such as sporo-pollenins.

Other possible FCAs include sodium benzoate, hydrogenated oils which are solid at room temperature, talc, titanium dioxide, aluminium dioxide, silicon dioxide and  
30 starch.

In embodiments, a plurality of different FCAs can be used.



The host liquid is preferably water, although it can be a solution of an organic co-solvent, or plurality of organic co-solvents, and water; the latter being especially useful with active agents and FCAs that are insoluble or substantially insoluble in water alone. Preferred organic co-solvents include methanol, ethanol, propan-1-ol, 5 propan-2-ol and acetone; with ethanol being the most preferred.

Spray drying is a well-known and widely used technique for producing particles of material. To briefly summarise, the material to be made into particles is dissolved or dispersed in a liquid or can be made into a liquid which is sprayed through a 10 nozzle under pressure to produce a mist or stream of fine droplets. These fine droplets are usually exposed to heat which evaporates the moisture in the droplets almost instantaneously, leaving dry powder particles.

Spray drying is a widely used technique and many types of spray drying apparatus 15 are known. The process is relatively cheap and simple. A standard method for producing particles of an active material involves using a conventional spray dryer, such as a Büchi B-191 under a "standard" set of parameters. Such standard parameters are set out in Table 1.

20 Table 1: "Standard" parameters used in spray drying using the Büchi B-191 spray dryer (Büchi two fluid nozzle, internal setting, 0.7mm mixing needle and cap, 100% aspirator setting).

Atomisation pressure	Inlet temp	Outlet temp	Total solid conc'n (% w/w) in solvent	Solvent (host liquid)	Feed rate (ml/min)
5 - 6 bar	150°C	~100°C	1	Aqueous	5

It has been discovered that it is possible to enhance the FPF of a dry powder composition by co-spray drying the active agent with one or more force control 25 agents (FCAs) and/or excipients in the spray drying feedstock.

The particles produced in this way will comprise both the active agent and the FCA and so the FCA will actually be administered to the lower respiratory tract or deep lung upon inhalation of the dry powder composition. This is in contrast to the 30 additive material used in the prior art, which often was not administered to the deep lung, for example because it remains attached to the large carrier particles.

Thus, it is important that the selected FCA does not have a detrimental effect when administered to the lower respiratory tract or deep lung. Amino acids such as leucine, lysine and cysteine are all harmless in this regard, as are other FCAs such as phospholipids and magnesium stearate, when present in small quantities.

The effects of co-spray drying an active agent and a FCA are illustrated in the following discussion of various experiments and the results obtained. In the experiments, the active agent used is heparin. The reason for selecting this active agent to illustrate and test the present invention is that heparin is a "sticky" compound and this tends to have a detrimental effect on the FPF and FPD of the dry powder. Therefore, obtaining good values of FPF and FPD using heparin is an indication that the compositions really do exhibit good and improved properties, regardless of the "difficult" nature of the active agent included.

15

The preferred active agents include:

1) steroid drugs such as, for example, alcometasone, beclomethasone, beclomethasone dipropionate, betamethasone, budesonide, clobetasol, deflazacort, diflucortolone, desoxymethasone, dexamethasone, fludrocortisone, flunisolide, fluocinolone, fluometholone, fluticasone, fluticasone propionate, hydrocortisone, triamcinolone, nandrolone decanoate, neomycin sulphate, rimexolone, methylprednisolone and prednisolone;

20

2) antibiotic and antibacterial agents such as, for example, metronidazole, sulphadiazine, triclosan, neomycin, amoxicillin, amphotericin, clindamycin, aclarubicin, dactinomycin, nystatin, mupirocin and chlorhexidine;

25

3) systemically active drugs such as, for example, isosorbide dinitrate, isosorbide mononitrate, apomorphine and nicotine;

30

4) antihistamines such as, for example, azelastine, chlorpheniramine, astemizole, cetirizine, cinnarizine, desloratadine, loratadine, hydroxyzine, diphenhydramine, fexofenadine, ketotifen, promethazine, trimeprazine and terfenadine;

- 5) anti-inflammatory agents such as, for example, piroxicam, nedocromil, benzydamine, diclofenac sodium, ketoprofen, ibuprofen, heparinoid, nedocromil, cromoglycate, fasafungine and iodoxamide;
- 5 6) anticholinergic agents such as, for example, atropine, benzatropine, biperiden, cyclopentolate, oxybutinin, orphenadine hydrochloride, glycopyrronium, glycopyrrolate, procyclidine, propantheline, propiverine, tiotropium, tropicamide, trospium, ipratropium bromide and oxitropium bromide;
- 10 7) anti-emetics such as, for example, bestahistine, dolasetron, nabilone, prochlorperazine, ondansetron, trifluoperazine, tropisetron, domperidone, hyoscine, cinnarizine, metoclopramide, cyclizine, dimenhydrinate and promethazine;
- 15 8) hormonal drugs such as, for example, protirelin, thyroxine, salcotonin, somatropin, tetracosactide, vasopressin or desmopressin;
- 9) bronchodilators, such as salbutamol, fenoterol and salmeterol;
- 20 10) sympathomimetic drugs, such as adrenaline, noradrenaline, dexamfetamine, dipirefin, dobutamine, dopexamine, phenylephrine, isoprenaline, dopamine, pseudoephedrine, tramazoline and xylometazoline;
- 11) anti-fungal drugs such as, for example, amphotericin, caspofungin, clotrimazole, econazole nitrate, fluconazole, ketoconazole, nystatin, itraconazole, terbinafine, voriconazole and miconazole;
- 25 12) local anaesthetics such as, for example, amethocaine, bupivacaine, hydrocortisone, methylprednisolone, prilocaine, proxymetacaine, ropivacaine, tyrothricin, benzocaine and lignocaine;
- 30 13) opiates, preferably for pain management, such as, for example, buprenorphine, dextromoramide, diamorphine, codeine phosphate, dextropropoxyphene,

dihydrocodeine, papaveretum, pholcodeine, loperamide, fentanyl, methadone, morphine, oxycodone, phenazocine, pethidine and combinations thereof with an anti-emetic;

5 14) analgesics and drugs for treating migraine such as clonidine, codine, coproxamol, dextropropoxyphene, ergotamine, sumatriptan, tramadol and non-steroidal anti-inflammatory drugs;

15) narcotic agonists and opiate antidotes such as naloxone, and pentazocine;

10

16) phosphodiesterase type 5 inhibitors, such as sildenafil (viagra); and

17) pharmaceutically acceptable salts of any of the foregoing.

15 In preferred embodiments, the active agent is heparin, apomorphine, glycopyrrolate, or clobazam.

Preferably, the active agent is a small molecule, as opposed to a macromolecule.

Preferably, the active agent is not a protein, and more preferably, the active agent is  
20 not insulin.

The active agent, preferably, exhibits greater than 20, 25, 30, and, more preferably, 40% bio-availability when administered via the lung in the absence of a penetration enhancer. Tests suitable for determining bio-availability are well known to those  
25 skilled in the art and an example is described in WO 95/00127. Agents that exhibit bio-availability of less than 20%, such as a majority of macromolecules, are insufficiently rapidly cleared from the deep lung and, as a result, accumulate to an unacceptable extent if administered to this location on a long term basis.

30 A plurality of active agents can be employed in the practice of the present invention.

Unless otherwise indicated, the FPF and FDP figures given in the following sections of this specification were obtained by firing capsules, filled with approximately 20 mg of material, from a Monohaler into a multi stage liquid impinger (MSLI), at a flow rate of 90 lpm, or a twin stage or rapid twin stage impinger (TSI or rTSI) at 60 lpm. The "delivered dose" or "DD", which is referred to in some of the following sections, is the same as the emitted dose or ED (as defined above).

In order to illustrate how the present invention works, firstly the effect of adjusting the solid concentration of active agent was investigated. The active agent was spray dried (without an FCA) using the standard parameters as shown in Table 1, but the solid concentration of active agent was increased from 1% w/w to 2 and 5% w/w total solids. The effects of these changes on the FPFs were then investigated and the results were as follows.

Table 2: FPF (%) less than 5µm of the delivered dose (DD) for spray dried heparin using "standard" spray drying parameters

Description	Test	FPF <5µm (DD) (%)
1% w/w heparin	MSLI	17.0
1% w/w heparin	TSI	20.3

The FPF for heparin spray dried alone, that is, without a co-spray dried FCA, using the "standard" spray drying parameters (see Table 1) was 17-20% as shown in Table 2. Testing was done with both a multi stage liquid impinger (MSLI) and a twin stage impinger (TSI).

Table 3: FPF (%) less than 5 $\mu$ m of DD for heparin spray dried from increasing solid concentrations

Description	Test	FPF <5 $\mu$ m (DD) (%)
2% w/w heparin	rTSI	21.3
5% w/w heparin	rTSI	8.3

Increasing the solid concentration of heparin from 1% w/w (Table 2) to 5% w/w  
5 (Table 3) caused a large reduction in FPF of heparin from approximately 20% FPF  
to 8.3%, when tested using a rapid-TSI. 2% w/w solid content did not seem to have  
an effect on FPF.

Thus, increasing the solid content of the feed solution did not improve the FPF of  
10 the active particles. Increasing the solid content as high as 5% w/w reduced the  
FPF by more than 10%. Increasing the solid content of a feedstock without  
changing any of the other parameters generally causes an increase in particle size, as  
each droplet will have a greater mass of solid which needs to dry in the same  
amount of time.

15 Accordingly, although a solid content of up to 10 % w/w active agent, and in some  
cases as much as 25% w/w active agent, can be used, it is preferred for up 5%w/w,  
and more preferably 2 % w/w active agent to be used in the spray drying process of  
the present invention. It is also preferred for at least 0.05, more preferably 0.5 %  
20 w/w to be employed.

Next, the effect of spray drying an active agent with various organic solvents was  
evaluated. The "standard" parameters as outlined in Table 1 were used to spray dry  
heparin, with the only difference being that the heparin was spray dried from 10%  
25 w/w organic solvent (propan-1-ol, methanol or ethanol) in water. The results are set  
out in Table 4.

Table 4: FPF (%) less than 5µm of DD for heparin spray dried from an organic solvent.

Spray drying feedstock % w/w heparin	Solvent % w/w	Test	FPF <5µm (DD) (%)
1	10 % methanol	MSLI	2.3
1	10% ethanol	MSLI	6.2
1	10% propan-1-ol	MSLI	2.0

Spray drying 1% w/w heparin from 10% methanol, ethanol and propan-1-ol resulted in a lowering of FPF (Table 4) from approximately 20% when spray dried from aqueous solvent using identical parameters (Table 2) to 2-6% FPF.

One might expect that adding an organic solvent to the feedstock would cause an increase of the FPF, as a result of a reduction in the viscosity of the feedstock, and a lower energy input being required to generate smaller particles. However, the results obtained from 2-fluid nozzle spray drying of heparin from feedstocks containing 10% organic solvent (Table 4) show a reduction in FPF.

As a further test, an active agent was spray dried using the standard parameters used above (Table 1), but the effect of temperature on the particles produced was investigated by spray drying with inlet temperatures of 75°C to 220°C. The results are set out in Table 5.

Table 5: FPF (%) less than 5µm of DD for heparin spray dried using different inlet temperatures.

Inlet temperature	Approx. outlet temperature	Test	FPF <5µm (DD) (%)
220°C	135°C	MSLI	17.5
75°C	35°C	rTSI	22.5

Thus, it can be seen that spray drying heparin at a higher or lower inlet temperature relative to the "standard" 150°C normally used did not offer a substantial improvement in FPF.

A preferable range for the inlet temperature is 40°C to 300°C, preferably 75°C to 220°C. A preferable range for the outlet temperature is 20°C to 200°C, preferably 35°C to 135°C.

- 5 The effects of co-spray drying an active agent with varying amounts of the l-leucine, a FCA, from aqueous solution were then studied. Standard Büchi spray drying parameters were used, as shown in Table 1. L-leucine was included in the solution of heparin such that the percentage of l-leucine ranged from 2-50% w/w. The results are set out in Table 6.

10

Table 6: FPF (%) less than 5µm of DD for heparin co-spray dried with l-leucine.

Spray drying feedstock % w/w heparin	Co-spray drying with l-leucine % w/w	Test	FPF <5µm (DD) (%)
1	2%	rTSI	20.0
1	5%	MSLI	32.8
1	10%	MSLI	30.8
1	25%	MSLI	35.4
1	50%	MSLI	51.7

- The results show that increasing the percentage of l-leucine included in the feedstock for spray drying resulted in a steady improvement in FPF from approximately 20% FPF with 2% leucine, to 50% FPF with 50% leucine (Table 6).
- 15

- Next, 1% total solids solution was sprayed from a 2-fluid nozzle into a Büchi spray drier. Blends of heparin and l-leucine were prepared at different weight percentages of l-leucine. Powders of 2%, 5%, 10%, 25% and 50% w/w l-leucine were prepared.
- 20 The spray drier feed flow rate was 120 ml/hr, the inlet temperature was 150°C, and flush nozzle setting was used. The schematic set-up of the two-fluid nozzle spray drier is shown in Figure 1.

- In a first MSLI study, an internal nozzle alignment was used and the powder was not subjected to a secondary drying process. The feed rate used was 300 ml/hr.
- 25



20 mg of powder was dispersed in each case and the results set out in Table 7 indicate an improvement of FPF with addition of a FCA, although the FPD does not improve with the addition of more than 10% l-leucine due to the relative reduction of the heparin content.

5

Table 7: MSLI study of co-spray dried heparin and varying concentrations of leucine

Formulation	Test	ED (mg)	FPF% (emitted dose)	FPD (mg)
Heparin (0% leucine)	MSLI	10	17	1.8
Heparin + leucine (5% w/w)	MSLI	11	33	3.6
Heparin + leucine (10% w/w)	MSLI	13	31	3.9
Heparin + leucine (25% w/w)	MSLI	10	35	3.7
Heparin + leucine (50% w/w)	MSLI	6	52	3.0

Thus, in preferred embodiments, the active agent is spray dried with from 0.1 to 50% w/w FCA to active agent, preferably from 1 to 10% w/w FCA to active agent, and more preferably less than 5% w/w FCA to active agent. An added advantage of employing the preferred amounts of FCA is that the risk of toxicity problems is reduced.

15 In further preferred embodiments, the FCA is an amino acid, and more preferably the FCA is one or more of leucine, preferably l-leucine, isoleucine, lysine and cysteine. Most preferably, the active agent is co-spray dried with l-leucine.

It has been found that co-spray drying an active agent with an FCA, and in particular with l-leucine, isoleucine, lysine and cysteine, leads to significant changes in the particle cohesion, greatly enhancing the properties of the dry powder when administered by pulmonary inhalation. It has also been discovered that the changes to the FPF and FPD are, to an extent, dependent upon the amount of FCA being co-spray dried.

25

Where the spray drying takes place under "standard" parameters and using conventional spray drying apparatus, it has been found that spray drying an active agent with an FCA can lead to unusual particle morphology. At low concentrations of FCA, the surfaces of the particles show dimples or depressions. As the amount of co-spray dried FCA is increased, these dimples become more extreme, with the particles eventually having a shrivelled or wrinkled surface.

The morphology of the particles was viewed using scanning electron micrographs (SEMs). A sample preparation for this is set out below.

Pieces of double-sided carbon tape were placed on a numbered planchette. The backing was removed and small amounts of samples placed on them (the pieces of carbon tape were identified for different samples where appropriate). The backing was pressed on to ensure firm adherence of the sample to the tape. Excess sample was tapped off. Samples were coated in an Edwards Sputter Coater S150B at HT voltage 7 for an appropriate length of time (approximately 12 minutes).

SEM details: Jeol 6310. 10kV accelerating voltage. Spot size 13. Working distance 15. Noise reduction 20.

SEM micrographs of 2-fluid nozzle spray dried powders (Figures 2a-d) illustrate a clear relationship between the increasing percentage of l-leucine and an increasingly dimpled or wrinkled surface of the particles. The particles with the highest l-leucine content appear to be extremely wrinkled and, in selected cases, are possibly burst as an extreme result of "blowing", a phenomenon whereby the particles form a shell or skin which inflates and then collapses.

Droplets from the two fluid nozzle are initially dried at a relatively high rate during spray drying and this creates a viscous layer of material around the exterior of the liquid droplet. As the drying continues, the viscous layer is firstly stretched (like a balloon) by the increased vapour pressure inside the viscous layer as the solvent evaporates. The solvent vapour diffuses through the growing viscous layer until it is exhausted and the viscous layer then collapses, resulting in the formation of craters

in the surface or wrinkling of the particles. The viscosity of the viscous layer has been related to the glass transition temperature of the material by the WLF (Williams, Landel, Ferry) Equation (see Alexander et al, Drying Technology; Vol. 3, No. 3, 1985).

5

Figure 2a is an SEM micrograph of 2-fluid nozzle spray dried heparin (without secondary drying). The particles are generally spherical in shape and the surfaces are substantially smooth. However, the particles each have one (smooth) crater or dimple in their surface.

10

Figure 2b is an SEM micrograph of 2-fluid nozzle spray dried heparin with 5% leucine (without secondary drying). The particles now exhibit more dimples or craters on their surface. The particles still have a generally smooth surface.

15

Figure 2c is an SEM micrograph of 2-fluid nozzle spray dried heparin with 25% leucine (without secondary drying). With the increase in FCA, the surface of the particles no longer appears smooth and the generally spherical shape has disappeared. The particles have a shrivelled, deflated appearance.

20

Figure 2d is an SEM micrograph of 2-fluid nozzle spray dried heparin with 50% leucine (without secondary drying). The shrivelling observed in the particles of Figure 2c has become more pronounced and the particles appear to have completely collapsed, looking like empty skins or shells.

25

This change in the surface morphology of these co-spray dried particles appears to reduce the cohesion between the particles. Conventional particles of active material are generally spherical in shape, as seen in Figure 2a. This relatively smooth, regular shape of the fine particles means that they are likely to agglomerate, as discussed above. However, less agglomeration is observed as the irregularity of the surface of the co-spray dried particles increases. This suggests that the dimpled or wrinkled surfaces provide less surface area for attraction between the fine particles. It is also speculated that this particle morphology may even help the particles to fly when they are expelled for the inhaler device. This, together with the reduced

30

agglomeration, means that more of the active particles are capable of reaching the lower respiratory tract or deep lung.

Next, the effect of spray drying an active agent with various excipients was investigated. Standard spray drying parameters as shown in Table 1 were used and the various excipients tested were lactose, dextrose, mannitol and human serum albumin (HSA). The excipients were co-spray dried with heparin from aqueous solution. Between 5-50% w/w of the excipients were included, with total solid content not exceeding 1% w/w of the solution.

10

Table 9: FPF (%) less than 5 $\mu$ m of DD for heparin co-spray dried with excipients.

Spray drying feedstock % w/w	Co-spray drying excipient % w/w	Test	FPF <5 $\mu$ m (DD) (%)
1	5% lactose	rTSI	7.0
1	20% lactose	rTSI	5.3
1	50% lactose	rTSI	10.3
1	5% dextrose	rTSI	11.0
1	50% dextrose	rTSI	1.7
1	5% mannitol	rTSI	14.0
1	20% mannitol	rTSI	11.3
1	5% HSA	rTSI	34.0
1	50% HSA	rTSI	28.0

Inclusion of lactose (5-50%); dextrose (5-50%) and mannitol (5-20%) did not improve FPF (Table 9). In fact, for all of these excipients, FPFs fell to below the "standard" 20% for spray drying heparin. However, inclusion of 5% HSA gave an improvement of approximately 15%.

As the presence of the HSA in the active particle clearly reduces the particle cohesion, thereby increasing the FPF, HSA is considered, for the purpose of the present invention, to be a FCA. However, in another embodiment of the invention, the FCA is not HSA.

20

According to another embodiment of the present invention, the active agent is co-spray dried with HSA. Preferably, the active agent is co-spray dried with up to 50% w/w HSA, and more preferably with from 2 to 25% w/w HSA.

5 In view of the increased FPF and FPD obtained, especially when co-spray drying an active agent with an FCA, it may be possible to do away with the large carrier particles in a dry powder comprising an active agent which has been co-spray dried with a force control agent. However, it may still be desirable to include carrier particles, especially where the active agent is to be administered in small amounts, as  
10 the bulk of the larger carrier particles will help to ensure that an accurate dose is dispensed.

Alternative FCAs which could be co-spray dried with the heparin include phospholipids and lecithins. However, where the active agent is insoluble in  
15 organic solvents, whilst the FCA is insoluble in an aqueous phase, or vice versa, in order to co-spray dry these incompatible materials, one must use a technique such as hydrophobic ion pairing.

#### Alternative Droplet Formation

20 It has further been discovered that the FPF and FPD of the dry powder formulation is also affected by the means used to create the droplets which are spray dried. Different means of forming droplets can affect the size and size distribution of the droplets, as well as the velocity at which the droplets travel when formed and the gas flow around the droplets. In this regard, the velocity at which the droplets travel  
25 when formed and the gas (which is usually air) flow around the droplets can dramatically affect size, size distribution and shape of resulting dried particles.

According to a second aspect of the invention, a method of preparing a dry powder composition is provided, wherein the active agent is spray dried using a spray drier  
30 comprising a means for producing droplets moving at a controlled velocity and of a predetermined droplet size. The velocity of the droplets is preferably controlled relative to the body of gas into which they are sprayed. This can be achieved by

controlling the droplets' initial velocity and/or the velocity of the body of gas into which they are sprayed.

It is clearly desirable to be able to control the size of the droplet formed during the spray drying process and the droplet size will affect the size of the dried particle. Preferably, the droplet forming means also produces a relatively narrow droplet, and therefore particle, size distribution. This will lead to a dry powder formulation with a more uniform particle size and thus a more predictable and consistent FPF and FPD.

10

The ability to control the velocity of the droplet also allows further control over the properties of the resulting particles. In particular, the gas speed around the droplet will affect the speed with which the droplet dries. In the case of droplets which are moving quickly, such as those formed using a 2-fluid nozzle arrangement (spraying into air), the air around the droplet is constantly being replaced. As the solvent evaporates from the droplet, the moisture enters the air around the droplet. If this moist air is constantly replaced by fresh, dry air, the rate of evaporation will be increased. In contrast, if the droplet is moving through the air slowly, the air around the droplet will not be replaced and the high humidity around the droplet will slow the rate of drying. As discussed below in greater detail, the rate at which a droplet dries affects various properties of the particles formed, including FPF and FPD.

15  
20

Preferably the velocity of droplets at 10 mm from their point of generation is less than 100 m/s, more preferably less than 50 m/s, most preferably less than 20 m/s. Preferably the velocity of the gas, used in the generation of the droplets, at 10 mm from the point at which they are generated is less than 100 m/s, more preferably less than 50 m/s, most preferably less than 20 m/s. In an embodiment, the velocity of the droplets relative to the body of gas into which they are sprayed, at 10 mm from their point of generation, is less than 100 m/s, more preferably less than 50 m/s, most preferably less than 20 m/s.

25  
30

Preferably, the means for producing droplets moving at a controlled velocity and of a predetermined size is an alternative to the commonly used 2-fluid nozzle. In one embodiment, an ultrasonic nebuliser (USN) is used to form the droplets in the spray drying process.

5

Whilst ultrasonic nebulisers (USNs) are known, these are conventionally used in inhaler devices, for the direct inhalation of solutions containing drug, and they have not previously been widely used in a spray drying apparatus. However, it has been discovered that the use of such a nebuliser in spray drying has a number of  
10 important advantages and these have not previously been recognised.

USNs use an ultrasonic transducer which is submerged in a liquid. The ultrasonic transducer (a piezoelectric crystal) vibrates at ultrasonic frequencies to produce the short wavelengths required for liquid atomisation. In one common form of USN,  
15 the base of the crystal is held such that the vibrations are transmitted from its surface to the nebuliser liquid, either directly or via a coupling liquid, which is usually water. When the ultrasonic vibrations are sufficiently intense, a fountain of liquid is formed at the surface of the liquid in the nebuliser chamber. Large droplets are emitted from the apex and a "fog" of small droplets is emitted. A  
20 schematic diagram showing how the USN works is shown in Figure 3.

The attractive characteristics of USNs for producing fine particle dry powders include: low spray velocity; the small amount of carrier gas required to operate the nebulisers; the small droplet size and narrow droplet size distribution produced; the  
25 simple nature of the USNs (the absence of moving parts which can wear, etc.); and the ability to accurately control the gas flow around the droplets, thereby controlling the rate of drying.

To elaborate, USNs do not separate the liquid into droplets by increasing the  
30 velocity of the liquid. Rather, the necessary energy is provided by the vibration caused by the ultrasonic nebuliser.

Thus, as an alternative to the conventional Büchi two-fluid nozzle, an ultrasonic nebuliser (Mini Humidifier) may be used to generate droplets of active agent, which are then dried within the Büchi drying chamber. In one arrangement, the USN is placed in the feed solution comprising an active agent in a specially designed glass chamber which allows introduction of the cloud of droplets generated by the USN directly into the heated drying chamber of the spray dryer.

The two-fluid nozzle is left in place to seal the hole in which it normally sits, but the compressed air was not turned on. The drying chamber is then heated up to 150°C inlet temperature, with 100% aspirator setting. Due to the negative pressure of the Büchi system, the nebulised cloud of droplets is easily drawn into the drying chamber, where the droplets are dried to form particles, which are subsequently classified by the cyclone, and collected in the collection jar. It is important that the level of feed solution in the chamber is regularly topped up to avoid over concentration of the feed solution as a result of continuous nebulisation.

In an embodiment of the present invention, the method of preparing the active particles involves the use of an ultrasonic nebuliser. Preferably, the ultrasonic nebuliser is incorporated in a spray drier.

Two theories have been developed which describe the mechanism of liquid disintegration and aerosol production in ultrasonic devices (Mercer 1981, 1968 and Sollner 1936). Lang (1962) observed that the mean droplet size generated from thin liquid layers was proportional to the capillary wavelength on the liquid surface. Using the experimentally determined factor of 0.34, the droplet diameter D is given by:

$$d_p = 0.34 (8\pi\gamma/pf^2)^{1/3}$$

p = solution density g cm<sup>-3</sup> (water = 1)

γ = surface tension dyn cm<sup>-1</sup> (water = 70)

f = frequency (MHz)



This means that for a frequency of 1.7 MHz the calculated droplet size is 2.9 $\mu$ m and for 2.4 MHz the calculated droplet size is 2.3  $\mu$ m. Atomisers are also available with frequencies up to 4 MHz with a calculated droplet size of 1.6  $\mu$ m.

5 Clearly, this allows the size of the droplets to be accurately and easily controlled, which in turn means that the active particle size can also be controlled (as the dried particle size will depend, to a great extent, on the size of the droplet).

10 Firstly, a USN was used to prepare dry powders using a feed solution of an active agent (heparin) alone, and a blend of active agent with 1% to 5% and 10% w/w FCA (l-leucine). The ultrasonic nebuliser feed flow rate was 130 ml/hr. The furnace temperature of the nebulised powders was set at 350°C. Figure 4 shows a schematic drawing of the ultrasonic set-up.

15 In order to test the processing of the powders, work was conducted using a Monohaler and a capsule filled with 20 mg powder and fired into a rapid TSI in the manner explained previously. The study used a TSI flow rate of 60lpm with a cut-off of approximately 5 $\mu$ m.

20 Three measurements were made for each blend and the results are summarised below in Table 10, giving the average values of the three sets of results obtained.

Table 10: rapid TSI results using the dry powder produced using a USN with varying amounts of FCA

Formulation	FPF% (metered dose)	FPD (mg)
Heparin (0% leucine)	1.1	0.22
Heparin + leucine (1% w/w)	17.4	3.5
Heparin + leucine (2% w/w)	30.2	6.0
Heparin + leucine (3% w/w)	28.6	5.7
Heparin + leucine (4% w/w)	48.4	9.7
Heparin + leucine (5% w/w)	41.5	8.3
Heparin + leucine (10% w/w)	55.8	11.8

The rapid TSI results using the dry powder produced using the USN indicate a low aerosolisation efficiency for pure heparin particles, but an improvement appeared in FPF with addition of l-leucine as a FCA.

- 5 The morphology of the particles was viewed using scanning electron micrographs (SEMs) prepared as set out above.

Figure 5a shows SEM micrographs of USN spray dried heparin alone (without secondary drying), whilst Figure 5b shows SEM micrographs of USN spray dried  
10 heparin with 10% leucine (without secondary drying).

As can be clearly seen from the SEMs, the shape of particles formed by co-spray drying an active agent and leucine using a USN differs to that of particles formed by co-spray drying heparin and leucine using a conventional 2-fluid nozzle spray drying  
15 technique.

The SEM micrographs of pure heparin generated using a USN show that the particles have a size of approximately  $2\mu\text{m}$  or less. The SEMs also show that these particles tend to form "hard" agglomerates of up to  $200\mu\text{m}$ .

20

In contrast, the SEMs of nebulised heparin and leucine show that the primary particles produced are of the same size as the pure heparin particles. However, these particles are discrete and agglomerates are not evident.

- 25 What is more, the distinctive dimples or wrinkles observed on the surface of the particles prepared by co-spray drying heparin and leucine using a 2-fluid nozzle spray drier (Figures 2a-2d) are not present when the particles are spray dried using a USN. Despite this, the co-spray dried particles formed using a USN still have an improved FPF and FPD over particles formed in the same way but without the  
30 FCA. In this case, this improvement is clearly not due to the shape of the particles.

We believe the leucine concentration at the surface of the solid particles is governed by several factors. These include the concentration of leucine in the solution which

forms the droplets, the relative solubility of leucine compared to heparin, the surface activity of leucine, the mass transport rate within the drying droplet and the speed at which the droplets dry. If drying is very rapid it is thought that the leucine content at the particle's surface will be lower than that for a slower drying rate. The  
5 leucine surface concentration is determined by the rate of leucine transport to the surface, and its precipitation rate, during the drying process.

As mentioned above, high gas flow rates around the droplets can accelerate drying and it is thought that, because the gas flow around droplets formed using a USN is  
10 low in comparison to that around droplets formed using conventional 2-fluid nozzles, droplets formed using the former technique dry more slowly than those produced by using conventional 2-fluid nozzles. The leucine (or other FCA) concentration on the shell of droplets and dried particles produced using a USN can be higher as a result. It is considered that these effects reduce the rate of solvent  
15 evaporation from the droplets and prevent "blowing" and, therefore, are responsible for the physically smaller and smoother primary particles we have observed (Kodas, T.T and Hampden Smith, M., 1999, Aerosol Processing of materials, 440). In this last regard, and as previously noted, droplets formed by the 2-fluid nozzle system have rapid air flow around them and they, therefore, dry very  
20 rapidly, and suffer from the effects of blowing.

In a particle size study, the particle size of the spray dried particles formed using the USN was analysed. The dry powders were dispersed at 4bar in a Helos disperser. The values of FPF <5µm and D10, D50 and D90 of the ultrasonic nebulised  
25 powders were measured and are indicated in Table 11 (10% by volume of the particles are of a size, measured by Malvern, that is below the D10 value. 50% by volume of the particles are of a size, measured by Malvern, that is below the D50 value and so on). The values are an average of three measurements.

Table 11: Particle size study of spray dried particles using USN, without secondary drying

Formulation	D10 ( $\mu\text{m}$ )	D50 ( $\mu\text{m}$ )	D90 ( $\mu\text{m}$ )	FPF% (<5 $\mu\text{m}$ )
Heparin (0% leucine)	0.43	1.07	4.08	90.52
Heparin + leucine (1% w/w)	0.41	0.90	1.79	99.97
Heparin + leucine (2% w/w)	0.41	0.89	1.75	100
Heparin + leucine (3% w/w)	0.41	0.88	1.71	100
Heparin + leucine (4% w/w)	0.41	0.86	1.71	100
Heparin + leucine (5% w/w)	0.41	0.90	1.84	100
Heparin + leucine (10% w/w)	0.41	0.89	1.76	100

Figure 6 shows a typical size distribution curve of three repeated tests of pure heparin powder generated using an ultrasonic nebuliser. The main peak represents the size of the individual active particles, ranging between 0.2 $\mu\text{m}$  and 4.5 $\mu\text{m}$  in diameter. The second, smaller peak between diameters of 17 to 35 $\mu\text{m}$  represents agglomerates of active particles.

Sympatec particle sizing (Helos dry dispersed) results showed that ultrasonic nebulised powders have a narrower size distribution and smaller mean particle size than the 2-fluid nozzle spray dried powders.

Figure 7a shows a comparison between particle size distribution curves of 2-fluid nozzle spray dried powders and ultrasonic nebulised powders comprising a blend of heparin with 2% leucine w/w.

Figure 7b shows a comparison between particle size distribution curves of 2-fluid nozzle spray dried powders and ultrasonic nebulised powders comprising a blend of heparin with 5% leucine w/w.

Figure 7c shows a comparison between particle size distribution curves of 2-fluid nozzle spray dried powders and ultrasonic nebulised powders comprising a blend of heparin with 10% leucine w/w.

These figures show a gradual disappearance of the second peak, indicating that the incidence of agglomerates is reduced as the amount of co-spray dried FCA is increased.

5 For the USN, spray dried material, agglomerate peaks disappears under the same test conditions when > 3 % leucine is added. For the 2-fluid nozzle spray dried material, agglomerate peaks disappear under the same test conditions when >10% leucine is added. This indicates that adding leucine as an FCA reduces the strength of the agglomerates in heparin powder. It further suggests that ultrasonic nebulised  
10 materials de-agglomerate more easily at lower leucine (FCA) contents. This may be related to the surface concentration of the leucine (FCA), as mentioned above.

The SEM images of ultrasonic nebulised powders (Figures 5a and b) also support the finding that addition of leucine facilitates aerosolisation. SEMs of pure heparin  
15 showed that although heparin primary particles are <2µm, large distinct agglomerates are formed. The SEMs of all of the powders comprising heparin and leucine show that the primary particle size is still <2µm, but the large agglomerates are not evident.

20 It can be seen that particles formed using a spray drying process involving an ultrasonic nebuliser have been found to have a greater FPF than those produced using a standard spray drying apparatus, for example with a two nozzle configuration.

25 What is more, the particles formed using a spray drying process using a USN have been found to have a narrower particle size distribution than those produced using a standard spray drying apparatus, for example with a two nozzle configuration.

Similar results to those shown above when using USNs are expected for spray  
30 drying using other means which produce low velocity droplets. For example, further alternative nozzles may be used, such as electrospray nozzles or vibrating orifice nozzles. These nozzles, like the ultrasonic nozzles, are momentum free, resulting in a spray which can be easily directed by a carrier air stream.

Another attractive type of nozzle for use in a spray drying process is one which utilises electro-hydrodynamic atomisation. A tailor cone is created at a fine needle by applying high voltage at the tip. This shatters the droplets into an acceptable  
5 monodispersion. This method does not use a gas flow, except to transport the droplets after drying. An acceptable monodispersion can also be obtained utilising a spinning disc generator.

The nozzles such as ultrasonic nozzles, electrospray nozzles or vibrating orifice  
10 nozzles can be arranged in a multi nozzle array, in which many single nozzle orifices are arranged in a small area and facilitate a high total throughput of feed solution. The ultrasonic nozzle is an ultrasonic transducer (a piezoelectric crystal). If the ultrasonic transducer is located in an elongate vessel the output may be raised  
15 significantly.

#### Moisture Profiling

When active particles are produced by spray drying, some moisture will remain in the particles. This is especially the case where the active agent is temperature sensitive and does not tolerate high temperatures for the extended period of time  
20 which would normally be required to remove further moisture from the particles.

The amount of moisture in the particles will affect various particle characteristics, such as density, porosity, flight characteristics, and the like.

25 Therefore, according to a third aspect of the present invention, a method of preparing a dry powder composition is provided, wherein the method comprises a step of adjusting the moisture content of the particles.

In one embodiment, the moisture adjustment or profiling step involves the removal  
30 of moisture. Such a secondary drying step preferably involves freeze-drying, wherein the additional moisture is removed by sublimation. An alternative type of drying for this purpose is vacuum drying.

Generally, the secondary drying takes place after the active has been co-spray dried with a force control agent. In another embodiment, the secondary drying takes place after nebulised active agent has been spray dried, wherein the active agent was optionally in a blend with a FCA.

5

The secondary drying step has two particular advantages. Firstly, it can be selected so as to avoid exposing the pharmaceutically active agent to high temperatures for prolonged periods. Furthermore, removal of the residual moisture by secondary drying is significantly cheaper than removing all of the moisture from the particle by spray-drying. Thus, a combination of spray drying and freeze-drying or vacuum drying is economical and efficient, and is suitable for temperature sensitive pharmaceutically active agents.

15 In order to establish the effect of secondary drying of the powders, samples of active agent alone and of a combination of active agent (heparin) and an FCA (leucine 10% w/w), were secondary dried at 50°C under vacuum for 24 hours.

20 The results set out in Table 12 indicate the secondary drying step further raised the FPF and FPD, when they are compared to the results in Table 10, which relates to equivalent particles which have not undergone secondary drying.

Table 12: rapid TSI results using the dry powder produced using a USN with varying amounts of FCA, after secondary drying

Formulation	FPF% (metered dose)	FPD (mg)
Heparin (0% leucine)	4.1	0.82
Heparin + leucine (10% w/w)	70.8	14.2

25

In a later stage experiments have been conducted on samples of active agent (heparin) and an FCA (leucine 5% w/w), were secondary dried at 40°C under vacuum for 24 hours.

Particle size tests were also conducted to show the effect of secondary drying. The particle size of the spray dried particles formed using the USN was analysed. The dry powders were dispersed at 4bar in a Helos disperser. The powders were secondary dried over 24 hours under vacuum.

5

The values of FPF <5µm and D10, D50 and D90 of the ultrasonic nebulised powders were measured and are indicated in Table 14.

Table 14: Particle size study of spray dried particles using USN, after secondary drying

Formulation	D10	D50	D90	FPF% (<5µm)
Heparin (0% leucine)	0.44	1.06	2.93	92.35
Heparin + leucine (10% w/w)	0.40	0.87	1.77	100

10

Thus, by comparing the results in Table 14 with those of Table 11, one can see that secondary drying particles did not result in any significant change in particle size, both for active agent alone and for a blend of active agent and FCA.

15

Figure 8 shows a comparison between particle size distribution curves of secondary dried and not secondary dried powders. The powder used was heparin with 10% leucine w/w. Clearly, there is virtually no difference between the curves, illustrating that secondary drying does not have an effect on particle size.

20

Then, in order to establish whether the effect of secondary drying varied between particles produced using a USN and a 2-fluid nozzle, the particle size study of secondary drying with spray dried particles formed using the USN was repeated but using a 2-fluid nozzle spray drier. Once again, the powders were secondary dried over 24 hours under vacuum. Values of FPF <5µm and D10, D50 and D90 of the

25

spray dried powders are indicated in Table 15 below.



**Table 15: Particle size study of 2-fluid nozzle spray dried particles after secondary drying**

Formulation	D10	D50	D90	FPF% (<5µm)
Heparin + leucine (2% w/w)	0.59	2.09	5.19	89.57
Heparin + leucine (5% w/w)	0.61	2.16	4.77	91.18
Heparin + leucine (10% w/w)	0.58	2.04	3.93	96.6
Heparin + leucine (25% w/w)	0.63	2.34	4.85	91.15
Heparin + leucine (50% w/w)	1.05	3.03	6.62	80.03

Figures 2e to 2h show SEM micrographs of 2-fluid nozzle spray dried heparin with 2, 5, 10 and 50% leucine, after secondary drying. When one compares the particles in these Figures to those in Figures 2a-d, it can be seen that the secondary drying does appear to increase the "collapse" of the particles. Thus, even at low percentages of FCA, the secondary dried particles have a more wrinkled or shrivelled shape.

10

**Table 16: Moisture content of 2 fluid nozzle spray dried particles under standard condition**

Formulation	% w/w Moisture before secondary drying	% w/w Moisture after secondary drying
Heparin + Leucine 5%	9.57	2.18

The above discussed experiments and the moisture content values determined by Karl-Fisher methodology set out in Table 16 show that secondary drying significantly reduces the moisture content of heparin particles (by approximately 6.5 %). This would imply that the heparin is drying in such a way that there is a hard outer shell holding residual moisture, which is driven off by secondary drying, and entrapped moisture is trapped with in a central core. One could infer that the residence time of the particle in the drying chamber is too short, and that the outer shell is being formed rapidly and is too hard to permit moisture to readily escape during the initial spray drying process.

20

Secondary drying can also be beneficial to the stability of the product, by bringing down the moisture content of a powder. It also means that drugs which may be very heat sensitive can be spray dried at lower temperatures to protect them, and then subjected to secondary drying to reduce the moisture further, and protect the drug.

5

In another embodiment of the third aspect of the invention, the moisture profiling involves increasing the moisture content of the spray dried particles.

Preferably, the moisture is added by exposing the particles to a humid atmosphere.

10 The amount of moisture added can be controlled by varying the humidity and/or the length of time for which the particles are exposed to this humidity.

From the results presented herein, it can be seen that improvement in the FPF of spray dried active agents can be achieved by using one or more of the following:

15

- 1) co-spray drying the active agent with a force control agent;
- 2) using a means of producing droplets for spray drying which results in slow velocity droplets, the size of which can be accurately controlled; and
- 3) moisture profiling of the spray dried particles.

20

The above discussion and experiments focussed on conventional spray drying apparatus and ultrasonic nebulizing apparatus. However, it should be noted that further changes to the apparatus may be made to ensure that the particles collected at the end of the spray drying process have the optimum properties.

25

For example, the nature of the drying chamber may be changed, to get better drying and/or other advantages. Thus, in one embodiment of the invention, a spray drying apparatus comprising a drying chamber with heated walls may be used. Such drying chambers are known and they have the advantage that the hot walls discourage  
30 deposition of the spray dried material on them. However, the heated walls create a temperature gradient within the drying chamber, where the air in the outer area of the chamber is hotter than that in the centre of the chamber. This uneven temperature can cause problems because particles which pass through different

parts of the drying chamber will have slightly different properties as they may well dry to differing extents.

5 In an alternative embodiment, the spray drying apparatus comprises a radiative heat source in the drying chamber. Such heat sources are not currently used in spray drying. This type of heat source has the advantage that it does not waste energy heating the air in the drying chamber. Rather, only the droplets/particles are heated as they pass through the chamber. This type of heating is more even, avoiding the temperature gradients mentioned above in connection with drying chambers with  
10 heated walls. This also allows the particles to dry from inside the droplets thus reducing or avoiding crust forming.

In yet another embodiment, the spray dried particles are collected using a vertical drying column. These columns are already known in spray drying devices and they  
15 collect the spray dried particles by carrying the particles up a vertical column using an air flow, rather than simply relying on gravity to collect the particles in a collection chamber. The advantage of using such a vertical drying column to collect the spray dried particles is that it allows for aerodynamic classification of the particles. Fine particles tend to be carried well by the air flow, whilst larger particles  
20 are not. Therefore, the vertical drying column does not collect these larger particles.

### 25 Micronised Dry Powder Particles

The word "milling" as used herein refers to any mechanical process which applies sufficient force to the particles of active material that it is capable of breaking coarse particles (for example, particles with a MMAD greater than 100 $\mu$ m) down to fine particles (for example, having a MMAD not more than 50 $\mu$ m) or which applies  
30 a relatively controlled compressive force.

Fine particles of active material suitable for pulmonary administration have often been prepared by milling in the past. However, when using many of the known

milling techniques, once the particles reach a minimum size, referred to as the "critical size", they tend to re-combine at the same rate as being fractured, or do not fracture effectively and therefore no further reduction in the particle size is achieved. Critical sizes are specific to particular mills and sets of milling conditions.

5

Thus, manufacture of fine particles by milling can require much effort and there are factors which consequently place limits on the minimum size of particles of active material which can be achieved, in practice, by such milling processes.

10 Improvements have been made to conventional milling methods by co-milling active material with additive materials. Such "co-milling" is described in WO 02/43701. This earlier patent application describes methods for making composite active particles for use in a pharmaceutical composition for pulmonary  
15 administration using a milling step. In these improved methods, particles of active material are milled in the presence of particles of an additive material which is suitable for the promotion of the dispersal of the composite active particles upon actuation of an inhaler. This application is directed to methods of compressive milling, such as Mechano-Fusion and ball milling, or to impact milling in a non-compressible fluid, such as a high pressure homogeniser.

20

The resultant composite active particles are fine particles of active material which have, upon their surfaces, an amount of the additive material. The additive material is preferably in the form of a coating on the surfaces of the particles of active material. The coating may be a discontinuous coating. The additive material may be  
25 in the form of particles adhering to the surfaces of the particles of active material.

At least some of the composite active particles may be in the form of agglomerates. However, when the composite active particles are included in a pharmaceutical composition, the additive material promotes the dispersal of the composite active  
30 particles on administration of that composition to a patient, via actuation of an inhaler.

"Actuation of an inhaler" refers to the process during which a dose of the powder is removed from its rest position in the inhaler. That step takes place after the powder has been loaded into the inhaler ready for use. The effectiveness of that promotion of dispersal has been found to be enhanced in comparison to a composition made  
5 by simple blending of similarly sized particles of active material with additive material.

In the prior art, it is stated that milling can be used to substantially decrease the size of particles of active agent. However, if the particles of active agent are already  
10 fine, for example have a MMAD of less than 20µm prior to the milling step, the size of those particles may not be significantly reduced where the milling of these active particles takes place in the presence of an additive material. Rather, milling of fine active particles with additive particles using the methods described in the prior art (for example, in WO 02/43701) will result in the additive material becoming  
15 deformed and being smeared over or fused to the surfaces of the active particles. The resultant composite active particles have been found to be less cohesive after the milling treatment. However, there is still the disadvantage that this is not combined with a significant reduction in the size of the particles.

20 The co-milling processes described in the prior art favour the use of the milling processes known as the Mechano-Fusion and Cyclomix methods. These processes were found to apply a high enough degree of force to separate the individual particles of active material and to break up tightly bound agglomerates of the active particles such that effective mixing and effective application of the additive material  
25 to the surfaces of those particles is achieved. An especially desirable aspect of the described co-milling processes was that the additive material becomes deformed in the milling and may be smeared over or fused to the surfaces of the active particles.

The milling steps used in the prior art co-milling generally involve bringing the  
30 additive particles into close contact with the surfaces of the active particles. In order to achieve coated particles, a degree of intensive mixing is required to ensure a sufficient break-up of agglomerates of both constituents, dispersal and even distribution of additive over the active particles. The process uses shear to mix the

constituents and to break up their constituent agglomerates, and then compressive force to smear the additive and mechanically fuse it to the host surface.

5 A wide range of milling devices and conditions are said to be suitable to achieve the desired results discussed above. The milling conditions, for example, intensity of milling and duration, should be selected to provide the required degree of force.

Ball milling is a suitable milling method. Centrifugal and planetary ball milling are especially preferred methods. Alternatively, a high pressure homogeniser may be  
10 used in which a fluid containing the particles is forced through a valve at high pressure producing conditions of high shear and turbulence. Such homogenisers may be more suitable than ball mills for use in large scale preparations of the composite active particles.

15 Suitable homogenisers include EmulsiFlex high pressure homogenisers which are capable of pressures up to 4000 bar, Niro Soavi high pressure homogenisers (capable of pressures up to 2000 bar), and Microfluidics Microfluidisers (maximum pressure 2750 bar). The milling step may, alternatively, involve a high energy media mill or an agitator bead mill, for example, the Netzsch high energy media mill, or  
20 the DYNO-mill (Willy A. Bachofen AG, Switzerland). Alternatively the milling may be a dry coating high energy process such as a Mechano-Fusion system (Hosokawa Micron Ltd) or a Hybridizer (Nara).

Especially preferred prior art co-milling methods are those involving the Mechano-  
25 Fusion, Hybridiser and Cyclomix instruments. Indeed, the milling step is said to preferably involve the compression of the mixture of active and additive particles in a gap (or nip) of fixed, predetermined width, for example as in the Mechano-Fusion and Cyclomix methods.

30 In light of the foregoing, it is an aim of the present invention to achieve a further reduction in particle size whilst co-milling active and additive particles to produce composite active particles. In particular, it is an aim of the present invention to

provide composite active particles having an enhanced FPD and FPF, compared to those disclosed in the prior art.

5 According to a first aspect of the present invention, a method is provided for making composite active particles for use in a pharmaceutical composition for pulmonary inhalation, the method comprising jet milling active particles in the presence of particles of additive material, preferably wherein the jet milling is conducted using air or a compressible gas or fluid.

10 The additive materials used in this co-jet milling process can be any of the additive materials discussed herein.

In one embodiment, the jet milling is carried out at an inlet pressure of between 0.1 and 3 bar, to achieve blending of the active and additive particles.

15

In an alternative embodiment, the jet milling is carried out at an inlet pressure of between 3 and 12 bar, to achieve a reduction of the sizes of the active and additive particles.

20 In a preferred embodiment of the invention, the additive particles comprise an amino acid, a metal stearate or a phospholipid. More preferably, the additive particles comprise one or more of L-, D- or DL- forms of leucine, isoleucine, lysine, valine, methionine, phenylalanine, or Aerocine, lecithin or magnesium stearate. In one embodiment, the additive particles comprise leucine and preferably l-leucine.

25

In another embodiment, 90% by mass of the active particles jet-milled are initially less than 20 $\mu$ m in diameter. More preferably, 90% by mass of the active particles jet-milled are initially less than 10 $\mu$ m in diameter, and most preferably less than 5 $\mu$ m in diameter.

30

In another embodiment, 90% by mass of the additive particles jet-milled are initially less than 20 $\mu$ m in diameter. More preferably, 90% by mass of the additive particles

jet-milled are initially less than 10 $\mu$ m in diameter, and most preferably less than 5 $\mu$ m in diameter or less than 3 $\mu$ m in diameter

5 In another embodiment, the jet milling is carried out at temperatures below room temperature, preferably at a temperature below 10°C, more preferably at a temperature below 0°C.

10 In accordance with a second aspect of the present invention, a pharmaceutical dry powder composition for pulmonary inhalation is provided, comprising composite active particles made by a method according to the first aspect of the invention.

The MMAD of the composite active particles is preferably not more than 10 $\mu$ m, and advantageously it is not more than 5 $\mu$ m, more preferably not more than 3 $\mu$ m, even more preferably not more than 2 $\mu$ m, more preferably not more than 1.5 $\mu$ m, even  
15 more preferably not more than 1.2  $\mu$ m and most preferably not more than 1 $\mu$ m.

Accordingly, advantageously at least 90% by weight of the composite active particles have a diameter of not more than 10 $\mu$ m, advantageously not more than 5 $\mu$ m, preferably not more than 3 $\mu$ m, even more preferably not more than 2.5 $\mu$ m,  
20 even more preferably not more than 2 $\mu$ m and more preferably not more than 1 $\mu$ m.

In a preferred embodiment of the present invention the resultant dry powder formulation has a reproducible FPF(ED) of at least 70%. Preferably, the FPF(ED) will be at least 80%, more preferably the FPF(ED) will be at least 85%, and most  
25 preferably the FPF(ED) will be at least 90%.

In a further preferred embodiment, the dry powder formulation has a reproducible FPF(MD) of at least 60%. Preferably, the FPF(MD) will be at least 70%, more preferably the FPF(MD) will be at least 80%, and most preferably the FPF(MD) will  
30 be at least 85%.

Jet mills are capable of reducing solids to particle sizes in the low-micron to submicron range. The grinding energy is created by gas streams from horizontal



grinding air nozzles. Particles in the fluidized bed created by the gas streams are accelerated towards the centre of the mill, colliding with slower moving particles. The gas streams and the particles carried in them create a violent turbulence and as the particles collide with one another they are pulverized.

5

In the past, jet-milling would not have been considered attractive for co-milling active and additive particles, with processes like Mechano-Fusion and Cyclomixing being clearly preferred. The collisions between the particles in a jet mill are somewhat uncontrolled and those skilled in the art, therefore, would have  
10 considered it unlikely for this technique to be able to provide the desired deposition of a coating of additive material on the surface of the active particles. Moreover, it was believed that, unlike the situation with Mechano-Fusion and Cyclomixing, segregation of the powder constituents occurred in jet mills, such that the finer particles, that were believed to be the most effective, could escape from the process.  
15 In contrast, it could be clearly envisaged how techniques such as Mechano-Fusion would result in such coating.

As the name suggests, Mechano-Fusion is a dry coating process designed to mechanically fuse a first material onto a second material. The first material is  
20 generally smaller and/or softer than the second. The Mechano-Fusion and Cyclomix working principles are distinct from alternative milling techniques in having a particular interaction between an inner element and a vessel wall, and are based on providing energy by a controlled and substantial compressive force.

25 The fine active particles and the additive particles are fed into the Mechano-Fusion driven vessel, where they are subject to a centrifugal force and are pressed against the vessel inner wall. The powder is compressed between the fixed clearance of the drum wall and a curved inner element with high relative speed between drum and element. The inner wall and the curved element together form a gap or nip in which  
30 the particles are pressed together. As a result, the particles experience very high shear forces and very strong compressive stresses as they are trapped between the inner drum wall and the inner element (which has a greater curvature than the inner drum wall). The particles are pressed against each other with enough energy to

locally heat and soften, break, distort, flatten and wrap the additive particles around the core particle to form a coating. The energy is generally sufficient to break up agglomerates and some degree of size reduction of both components may occur.

- 5 As illustrated by the experimental results set out below, it has been surprisingly found that co-milling active particles with additive particles using jet milling results in composite active particles having significantly better FPF and FPD than those produced by co-milling using Mechano-Fusion.
- 10 A number of formulation approaches were examined. As Mechano-Fusion of drug particles had been shown in the prior art to significantly reduce cohesion, this was further tested. The aim was to Mechano-Fuse active particles with additive particles in order to significantly reduce powder cohesion and adhesion, and to allow resuspension and dispersion to occur in both high energy active and lower energy
- 15 passive devices.

Jet milling has previously been shown to be capable of significantly reducing the median primary particle size of active particles (for example, from 3 or 2 $\mu$ m to 1 $\mu$ m), while also allowing good aerosolisation from a delivery device. This further

20 reduction in primary particle size is considered to be advantageous for delivery of systemically targeted molecules to the deep lung. The aim was to co-jet mill active particles with additive particles in order to reduce primary particle size while still achieving a reduction in the level of powder cohesion and adhesion. This was tested at high and low air pressures.

25

#### Test Methods

All materials were evaluated in the Next Generation Impactor (NGI). Details of the test are provided in each case.

- 30 In addition, some of the resulting powders were characterised by a standard dispersion test. This process required feeding approximately 20mg of test powder into the Malvern Mastersizer via a modified Sirocco powder feeder. The powder was challenged with 4 dispersion energies, provided by 4 air pressure variants (2, 1,

0.5 and 0.1 bar). This spectrum of dispersion energies had been shown to characterise the level of cohesion within a test powder, and to be a good predictor of aerosolisation behaviour in a passive DPI. Data were presented in the form of particle size distribution and the changes in d50 and d97 values as a function of dispersion energy. d50 is the particle size measured by Malvern, for which 50% of the particles by volume are less than this size. d97 is the particle size measured by Malvern, for which 97% of the particles by volume are less than this size.

Formulations were processed using:

- 1) The Hosokawa Micron Mechano-Fusion AMS Mini system. This system was operated with a novel rotor, providing a 1mm compression gap; and
- 2) The Hosokawa Micron AS50 spiral jet mill.

The in-vitro testing was performed using an Aspirair (trade mark) device.

15

The formulations were composed of one or more of the following constituents:

Magnesium stearate (standard grade)

L-Leucine (Ajinomoto) and jet milled by Micron Technologies

Sorbolac 400 lactose

20 Micronised clobazam

Micronised apomorphine hydrochloride

Micronised lactose

Re-condensed Leucine (Aerocine)

#### 25 Mechano-Fused Formulations including Additive Material

19.0g of Sorbolac 400 lactose and 1.0g of micronised L-leucine were combined in the Mechano-Fusion system. The material was processed at a setting of 20% power for 5 minutes, followed by a setting of 80% power for 10 minutes. This material was given the reference "1A".

30

A batch of micronised apomorphine hydrochloride was gently pressed through a 212µm metal sieve, using the rounded face of a metal spatula. 3.6g of this was then combined with 14.4g of "1A" in the Mechano-Fusion system. The material was

processed at a setting of 20% power for 5 minutes. After blending, this powder was rested overnight, and then was gently pushed through a 300µm metal sieve with a spatula. This material was recorded as "1B".

- 5 The content uniformity of this blend was assessed by taking 10 approximately 2mg samples, recording the weights on a 4 figure balance, and then assaying for drug content by HPLC. The "1B" batch had an average drug content of 22.6%, with relative standard deviation of 4.0%.
- 10 19.0g of Sorbolac 400 lactose and 1.0g of micronised L-leucine were combined in the Mechano-Fusion system. The material was processed at a setting of 20% power for 5 minutes, followed by a setting of 80% power for 10 minutes. This material was recovered and recorded as "2A".
- 15 15.0g of apomorphine hydrochloride and 0.75g of micronised L-leucine were combined in the Mechano-Fusion system. The material was processed at a setting of 20% power for 5 minutes, followed by a setting of 80% power for 10 minutes. This material was recovered and recorded as "2B".
- 20 4.2g of "2B" was then combined with 15.8g of "2A" in the Mechano-Fusion system. The material was processed at a setting of 20% power for 5 minutes. After blending, this powder was rested overnight, and then was gently pushed through a 300µm metal sieve with a spatula. This material was recorded as "2C".
- 25 The content uniformity of this blend was assessed by taking 10 approximately 2mg samples, recording the weights on a 4 figure balance, and then assaying for drug content by HPLC. The "2C" batch had an average drug content of 23.5%, with relative standard deviation of 3.2%.
- 30 A number of foil blisters were filled with approximately 2mg of "1B" and "2C". These were then fired from an Aspirair device into an NGI at a flow rate of 60l/m. The Aspirair was operated with a reservoir of 15ml of at 1.5 bar. This in vitro test was conducted 3 times. The results are summarised in Tables 1 and 2 below.

Table 1

Formulation	MD (mg)	DD (mg)	FPD ( $<5\mu\text{m}$ ) (mg)	FPF % ( $<5\mu\text{m}$ )	MMAD
1B	335	309	200	65	1.36
	367	349	210	60	1.67
	334	308	184	60	1.42
2C	453	412	214	52	1.51
	432	387	196	51	1.55
	396	357	164	46	1.81

Table 2 (\* Percentages of MD)

Formulation	*recovery	*throat	*blister	*device
1B	74%	25%	4%	1%
	81%	28%	3%	1%
	74%	30%	5%	2%
2C	96%	35%	7%	1%
	92%	35%	7%	1%
	84%	39%	8%	1%

5

These initial tests on the first apomorphine HCl formulations, showed device retention was reduced in comparison with the concurrent non-FCA formulations. Also, very fine MMADs indicated near perfect dispersion. However, when the Mechano-Fused particles were dispersed, these benefits were offset by substantially increased throat deposition.

10

#### Comparison of Co-Jet Milled and Mechano-Fused Formulations (Clobazam)

1.01g of micronised clobazam was weighed out, and then gently pressed through a 300 $\mu\text{m}$  metal sieve, using the rounded face of a metal spatula. This formulation was recorded as "3A".

15

9.37g of micronised clobazam was then combined with 0.50g of micronised L-leucine in the Mechano-Fusion system. The material was processed at a setting of 20% power for 5 minutes, followed by a setting of 80% power for 10 minutes. This material was recorded as "4A". After blending, this powder was then gently pushed through a 300 $\mu\text{m}$  metal sieve with a spatula. This material was recorded as "4B".

20

9.57g of micronised clobazam was then combined with 0.50g of magnesium stearate in the Mechano-Fusion system. The material was processed at a setting of 20% power for 5 minutes, followed by a setting of 80% power for 10 minutes. This material was recorded as "5A". After blending, this powder was rested overnight, and then was gently pushed through a 300µm metal sieve with a spatula. This material was recorded as "5B".

9.5g of micronised clobazam was then combined with 0.50g of micronised L-leucine in the Mechano-Fusion system. The material was processed at a relatively low speed setting of 20% power for 5 minutes. This process was intended only to produce a good mix of the components. This material was recorded as "6A".

6.09g of "6A" fed at approximately 1g per minute into an AS50 spiral jet mill, set with an injector pressure of about 7 bar and a grinding pressure of about 5 bar. The resulting material was recovered and recorded as "6B".

After milling, this powder was rested overnight, and then was gently pushed through a 300µm metal sieve with a spatula. This material was recorded as "6C".

9.5g of micronised clobazam was then combined with 0.50g of magnesium stearate in the Mechano-Fusion system. The material was processed at a setting of 20% power for 5 minutes. This material was recorded as "7A".

6.00g of "7A" was fed at approximately 1g per minute into the AS50 spiral jet mill, set with an injector pressure of about 7 bar and a grinding pressure of about 5 bar. The resulting material was recovered and recorded as "7B".

After milling, this powder was gently pushed through a 300µm metal sieve with a spatula. This material was recorded as "7C".

A batch of re-condensed leucine (also referred to as "Aerocine") was produced by subliming to vapour a sample of leucine in a tube furnace, and re-condensing as a

very finely dispersed powder as the vapour cooled. This batch was identified as "8A".

5 9.5g of micronised clobazam was then combined with 0.50g of Aerocine, in the Mechano-Fusion system. The material was processed at a setting of 20% power for 5 minutes, followed by a setting of 80% power for 10 minutes. . This material was recorded as "8B". After blending, this powder was rested overnight, and then was gently pushed through a 300µm metal sieve with a spatula. This material was recorded as "8C".

10

9.5g of micronised clobazam was combined with 0.50g of Aerocine in the Mechano-Fusion system. The material was processed at a setting of 20% power for 5 minutes. 7.00g of this powder was then fed into the AS50 spiral jet mill, set with an injector pressure of about 7 bar and a grinding pressure of about 5 bar. The  
15 resulting material was recovered and recorded as "9A".

After milling, this powder was gently pushed through a 300µm metal sieve with a spatula. This material was recorded as "9B".

20 A number of foil blisters were filled with approximately 2mg of the following formulations:

3A - no milling & no FCA

4B - leucine & Mechano-Fused

25 5B - magnesium stearate & Mechano-Fused

6C - leucine & co-jet milled

7C - magnesium stearate & co-jet milled

8C - Aerocine & co-jet milled

9B - Aerocine & Mechano-Fused.

30

These formulations were then fired from an Aspirair device into an NGI at a flow rate of 60l/m. The Aspirair was operated under 2 conditions for each formulation: with a reservoir of 15ml of air at 1.5 bar or with a reservoir of 30ml of air at 0.5 bar.

These in vitro tests were conducted in each case once to screen, and then the selected primary candidate was retested.

Through life dose uniformity for the selected candidate was tested by firing 30  
5 doses, with the emitted doses collected by DUSA.

Full details of the results are attached. The impactor test results are summarised in Tables 3, 4 and 5 below.



Table 3

Formulation	MD (mg)	DD (mg)	FPD(mg) ( $<5\mu\text{m}$ )	MMAD
3A 0.5 bar 30ml	2.04	1.12	0.88	2.91
3A 1.5 bar 15ml	1.92	1.74	1.23	2.86
4B 0.5 bar 30ml	1.84	1.48	0.82	3.84
4B 1.5 bar 15ml	1.80	1.56	0.81	3.32
5B 0.5 bar 30ml	1.84	1.53	1.17	2.34
5B 1.5 bar 15ml	1.85	1.55	1.12	2.22
6C 0.5 bar 30ml	1.93 1.86	1.80 1.73	1.67 1.62	2.11 2.11
6C 1.5 bar 15ml	1.85 1.97	1.76 1.86	1.61 1.67	1.26 2.07
6C 1.5 bar 15ml (silicon coated plates)	1.74	1.65	1.46	2.03
7C 0.5 bar 30ml	2.06	1.99	1.87	1.97
7C 1.5 bar 15ml	1.89	1.78	1.63	1.79
8C 0.5 bar 30ml	1.82	1.73	1.62	2.02
8C 1.5 bar 15ml	1.81	1.74	1.57	2.01
9B 0.5 bar 30ml	1.88	1.73	1.04	3.48
9B 1.5 bar 15ml	1.80	1.64	0.94	3.12

Table 4

Formulation	FPF(MD) % ( $<5\mu\text{m}$ )	FPF(ED) % ( $<5\mu\text{m}$ )	FPF(ED) % ( $<3\mu\text{m}$ )	FPF(ED) % ( $<2\mu\text{m}$ )	FPF(ED) % ( $<1\mu\text{m}$ )
<b>3A</b> 0.5 bar 30ml	43	78	49	32	17
<b>3A</b> 1.5 bar 15ml	64	71	45	24	6
<b>4B</b> 0.5 bar 30ml	45	55	28	15	7
<b>4B</b> 1.5 bar 15ml	45	52	30	18	9
<b>5B</b> 0.5bar 30ml	64	77	54	42	30
<b>5B</b> 1.5 bar 15ml	61	72	52	38	25
<b>6C</b> 0.5 bar 30ml	87 87	93 94	77 76	44 44	8 9
<b>6C</b> 1.5 bar 15ml	87 85	91 90	89 73	79 44	27 10
<b>6C</b> 1.5 bar 15ml (silicon coated plates)	84	89	74	45	8
<b>7C</b> 0.5 bar 30ml	91	94	79	50	14
<b>7C</b> 1.5 bar 15ml	86	92	82	56	16
<b>8C</b> 0.5 bar 30ml	89	93	79	48	12
<b>8C</b> 1.5 bar 15ml	87	90	76	46	9
<b>9B</b> 0.5 bar 30ml	55	60	34	24	15
<b>9B</b> 1.5 bar 15ml	52	57	34	24	15


Table 5

Formulation	*recovery	*throat	*blister	*device
3A 0.5 bar 30ml	102%	3%	1%	43%
3A 1.5 bar 15ml	96%	15%	1%	8%
4B 0.5 bar 30ml	97%	15%	7%	12%
4B 1.5 bar 15ml	95%	27%	6%	8%
5B 0.5 bar 30ml	97%	7%	13%	4%
5B 1.5 bar 15ml	98%	14%	12%	4%
6C 0.5 bar 30ml	97% 101%	2% 3%	1% 1%	6% 5%
6C 1.5 bar 15ml	99% 104%	6% 6%	1% 3%	4% 3%
6C 1.5 bar 15ml (silicon coated plates)	91%	8%	1%	4%
7C 0.5 bar 30ml	110%	2%	1%	3%
7C 1.5 bar 15ml	99%	6%	2%	3%
8C 0.5 bar 30ml	99%	3%	1%	4%
8C 1.5 bar 15ml	95%	6%	1%	3%
9B 0.5 bar 30ml	96%	16%	2%	7%
9B 1.5 bar 15ml	95%	26%	4%	5%

From these results it can be seen that the co-jet milled formulations exhibited exceptional FPFs, which were significantly better than those of the Mechano-Fused formulations. This improvement would appear to be largely due to reduced throat deposition, which was less than 8% for the co-jet milled formulations, compared to 15% for the pure drug and up to 27% for the Mechano-Fused formulations.

Through life dose uniformity for the primary candidate, 6C,

was tested by firing 30 doses, with the emitted doses collected by DUSA.  
Through life dose uniformity results are presented below:



5

The mean ED was 1965  $\mu\text{g}$ , with an RSD of 2.8%.

This material consequently demonstrated excellent through life dose reproducibility.

10 The results of dispersion testing of these powdered materials are provided in the Figures. The particle size distributions indicate both the level of size reduction obtained by the co-milling, and the level of dispersion efficiency at varied pressures. The d50 and d97 plots provide a further indication of this dispersibility of the powders as a function of pressure.

15

The graphs in Figures 1A to 6A figures show the particle size distribution, with the four curves representing powder jet-milled at different pressures, namely at 2.0 bar, 1.0 bar, 0.5 bar and at 0.1 bar. The graphs in Figure 1B to 6B show the level of dispersion efficiency at different pressures, in terms of d50 and d97.

Figures 1A and 1B are the results of testing formulation "3A".

Figures 2A and 2B are the results of testing formulation "4B".

Figures 3A and 3B are the results of testing formulation "5B".

5 Figures 4A and 4B are the results of testing formulation "6C".

Figures 5A and 5B are the results of testing formulation "7C".

Figures 6A and 6B are the results of testing formulation "8C".

Figures 7A and 7B are the results of testing formulation "9B".

10 From the graphs, one can see that formulation 5B exhibited much the best dispersion.

This set of dispersibility tests shows that the MechanoFused powders disperse more easily at lower pressures than the original drug, and that magnesium stearate gives  
15 the best dispersion within these, followed by Aerocine and leucine. The co-jet milled powders do not appear to disperse any more easily in this test than the original drug, however the primary particle sizes (d50) are reduced.

#### 20 Comparison of Co-Jet Milled and Mechano-Fused Formulations (Apomorphine)

Next, in order to establish the effect of co-jet milling on different active agent, further apomorphine hydrochloride formulations were prepared and tested.

2.1g "2B" plus 0.4g micronised leucine were blended by hand in a mortar and pestle  
25 for 2 minutes. 2.5g micronised lactose was added and blended for a further 2 minutes. 5g micronised lactose was added and blended for another 2 minutes. This mixture was then processed in the AS50 Spiral jet mill using an inlet pressure of 7 bar and a grinding pressure of 5 bar, feed rate 5ml/min. This powder was gently pushed through a 300µm metal sieve with a spatula. This material was recorded as  
30 "10A".

1.5g "10A" was combined with 0.20g micronised L-leucine and 3.75g of Sorbolac 400 lactose by hand in a mortar with a spatula for 10 minutes. This powder was

gently pushed through a 300µm metal sieve with a spatula. This material was recorded as "10B".

5 9g micronised apomorphine HCl plus 1g micronised leucine were placed in the Mechano-Fusion system and processed at 20% (1000rpm) for 5 minutes. This initial blend was then processed in the AS50 Spiral jet mill using an inlet pressure of 7 bar and a grinding pressure of 5 bar, feed rate 5ml/min. This material was recorded as "11A".

10 After blending, this powder was rested overnight, and then was gently passed through a 300µm metal sieve by shaking. This material was recorded as "11B".

2g micronised apomorphine HCl plus 0.5g micronised leucine were blended by hand in mortar and pestle for 2 minutes. 2.5g micronised lactose was added and blended  
15 for a further 2 minutes. Then 5g micronised lactose was added and blended for another 2 minutes. This mixture was then processed in the AS50 Spiral jet mill using an inlet pressure of 7 bar and a grinding pressure of 5 bar, feed rate 5ml/min. This powder was gently pushed through a 300µm metal sieve with a spatula. This material was recorded as "12A".

20 16.5g of Sorbolac 400 and 0.85g of micronised leucine were placed in the Mechano-Fusion system and processed at 20% (1000rpm) for 5 minutes then at 80% (4000rpm) for 10 minutes. This material was recorded as "13A".

25 0.5g micronised apomorphine HCl plus 2.0g "13A" were blended by hand in a mortar with a spatula for 10 minutes. This powder was gently pushed through a 300µm metal sieve with a spatula. This material was recorded as "13B".

30 A number of foil blisters were filled with approximately 2mg of the following formulations:

10A - 20% apomorphine HCl, 5% l-leucine, 75% micronised lactose (co-jet milled)  
10C - 26.2% apomorphine HCl, 5% l-leucine, 68.7% sorbolac (geometric)

11B - 95% apomorphine HCl, 5% l-leucine (co-jet milled)

12A - 20% apomorphine HCl, 5% leucine, 75% micronised lactose (all co-jet milled)

13B - 20% apomorphine HCl, 5% l-leucine, 75% Sorbolac 400 (leucine & Sorbolac Mechano-Fused)

5

These were then fired from an Aspirair device into an NGI at a flow rate of 60l/m. The Aspirair was operated with a reservoir of 15ml of at 1.5 bar. Each in vitro test was conducted once to screen, and then the selected candidates were repeated. Further candidates were also repeated in ACI at 60 l/m.

10

Through life dose uniformity for the selected candidates was tested by firing 30 doses, with the emitted doses being collected.

Table 6

Formulation 2mg, 1.5 bar 15ml reservoir 60 l/min	MD (µg)	DD (µg)	FPD ( $<5\mu\text{m}$ ) (µg)	MMAD
10A	384	356	329	1.78
WHAT ARE THESE FIGURES???	(1920)	(1780)	(1645)	
13B	359	327	200	1.54
	(1793)	(1635)	(1000)	
10C	523	492	374	1.63
11B	1891	1680	1614	1.36
	1882	1622	1551	1.44
	1941	1669	1601	1.49
Ave.	1905	1657	1589	1.43
SD	32	31	33	0.07
RSD	1.7	1.9	2.1	4.6
11B	1895	1559	1514	1.58
	1895	1549	1485	1.62
	1923	1565	1504	1.62
<u>ACI</u>				
Ave.	1904	1558	1501	1.61
SD	16	8	15	0.02
RSD	1	1	1	1
12A	414	387	363	1.63
	410	387	363	1.66
	406	378	355	1.68
Ave.	410	384	360	1.66
SD	4	5	5	0.03
RSD	1	1	1	2
Total ave.	2050	1920	1800	
12A	395	365	341	1.80
	411	385	360	1.85
	400	370	349	1.84
<u>ACI</u>				
Ave.	402	373	350	1.83
SD	8	10	10	0.04
RSD	2	3	3	2
Total ave.	2011	1866	1750	



Table 7

Formulation 2mg, 1.5 bar 15ml reservoir 60 l/min	FPF(MD) % (<5um)	FPF(ED) % (<5um)	FPF(ED) % (<3um)	FPF(ED) % (<2um)	FPF(ED) % (<1um)
10A	86	93	87	60	13
13B	56	61	52	42	19
10C	72	76	67	51	16
11B	85	96	95	81	24
	82	96	93	77	22
	82	96	92	74	20
Ave.	83	96	93	77	22
SD		0	1.5	3.5	2
RSD		0	1.6	4.5	9.1
11B	80	97	94	74	14
	78	96	93	70	14
	78	96	94	72	12
<u>ACI</u>					
Ave.	79	96	94	72	13
SD		1	1	2	1
RSD		1	1	3	9
12A	88	94	89	68	13
	89	94	89	66	12
	87	94	88	64	12
Ave.	88	94	89	66	12
SD		0	1	2	1
RSD		0	1	3	5
12A	86	94	85	57	9
	88	93	84	55	8
	87	94	85	56	8
<u>ACI</u>					
Ave.	87	94	85	56	8
SD		1	1	1	1
RSD		1	1	2	7

Table 8

Formulation 2mg, 1.5 bar 15ml reservoir 60 l/min	Recovery	Throat	Blister	Device
10A	96%	5%	0.3%	7%
13B	94%	29%	3%	6%
10C	100%	16%	2%	4%
11B	101%	2%	0.6%	10%
	99%	2%	0.2%	14%
	102%	2%	0.3%	14%
Ave.	101%	2%	0.4%	13%
SD	1.5	0	0.2	2.3
RSD	1.5	0	57	18
11B	100%	1%	0.5%	17%
	100%	2%	0.1%	18%
	101%	2%	0.4%	18%
<u>ACI</u>				
Ave.	100%	2%	0.3%	18%
SD	1	1	0.2	1
RSD	1	35	62	3
12A	109%	4%	0.3%	6%
	108%	4%	0.2%	6%
	107%	4%	0.02%	7%
Ave.	108	4%	0.2	6%
SD	1	0	0.1	1
RSD	1	0	82	9
12A	104%	3%	0.4%	7%
	108%	4%	0.2%	6%
	105%	2%	0.4%	7%
<u>ACI</u>				
Ave.	106%	3%	0.3	7%
SD	2	1	0.1	1
RSD	2	33	35	9

The co-jet milled formulations once again exhibited exceptional FPFs, with the improvement largely due to reduced throat deposition which was less than 5%, compared to between 16 and 29% for the Mechano-Fused formulations. "12A" was produced as a repeat of "10A", but excluding the Mechano-Fused pre-blend (to show it was not required).

In order to investigate the cause of the unexpected differences between the co-jet milled formulations and those prepared by Mechano-Fusion, formulations "11B", "10A" and "2C" were fired from an Aspirair and plume and vortex behaviour recorded on digital video. The images were studied in light of the above differences in throat deposition.


Video of plume behaviour indicated a difference between the co-jet milled formulations and Mechano-Fused formulations. Mechano-Fused formulations showed a highly concentrated fast moving bolus at the front of the air jet. Most powder appeared to have been emitted after approximately 40ms. Co-jet milled formulations showed a greater spread of the plume. The plume front moves at a similar velocity, but the front is less concentrated, appears to slow more quickly and powder is emitted for considerably longer (i.e. >200ms).

Video of the vortex showed that the Mechano-Fused powders enter the vortex within 10ms, whereas co-jet milled formulations take at least 30ms. Similarly the Mechano-Fused powders appeared quicker to leave the vortex, with the co-jet milled materials forming a more prolonged fogging of the vortex. Greater device 'stick and scour' behaviour was also observed for co-jet milled materials.

Particle size distributions of the raw materials and selected formulations were determined by Malvern particle sizer, via the Scirroco dry powder disperser. The data are summarised below:

### Raw Materials

Micronised lactose (833704)




d(0.5) 2.8 $\mu\text{m}$

d(0.9) 6.3 $\mu\text{m}$

D[4,3] 3.3 $\mu\text{m}$

5

Apomorphine




d(0.5) 1.4 $\mu\text{m}$

d(0.9) 2.9 $\mu\text{m}$

D[4,3] 1.6 $\mu\text{m}$

10

Clobozam




d(0.5) 2.6 $\mu\text{m}$

d(0.9) 5.2 $\mu\text{m}$

D[4,3] 2.9 $\mu\text{m}$


## 5 Clobozam Formulations

(95% Clobozam, 5% MgSt MechanoFused)




10 d(0.5) 2.5μm d(0.9) 4.2μm D[4,3] 2.6μm

(95% Clobozam, 5% Aerocine, Co-jet milled)



15 d(0.5) 1.1μm d(0.9) 2.6μm D[4,3] 1.4μm

(95% Clobozam, 5% leucine, Co-jet milled)



d(0.5) 1.2μm

d(0.9) 2.5μm


D[4,3] 1.4μm

5

### Apomorphine Formulations

10

(75% lactose, 20% Apomorphine, 5% leucine, Co-jet milled)




d(0.5) 1.8μm

d(0.9) 243.6μm

D[4,3] 38.0μm

15

(75% lactose, 20% Apomorphine, 5% leucine, Co-jet milled)



d(0.5) 1.6μm

d(0.9) 261.0μm

D[4,3] 55.8μm

5

Where clobazam is co-milled with FCA, a significant drop in particle size is observed. This is not seen for the clobazam MechanoFused formulation here.

10

With the apomorphine-lactose co-milled materials, the size distribution is reduced, when compared to the particle size distribution of the micronised lactose which comprises 75% of the composition. However, size reduction is not as great with respect to pure apomorphine.

15

In vitro data confirm that Mechano-Fusion of active particles increased the throat deposition substantially. The higher the intensity of Mechano-Fusion used, the greater the apparent throat deposition. Increasing intensity of Mechano-Fusion has previously been associated with improvement in dispersibility. However, in this case, Mechano-Fusion with magnesium stearate gives lower throat deposition than Mechano-Fusion with leucine, and magnesium stearate generally gives improved dispersibility. Consequently, it is not a simple effect on dispersibility of the powder.

20

25

The throat deposition appears especially high for Mechano-Fused formulations containing leucine. It is speculated that this could be due to an agglomerating affect during Mechano-Fusion specific to leucine and not magnesium stearate, or an electrostatic effect specific to leucine.

However, co-jet milling produces materials which give very low throat deposition, low device deposition and excellent dispersion. This co-jet milling also produces a significant further size reduction: d50 changes from about 2µm to about 1µm.

5 When these factors are combined, a remarkable aerosolisation performance is obtained from the in-vitro tests. FPF( ED) are 90 to 96%. This excellent performance was obtained for leucine, Aerocine and magnesium stearate, and for 3 different formulations, including 2 different active agents, with or without lactose diluent.

10

It was noted that the co-jet milled materials were highly agglomerated in appearance, in contrast to the Mechano-Fused blends, which appeared as more free flowing powders.

15 Studies suggest that the difference between the performance of the co-jet milled and Mechano-Fused compositions is most apparent when the formulations are dispensed using an active device, such as Aspirair. Video of plume behaviour provided some indication of the reason for differences between the co-jet milled formulations and Mechano-Fused formulations. Mechano-Fused formulations  
20 showed a short fast bolus, whereas co-jet milled formulations showed a more drawn out plume. The "enhanced" flow properties of the Mechano-Fused powders appear to explain their worse Aspirair performance. A degree of powder hold-up appears to be beneficial.

25 These video observations suggest the throat deposition difference is related to the powder lifetime within the vortex, with a longer lifetime giving reduced deposition. This does not lead to a complete explanation or understanding of why such a large reduction in throat deposition is seen. However, lower aerosol concentration at plume front, lower momentum of aerosol plume (with lower cloud density and  
30 smaller particle size) and greater opportunity to be de-agglomerated are possible contributors.



In general, the co-milling of active particles with additive particles has yielded reduced device/blister retention compared to formulations prepared without additive particles. Mechano-Fusion was shown to give significantly greater blister retention than co-jet milling. The worst blister retention was seen for Mechano-Fused clobazam with magnesium stearate (13%). This appears related to the dusting nature of such formulations. The Mechano-Fused powders spread and flow more easily, which facilitates higher degrees of contact with the surfaces in bulk powder contact. The co-milled powders however are heavily agglomerated, so contact with surfaces is much reduced, and dust residues are also much less. The device retention also appears greater for Mechano-Fused than co-jet milled powders for clobazam. However, the device retention of apomorphine HCl co-jet milled with leucine appears notably high, at 13%. Device and blister retention does not appear substantially different between the 0.5 and 1.5 bar tests, except for the pure clobazam, where device retention approaches 50% for the 0.5 bar test.

It has also been discovered that the co-jet milling of active particles and additive particles has the added advantage that the additive particles act as a milling aid and actually enhance the milling action of the jet mill. In particular, it is believed that the additive particles are able to force open cracks on the surfaces of the active particles, assisting in the breaking apart of the active particles. This is another unexpected advantage, as this had not been observed when co-milling active and additive particles using other milling techniques.

The use of milling aids in milling (especially of pharmaceutical compositions) has generally been avoided as the milling agents are considered to be a potential source of contamination. Clearly, it would be unacceptable for a pharmaceutical composition intended for pulmonary inhalation to include any contaminants.

The finding that the additive materials of the present invention can act as milling aids when jet milling is particularly pleasing, as this means that the co-jet milling not only results in composite active particles, but also in particles of smaller particle size than achieved without the additive particles.

The reduction in particle size may also be increased by carrying out the co-jet milling at lower temperatures. Whilst the co-jet milling process may be carried out at temperatures between -20°C and 40°C, the particles will tend to be more brittle at lower temperatures, and they therefore fracture more readily so that the milled particles tend to be even smaller.

The optimum amount of additive material will depend on the chemical composition and other properties of the additive material and upon the nature of the active material and/or excipient material, if present. In general, the amount of additive material in the composite active particles will be not more than 60% by weight, based on the weight of the active material and any excipient material. However, it is thought that for most additive materials the amount of additive material should be in the range of 40% to 0.25%, preferably 30% to 0.5%, more preferably 20% to 2%, based on the total weight of the additive material and the active material being milled. In general, the amount of additive material is at least 0.01% by weight based on the weight of the active material.

Co-jet milling may be carried out at pressures between 0.1 and 12 bar. Varying the pressure allows one to control the degree of particle size reduction. At pressures in the region of 0.1-3 bar, and preferably 1-2 bar, the co-jet milling will primarily result in blending of the active and additive particles, so that the additive material coats the active particles. On the other hand, at 3-12 bar, and preferably 5-12 bar, the co-jet milling will additionally lead to particle size reduction.

Tests were carried out whereby pre-micronised lactose (as a drug model) was co-jet milled in an MC50 Hosakawa Micron with 5% magnesium stearate. At 2 bar milling pressure, the resultant material had a d50 of approximately 3µm, whilst milling the same mixture at around 7 bar resulted in material with a d50 of about 1µm. Thus, when operating with a jet milling pressure of 0.1-3 bar little milling, that is particle size reduction, is seen. From 3-12 bar milling pressure, increasing milling is seen, with the particle size reduction increasing with the increasing pressure. This means that the milling pressure may be selected according to the desired particle size in the resultant mixture.

Clearly, many different designs of jet mills exist and any of these may be used in the present invention. For example, in addition to the AS50 Spiral jet mill and the MC50 Hosakawa Micron used in the experiments discussed above, one can also use  
5 other spiral jet mills, pancake jet mills or opposed fluid bed jet mills. The feed rate for the jet mills will depend on their size. Small spiral jet mills might use a feed rate of, for example, 1 to 2g per minute, whilst industrial scale mills will have a feed rate in the order of kilograms per hour.

## Conclusions

The improvements in the dry powder inhaler devices and in the dry powder formulations mean that the desired dose efficiency can be achieved. The following  
15 tests demonstrate this.

The in-vitro testing was performed using the Aspirair device and using formulations prepared as follows.

20 120 g of Respitose SV003 lactose (45 to 63 $\mu$ m sieve fraction) and 30 g of micronised apomorphine hydrochloride and were combined into the mixing bowl of a Glen Creston GrindoMix high shear blender. The drug was sandwiched between Respitose layers. The material was processed at a setting of 2000rpm for 5 minutes. The blend was screened through a 250 $\mu$ m sieve.

25 Content uniformity was assessed by taking 10 samples of 3mg from the bulk powder.

The formulation contained a mean drug content of 20.8%, with a relative standard  
30 deviation of 1.97%.

2mg of powder was filled into 25 Aspirair foil blisters. 5 blisters were fired from an Aspirair device into a 60 litre per minute Andersen Cascade Impactor (ACI), with

air flow set at 60 litres per minute. The Aspirair was fired with 15ml of reservoir air at 1.5 bar. This was repeated 5 times

The results are summarised in Tables 1 and 2.

5

Table 1

Formulation	MD (mg)	DD (mg)	FPD (mg) ( $<5\mu\text{m}$ )	FPF(MD) % ( $<5\mu\text{m}$ )	FPF(ED) % ( $<5\mu\text{m}$ )
	0.38	0.36	0.29	75	81
	0.38	0.35	0.28	74	80
	0.40	0.37	0.30	75	81
	0.39	0.36	0.29	74	80
	0.38	0.35	0.29	75	82
Mean	0.39	0.36	0.29	75	81

Table 2

Formulation	FPF(ED) % ( $<3\mu\text{m}$ )	FPF(ED) % ( $<2\mu\text{m}$ )	MMAD	Blister retention (%)	Device retention (%)
	75	54	1.70	2	6
	74	52	1.73	2	6
	74	53	1.72	2	6
	74	55	1.66	2	6
	75	55	1.68	2	6
Mean	74	54	1.70	2%	6%

10

The formulations exhibited exceptional fine particle fractions of emitted dose and of metered dose. Also the performance is very consistent, between all 5 repeated tests.

15 In a further study, also using the CL1 Aspirair device, the following formulation was tested.

Respitose SV003 lactose (45 to 63 $\mu$ m sieve fraction) and micronised salbutamol sulphate were combined in the ratio 60:40.

5 1mg of powder was filled into 15 Aspirair foil blisters. 5 blisters were fired from an Aspirair device into a Next Generation Impactor with air flow set at 60 litres per minute. The Aspirair was fired with 15ml of reservoir air at 1.5 bar. This was repeated 3 times

10 The results are summarised in Tables 3 and 4.

Table 3

NGI	MD ( $\mu$ g)	ED ( $\mu$ g)	FPD >5 $\mu$ m ( $\mu$ g)	FPF(MD)% >5 $\mu$ m	MMAD
1	484	470	397	82	1.80
2	376	367	328	87	1.78
3	404	390	350	87	1.74

Table 4

NGI	FPF(ED)% >5 $\mu$ m	FPF(ED)% >3 $\mu$ m	FPF(ED)% >2 $\mu$ m	FPF(ED)% >1 $\mu$ m
1	85	73	53	21
2	89	78	55	17
3	90	79	56	19

15

Once again, the formulations exhibited exceptional and reproducible fine particle fractions of emitted dose and of metered dose.

## Claims

1. A dry powder inhaler device comprising a dry powder formulation comprising a pharmaceutically active agent, wherein upon actuation of the device, a dosing efficiency at 5 $\mu$ m of at least 70% is achieved.  
5
2. A device as claimed in claim 1, wherein a dosing efficiency at 3 $\mu$ m of at least 60% is achieved
- 10 3. A device as claimed in claim 1, wherein a dosing efficiency at 2 $\mu$ m of preferably at least 40% is achieved.
4. A device as claimed in any of the preceding claims, wherein the dry powder composition was prepared using a method comprising co-spray drying the  
15 pharmaceutically active agent with a force control agent.
5. A device as claimed in claim 4, wherein the force control agent is an amino acid, a phospholipid or a metal stearate, and is preferably leucine.
- 20 6. A device as claimed in any of claims 4 or 5, wherein the active agent is spray dried using a spray drier comprising a means for producing droplets moving at a controlled velocity and of a predetermined size.
7. A device as claimed in claim 6, wherein the spray drier comprises an  
25 ultrasonic nebuliser.
8. A device as claimed in any one of claims 4-7, wherein the method comprises adjusting the moisture content of the spray dried particles.
- 30 9. A device as claimed in any one of claims 1-3, wherein composite active particles for use in the pharmaceutical composition are prepared using a method comprising jet milling active particles in the presence of particles of additive

material.

10. A device as claimed in claim 9, wherein the additive material comprises an amino acid, a metal stearate or a phospholipid.

5

11. A device as claimed in claim 10, wherein the additive material comprises one or more of leucine, isoleucine, lysine, valine, methionine, phenylalanine, and preferably leucine.

10

**Abstract**

**Devices and Pharmaceutical Compositions for Enhancing Dosing Efficiency**

5

The present invention relates to enhancing the dosing efficiency of pharmaceutical dry powder formulations administered by pulmonary inhalation. In particular, the present invention relates to the provision of dry powder inhalers and dry powder  
10 compositions which reproducibly achieve a much higher delivered dose of the pharmaceutically active agent than currently achieved.



THE FOLLOWING DRAWINGS RELATE TO THE EMBODIMENTS OF THE  
INVENTION DESCRIBED IN THE SECTIONS HEADED:

“IMPROVED EVACUATION OF DOSE FROM PACKAGING”

&

“DOSE STORAGE PACK”




FIGURE 1(A)




FIGURE 2(A)




FIGURE 3(A)




FIGURE 4 (A)







FIGURE 5 (A)






FIGURE 7A (A)







FIGURE 7B (A)




(A)




(B)



(C)




(D)




(E)


FIGURE 8(A)



(F)



(G)



(H)




FIGURE 9 (A)




FIGURE 10 (A)






FIGURE 11 (A)

THE FOLLOWING DRAWINGS RELATE TO THE EMBODIMENTS OF THE  
INVENTION DESCRIBED IN THE SECTION HEADED:

“VALVE ENHANCEMENTS”




FIGURE 1 (b)




FIGURE 2(B)




FIGURE 3(B)




FIGURE 4 (B)






FIGURE 5(b)






FIGURE 8 (B)




FIGURE 9 (B)



THE FOLLOWING DRAWINGS RELATE TO THE EMBODIMENTS OF THE  
INVENTION DESCRIBED IN THE SECTION HEADED:

“POWDER ENTRAINMENT & DE-AGGLOMERATION”




Figure 1




FIG. 2




FIG. 3




FIG. 4




Figure 5a




Figure 6a




Figure 5b




Figure 6b




Figure 7




Figure 8




Figure 9




Figure 10




Figure 11




Figure 12






Figure 13




Figure 14




Figure 15




Figure 16




Figure 17




Figure 18

THE FOLLOWING DRAWINGS RELATE TO THE EMBODIMENTS OF THE  
INVENTION DESCRIBED IN THE SECTION HEADED:

“SPRAY DRIED POWDER PARTICLES”




Figure 1




Figure 2a




Figure 2b




Figure 2c




Figure 2d




Figure 2e




Figure 2f




Figure 2g




Figure 2h




Figure 3




Figure 4






Figure 5a




Figure 5b




Figure 6




Figure 7a

9/11




Figure 7b




Figure 7c




Figure 8

THE FOLLOWING DRAWINGS RELATE TO THE EMBODIMENTS OF THE  
INVENTION DESCRIBED IN THE SECTION HEADED:

"MICRONISED DRY POWDER PARTICLES"

Figure 1A




Figure 1B






Figure 2A




Figure 2B




Figure 3A




Figure 3B




Figure 4A




Figure 4B




Figure 5A




Figure 5B




Figure 6A




Figure 6B




Figure 7A





Figure 7B



**PCT/GB2004/001628**

